Gene therapy for CNS degeneration
Through recombinant gene therapy vectors and gene editing systems, the treatment difficulties of central nervous system degeneration-related diseases such as Parkinson's disease were solved, and wild-type or functional variant proteins and repair mutant genes were achieved in neurons, significantly improving dopamine Levels and symptoms.
Patent Information
- Application Number
- CN201980028117.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-04-27
- Filing Date
- 2019-04-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to effectively treat and prevent central nervous system degeneration-related conditions, such as Parkinson's disease, especially due to the lack of effective gene therapies and methods.
Recombinant gene therapy vectors and gene editing systems are provided, including encoding polynucleotides for Parkinsonin 2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2 or GBA genes, associated with viral vectors such as glands. Viruses (AAVs) are delivered to neurons, express wild-type or functional variant proteins, or are gene edited by Cas proteins and guide RNA to repair mutant genes.
In vivo and in vitro, inhibition of dopaminergic neuron degeneration or death was achieved, increasing dopamine levels, reducing α-synuclein and Lewy bodies expression, increasing mitochondrial autophagy, and improving symptoms of Parkinson's disease.
Smart Images

Figure CN112368390B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 664,006, filed April 27, 2018, the disclosure of which is incorporated herein by reference in its entirety for all purposes.
[0003] Incorporation of Sequence Listing
[0004] The sequence listing associated with this application is provided in text format in lieu of a paper copy and is incorporated herein by reference. The text file containing the sequence listing is named ROPA_009_01WO_ST25.txt. The text file is 254KB, created on April 29, 2019, and submitted electronically via EFS-Web. Technical Field
[0005] The present disclosure generally relates to gene therapy and / or gene editing for treating conditions associated with central nervous system degeneration, such as Parkinson's Disease. Specifically, the present disclosure provides compositions and methods for gene therapy or gene repair in neurons in vitro and in vivo. Background Art
[0006] Various genes are associated with central nervous system degenerative disorders such as Parkinson's disease (PD). These genes include PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. (Creed et al. (2018) Movement Disorders. 33:717-729; Blesa et al. (2014) Front. Neuroanatomy. 8:1-12; Alcalay et al. (2010) Arch Neurol. 67:1116-1122). PARK2, also known as PRKN, is associated with a form of PD (i.e., autosomal recessive juvenile PD). Despite extensive attempts, there are few reports of successful gene therapies for central nervous system degeneration.
[0007] There is a great need in the art for new compositions and methods for treating and preventing central nervous system degeneration. Summary of the Invention
[0008] The present disclosure provides, in part, compositions and methods for treating, preventing, inhibiting or delaying central nervous system degeneration. Specifically, the inventors disclose various embodiments of recombinant gene therapy vectors and methods related thereto, wherein the recombinant gene therapy vectors include Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, α-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene or glucocerebrosidase (GBA) gene or its functional fragment or variant.
[0009] The present inventors further disclose various embodiments of a gene editing system and methods related thereto, wherein the gene editing system includes a Cas protein, a guide RNA, and a repair template, wherein the repair template includes Parkinson protein 2, an E3 ubiquitin-protein ligase (PARK2) gene, a PTEN-induced putative kinase 1 (PINK1) gene, a protein deglycosylation enzyme DJ-1 (DJ-1) gene, a leucine-rich repeat kinase 2 (LRRK2) gene, an α-synuclein (SCNA) gene, a proto-oncogene c-Rel (c-Rel) gene, an ubiquitin-like modifier activating enzyme (ATG7) gene, a synaptic vesicle amine transporter (VMAT2) gene, or a glucocerebrosidase (GBA) gene or a functional fragment or variant thereof.
[0010] In a first aspect, the present disclosure provides a method for inhibiting degeneration or death of dopaminergic neurons, wherein the dopaminergic neurons include mutations in genes associated with Parkinson's disease (PD). The mutated gene can be parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, alpha-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene or glucocerebrosidase (GBA) gene. In the method of this aspect, the method comprises contacting the neuron with a recombinant gene therapy vector comprising a polynucleotide encoding a wild-type protein expressed by a wild-type version of the mutated gene or a functional variant or fragment thereof; after contact with the recombinant gene therapy vector, the neuron expresses the wild-type protein or a functional variant or fragment thereof.
[0011] In some embodiments, the PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA protein comprises the amino acid sequence set forth in SEQ ID NOs: 1-9, respectively. In some embodiments, the gene is a PARK2 gene, and the wild-type PARK2 protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 10-17. In some embodiments, the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to the PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA polynucleotide sequence set forth in SEQ ID NOs: 18-26, respectively. In some embodiments, the gene is a PARK2 gene, and the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to a PARK2 isoform polynucleotide sequence set forth in any one of SEQ ID NOs: 27-34. In some embodiments, the polynucleotide is codon-optimized. In some embodiments, the polynucleotide comprises fewer than 40, fewer than 30, fewer than 20, or 10 or fewer CpG islands. In some embodiments, the polynucleotide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 10 CpG islands. In some embodiments, it comprises 5 to 20 CpG islands.
[0012] Various viral or non-viral vectors can be used. In some embodiments, the recombinant gene therapy vector is a recombinant adeno-associated virus (AAV). Any known serotype can be used. In some embodiments, the AAV has a serotype of AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10 or AAVrh74. In some embodiments, the recombinant gene therapy vector comprises a self-complementary AAV. In some embodiments, the recombinant gene therapy vector comprises a single-stranded AAV. In some embodiments, the AAV is a wild-type AAV or a modified AAV. In some embodiments, the AAV comprises a capsid protein that is at least 95% identical to a wild-type VP1, VP2 or VP3 capsid protein.
[0013] The recombinant gene therapy vector may comprise a gene regulatory element. In some embodiments, the recombinant gene therapy vector comprises a polynucleotide comprising, in the following 5' to 3' order, a eukaryotic active promoter sequence and a sequence encoding the wild-type protein or a functional fragment or variant thereof. The sequence encoding the wild-type protein or a functional fragment or variant thereof is operably linked to the eukaryotic active promoter sequence.
[0014] Without being limited by the examples of the present disclosure, in some embodiments, the recombinant gene therapy vector further comprises one or more of the following: a neuron-specific promoter, the neuron-specific promoter optionally being selected from the group consisting of: hSYN1 (human synaptophysin), INA (α-filament nectin), NES (nestin), tyrosine hydroxylase (TH), forkhead box A2 (FOXA2), calmodulin-dependent protein kinase II (CaMKII), and neuron-specific enolase (NSE) promoters; a ubiquitous promoter selected from the group consisting of: CMV, CAG, UBC, PGK, EF1-α, GAPDH, SV40, HBV, and chicken β-actin promoters; an enhancer; an intron; a poly-A signal; a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE); and a hepatitis post-transcriptional regulatory element (HPRE). The WPRE can be WPRE(r) or WPRE(x).
[0015] In various embodiments of any one of the vectors and methods disclosed herein, the vector comprises an expression cassette comprising, in 5' to 3' order:
[0016] HuBA promoter, the transgene, WPRE(x), and pA-globin-Oc;
[0017] CMV promoter, TPL-eMLP 5' enhancer, the transgene, WPRE(r), and pA-globin-Oc;
[0018] Syn promoter, the transgene, WPRE(r), 3'UTR (globin), and pAGH-Bt;
[0019] CBA promoter, the transgene and pAGH-Bt;
[0020] EF1a promoter, the transgene, and pA-globin-Oc;
[0021] HuBA promoter, the transgene, R2V17, and pAGH-Bt;
[0022] Syn promoter, the transgene, WPRE(x), 3'UTR (globin), and pAGH-Hs;
[0023] CaMKIIa promoter, the transgene, WPRE(r), and pAGH-Hs;
[0024] CMV and TPL promoters, the transgene, WPRE(r), and pAGH-Hs;
[0025] HuBA promoter, the transgene, and pAGH-Hs;
[0026] CMV and TPL promoters, eMPL, the transgene, R2V17, 3'UTR (globin), and pAGH-Bt;
[0027] EF1α promoter, the transgene, WPRE(r) and pAGH-Bt;
[0028] Syn promoter, the transgene, R2V17, and pA globin-Oc;
[0029] CaMKIIa promoter, the transgene, R2V17, and pA-globin-Oc;
[0030] CBA promoter, the transgene, WPRE(x), 3'UTR (globin), and pAGH-Hs.
[0031] CBA promoter, the transgene, 3'UTR (globin), and pAglobin-Oc;
[0032] CaMKIIa promoter, the transgene, R2V17 and pAGH-Bt;
[0033] EF1a promoter, the transgene, R2V17, 3'UTR (globin), and pAGH-Hs;
[0034] CMV promoter, the transgene, R2V17, 3'UTR (globin), and pAGH-Hs; or
[0035] CMV promoter, the transgene and pAGH-Hs,
[0036] Optionally wherein the transgene encodes PARK2.
[0037] The methods described in the present disclosure can have various effects. In some embodiments, the neurons express reduced amounts of alpha-synuclein and / or include reduced amounts of Lewy bodies after contact with the recombinant gene therapy vector. In some embodiments, the neurons express reduced amounts of monoamine oxidase after contact with the recombinant gene therapy vector. In some embodiments, the neurons produce and / or release increased amounts of dopamine after contact with the recombinant gene therapy vector. In some embodiments, the neurons experience increased mitochondrial autophagy after contact with the recombinant gene therapy vector.
[0038] In some embodiments, the amount of monoamine oxidase expressed by the neurons is lower compared to the amount of monoamine oxidase expressed in neurons not contacted with the recombinant gene therapy vector, optionally wherein the lower amount is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% lower than the amount expressed in the neurons not contacted with the recombinant gene therapy vector. In some embodiments, the amount of dopamine produced and / or released by the neurons is increased compared to the amount of dopamine produced and / or released by the neurons not contacted with the recombinant gene therapy vector, optionally wherein the increased amount is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least ten-fold greater than the amount produced and / or released by the neurons not contacted with the recombinant gene therapy vector. In some embodiments, the amount of autophagy experienced by the neurons is increased compared to the amount of autophagy experienced by neurons not contacted with the recombinant gene therapy vector, optionally wherein the increase is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least 10-fold greater than the amount experienced by the neurons not contacted with the recombinant gene therapy vector.
[0039] The neurons used in the methods described herein can have various characteristics. In some embodiments, the neurons are primary tyrosine hydroxylase-positive neurons. In some embodiments, the neurons are generated from induced pluripotent stem cells prepared from cells obtained from a subject diagnosed with Parkinson's disease.
[0040] On the other hand, the present disclosure provides a recombinant gene therapy vector comprising a polynucleotide encoding: wild-type Parkinson protein 2, E3 ubiquitin-protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, α-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene, or glucocerebrosidase (GBA) gene or a functional variant or fragment thereof; wherein the polynucleotide is operably linked to a eukaryotic active promoter; and wherein neurons transduced with the recombinant gene therapy vector express the wild-type protein or a functional variant or fragment thereof.
[0041] In some embodiments, the functional PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA protein comprises the amino acid sequence set forth in SEQ ID NOs: 1-9, respectively. In some embodiments, the gene is a PARK2 gene, and the wild-type PARK2 protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 10-17. In some embodiments, the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to the PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA polynucleotide sequence set forth in SEQ ID NOs: 18-26, respectively. In some embodiments, the gene is a PARK2 gene, and the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to the PARK2 isoform polynucleotide sequence set forth in any one of SEQ ID NOs: 27-34. In some embodiments, the vector comprises an expression cassette comprising, in 5' to 3' order:
[0042] HuBA promoter, the transgene, WPRE(x), and pA-globin-Oc;
[0043] CMV promoter, TPL-eMLP 5' enhancer, the transgene, WPRE(r), and pA-globin-Oc;
[0044] Syn promoter, the transgene, WPRE(r), 3'UTR (globin), and pAGH-Bt;
[0045] CBA promoter, the transgene and pAGH-Bt;
[0046] EF1a promoter, the transgene, and pA-globin-Oc;
[0047] HuBA promoter, the transgene, R2V17, and pAGH-Bt;
[0048] Syn promoter, the transgene, WPRE(x), 3'UTR (globin), and pAGH-Hs;
[0049] CaMKIIa promoter, the transgene, WPRE(r), and pAGH-Hs;
[0050] CMV and TPL promoters, the transgene, WPRE(r), and pAGH-Hs;
[0051] HuBA promoter, the transgene, and pAGH-Hs;
[0052] CMV and TPL promoters, eMPL, the transgene, R2V17, 3'UTR (globin), and pAGH-Bt;
[0053] EF1a promoter, the transgene, WPRE(r) and pAGH-Bt;
[0054] Syn promoter, the transgene, R2V17, and pA globin-Oc;
[0055] CaMKIIa promoter, the transgene, R2V17, and pA-globin-Oc;
[0056] CBA promoter, the transgene, WPRE(x), 3'UTR (globin), and pAGH-Hs.
[0057] CBA promoter, the transgene, 3'UTR (globin), and pAglobin-Oc;
[0058] CaMKIIa promoter, the transgene, R2V17 and pAGH-Bt;
[0059] EF1a promoter, the transgene, R2V17, 3'UTR (globin), and pAGH-Hs;
[0060] CMV promoter, the transgene, R2V17, 3'UTR (globin), and pAGH-Hs; or
[0061] CMV promoter, the transgene and pAGH-Hs,
[0062] Optionally wherein the transgene encodes PARK2.
[0063] In some embodiments, the polynucleotide is codon-optimized. In some embodiments, the polynucleotide includes any one of SEQ ID NO:35-38. In some embodiments, the recombinant gene therapy vector is a recombinant adeno-associated virus (rAAV). In some embodiments, the rAAV has a serotype of AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10 or AAVrh74. In some embodiments, the recombinant gene therapy vector includes a self-complementary or single-stranded AAV genome. In some embodiments, the AAV is a wild-type AAV or a modified AAV. In some embodiments, the AAV includes a capsid protein having at least 95% identity to a wild-type VP1, VP2 or VP3 capsid protein.
[0064] On the other hand, the present disclosure provides a method for treating Parkinson's disease (PD) in a subject having or at risk of having PD or inhibiting the onset of PD, the method comprising administering to the subject a recombinant gene therapy vector comprising a polynucleotide encoding wild-type Parkinson protein 2, an E3 ubiquitin-protein ligase (PARK2) gene, a PTEN-induced putative kinase 1 (PINK1) gene, a protein deglycosylation enzyme DJ-1 (DJ-1) gene, a leucine-rich repeat kinase 2 (LRRK2) gene, an α-synuclein (SCNA) gene, a proto-oncogene c-Rel (c-Rel) gene, an ubiquitin-like modifier activating enzyme (ATG7) gene, a synaptic vesicle amine transporter (VMAT2) gene, or a glucocerebrosidase (GBA) gene or a functional variant or fragment thereof; wherein administration of the recombinant gene therapy vector treats the Parkinson's disease in the subject or inhibits the onset of Parkinson's disease.
[0065] In some embodiments, the PD is early-onset PD, optionally early-onset autosomal recessive PD. In some embodiments, the subject comprises a mutation in the PARK2 gene, PINK1 gene, LRRK2 gene, SCNA gene, c-Rel gene, ATG7 gene, VMAT2, or GBA gene. In some embodiments, the PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA protein comprises the amino acid sequence shown in SEQ ID NOs: 1-9, respectively. In some embodiments, the gene is the PARK2 gene, and the wild-type PARK2 protein comprises the amino acid sequence shown in any one of SEQ ID NOs: 10-17. In some embodiments, the polynucleotide comprises a sequence having at least 70%, 75%, 80%, 85%, 95%, or 99% identity to the PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA polynucleotide sequence shown in SEQ ID NOs: 18-26, respectively. In some embodiments, the gene is a PARK2 gene, and the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to a PARK2 isoform polynucleotide sequence as set forth in any one of SEQ ID NOs: 27-34. In some embodiments, the polynucleotide is codon-optimized. In some embodiments, the polynucleotide comprises a sequence that is at least 70%, 75%, 80%, 85%, 95%, or 99% identical to a sequence as set forth in any one of SEQ ID NOs: 35-38.
[0066] In some embodiments, the recombinant gene therapy vector is a recombinant adeno-associated virus (AAV). In some embodiments, the AAV has a serotype of AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10 or AAVrh74. In some embodiments, the recombinant gene therapy vector comprises a self-complementary AAV genome. In some embodiments, the recombinant gene therapy vector comprises a single-stranded AAV. In some embodiments, the AAV is a wild-type AAV or a modified AAV. In some embodiments, the AAV comprises a capsid protein that is at least 95% identical to a wild-type VP1, VP2 or VP3 capsid protein.
[0067] In some embodiments, the recombinant gene therapy vector comprises a polynucleotide comprising, in the following 5' to 3' order, a eukaryotic active promoter sequence; and a sequence encoding the wild-type protein or a functional fragment or variant thereof; wherein the sequence encoding the wild-type protein or a functional fragment or variant thereof is operably linked to the eukaryotic active promoter sequence.
[0068] In some embodiments, the recombinant gene therapy vector further comprises one or more of the following: a neuron-specific promoter, optionally selected from the group consisting of hSYN1 (human synapsin), INA (α-filament nectin), NES (nestin), tyrosine hydroxylase (TH), forkhead box A2 (FOXA2), calmodulin-dependent protein kinase II (CaMKII), and neuron-specific enolase (NSE) promoters; a ubiquitous promoter selected from the group consisting of CMV, CAG, UBC, PGK, EF1-α, GAPDH, SV40, HBV, human β-actin promoter, and chicken β-actin promoter; an enhancer; an intron; a poly-A signal; a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE); and a hepatitis posttranscriptional regulatory element (HPRE).
[0069] The recombinant gene therapy vector or gene editing system can be administered in a variety of ways. In some embodiments, the administering step includes systemic, parenteral, intravenous, brain, cerebrospinal cord, intrathecal, intracisternal, intraputamen, intrahippocampal, intrastriatal or intraventricular administration. In some embodiments, the administering step includes intravenous, brain, cerebrospinal cord, intrathecal, intracisternal, intraputamen, intrahippocampal, intrastriatal or intraventricular injection. In some embodiments, the administering step includes intrathecal injection with a Threndelenburg tilt. In some embodiments, the administering step includes direct injection into the compact part of the substantia nigra of the brain. In some embodiments, the administering step includes introducing the recombinant gene therapy vector into the brain or cerebrospinal fluid (CSF) of the subject.
[0070] In some embodiments, the subject is administered 1×10 9 -1×10 14 In some embodiments, 1×10 9 -1×10 14 In some embodiments, 1×10 9 -1×10 14 In some embodiments, the subject is administered 1×10 7 -1×10 9 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0071] The methods of the present disclosure relate to both adult and juvenile forms of the disease. In some embodiments, the subject is an adult. In some embodiments, the subject is a child.
[0072] The methods described in the present disclosure can have various effects on the subject. In some embodiments, the number of dopaminergic neurons in the subject after the administering step is greater than the number of dopaminergic neurons in the subject before the administering step. In some embodiments, the dopamine level in the subject after the administering step is higher than the dopamine level in the subject before the administering step. In some embodiments, the number of dopaminergic neurons in a subject treated by the method is increased compared to the number of dopaminergic neurons in a subject not so treated. In some embodiments, the dopamine level in a subject treated by the method is increased compared to the dopamine level in a subject not so treated. In some embodiments, the dopamine level in the substantia nigra of a subject treated by the method is increased compared to the dopamine level in the substantia nigra of a subject not so treated. In some embodiments, the PRKN level in the CSF of the subject after the administering step is higher than the PRKN level in the CSF of the subject before the administering step. In some embodiments, the Unified Parkinson's Disease Rating Scale (UPDRS) score of the subject before the administering step is improved compared to the UPDRS score of the subject before the administering step. In some embodiments, the level of PRKN in the CSF of a subject treated by the method is increased compared to the level of PRKN in the CSF of a subject not so treated. In some embodiments, the level of PRKN in the substantia nigra of the subject after the administering step is higher than the level of PRKN in the substantia nigra of the subject before the administering step. In some embodiments, the UPDRS score of a subject treated by the method is improved compared to the UPDRS score of a subject not so treated. In some embodiments, the neurons of the subject express reduced amounts of alpha-synuclein and / or include reduced amounts of Lewy bodies after contact with the recombinant gene therapy vector.
[0073] On the other hand, the present disclosure provides a method for inhibiting degeneration or death of dopaminergic neurons, wherein the dopaminergic neurons have a mutated Parkin (PRKN) gene, the method comprising contacting the neurons with a gene editing system, the gene editing system comprising: a Cas protein or a polynucleotide encoding a Cas protein; a guide RNA (gRNA); and a repair template, the repair template comprising a functional Parkinson protein 2, an E3 ubiquitin-protein ligase (PARK2) gene, a PTEN-induced putative kinase 1 (PINK1) gene, a protein deglycosylation enzyme DJ-1 (DJ-1) gene, a leucine-rich repeat kinase 2 (LRRK2) gene, an α-synuclein (SCNA) gene, a proto-oncogene c-Rel (c-Rel) gene, an ubiquitin-like modifier activating enzyme (ATG7) gene, a synaptic vesicle amine transporter (VMAT2) gene, or a glucocerebrosidase (GBA) gene, or a functional variant or fragment thereof; wherein the gene editing system is capable of repairing the endogenous gene in the neuron or inserting a functional gene into the genome of the neuron.
[0074] In some embodiments, at least one component of the gene editing system is delivered via recombinant AAV. In some embodiments, the gene editing system is delivered via recombinant AAV.
[0075] On the other hand, the present disclosure provides a gene editing system for a cell, comprising: a Cas protein or a polynucleotide encoding a Cas protein; a guide RNA (gRNA); and a repair template, wherein the repair template comprises a functional Parkinson protein 2, an E3 ubiquitin-protein ligase (PARK2) gene, a PTEN-induced putative kinase 1 (PINK1) gene, a protein deglycosylation enzyme DJ-1 (DJ-1) gene, a leucine-rich repeat kinase 2 (LRRK2) gene, an α-synuclein (SCNA) gene, a proto-oncogene c-Rel (c-Rel) gene, an ubiquitin-like modifier activating enzyme (ATG7) gene, a synaptic vesicle amine transporter (VMAT2) gene, or a glucocerebrosidase (GBA) gene or a functional variant or fragment thereof; wherein the gene editing system is capable of repairing an endogenous gene in the cell or inserting a functional gene into the genome of the cell.
[0076] In some embodiments, at least one component of the gene editing system is delivered via recombinant AAV. In some embodiments, the gene editing system is delivered via recombinant AAV. In some embodiments, the cell is an isolated neuron. In some embodiments, the cell is a cell of a subject.
[0077] In another aspect, the present disclosure provides a recombinant gene therapy vector comprising a transgenic polynucleotide encoding an E3 ubiquitin protein ligase (PARK2) gene, wherein the transgenic polynucleotide is operably linked to a eukaryotic active promoter sequence.
[0078] In some embodiments, the transgenic polynucleotide shares at least 95% identity with one of SEQ ID NOs: 35-38.
[0079] In some embodiments, the promoter sequence is selected from Table 5.
[0080] In some embodiments, the vector further comprises a CMV enhancer.
[0081] In some embodiments, the vector further comprises a 5' untranslated region (UTR) selected from Table 6.
[0082] In some embodiments, the vector further comprises a 3' untranslated region selected from Table 7.
[0083] In some embodiments, the vector further comprises a polyadenylation sequence (polyA) selected from Table 8.
[0084] In some embodiments, the polynucleotide is codon-optimized.
[0085] In some embodiments, the expression cassette shares at least 95% identity with any one of SEQ ID NOs: 39-58.
[0086] In some embodiments, the vector is an adeno-associated virus (AAV) vector.
[0087] In some embodiments, the vector comprises two AAV inverted terminal repeats (ITRs) flanking the expression cassette.
[0088] In some embodiments, the AAV is of serotype AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10, or AAVrh74.
[0089] In some embodiments, the recombinant gene therapy vector comprises a self-complementary AAV.
[0090] In some embodiments, the recombinant gene therapy vector comprises a single-stranded AAV.
[0091] In some embodiments, the AAV is wild-type AAV or a modified AAV.
[0092] In some embodiments, the AAV comprises a capsid protein that is at least 95% identical to a wild-type VP1, VP2, or VP3 capsid protein.
[0093] In another aspect, the present disclosure provides a host cell comprising any of the aforementioned recombinant gene therapy vectors.
[0094] On the other hand, the present disclosure provides a method for inhibiting degeneration or death of dopaminergic neurons, wherein the dopaminergic neurons include a mutation in a gene associated with Parkinson's disease (PD), wherein the mutated gene is the Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene, the method comprising contacting the neurons with the recombinant gene therapy vector described in the present disclosure, wherein after contact with the recombinant gene therapy vector, the neurons express the wild-type protein.
[0095] In some embodiments, the neurons express reduced amounts of α-synuclein and / or comprise reduced amounts of Lewy bodies following contact with the recombinant gene therapy vector.
[0096] In some embodiments, the neurons express reduced amounts of monoamine oxidase following contact with the recombinant gene therapy vector.
[0097] In some embodiments, the neurons produce and / or release increased amounts of dopamine after contacting with the recombinant gene therapy vector.
[0098] In some embodiments, the neurons undergo increased mitophagy following contact with the recombinant gene therapy vector.
[0099] In some embodiments, the neurons express a lower amount of monoamine oxidase compared to the amount of monoamine oxidase expressed in neurons not contacted with the recombinant gene therapy vector, optionally wherein the lower amount is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% lower than the amount expressed in the neurons not contacted with the recombinant gene therapy vector.
[0100] In some embodiments, the amount of dopamine produced and / or released by the neurons is increased compared to the amount of dopamine produced and / or released by neurons that have not been contacted with the recombinant gene therapy vector, optionally wherein the increase is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least 10-fold greater than the amount produced and / or released by the neurons that have not been contacted with the recombinant gene therapy vector.
[0101] In some embodiments, the amount of autophagy experienced by the neurons is increased compared to the amount of autophagy experienced by neurons not contacted with the recombinant gene therapy vector, optionally wherein the increase is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least 10-fold greater than the amount experienced by the neurons not contacted with the recombinant gene therapy vector.
[0102] In some embodiments, the neurons are primary tyrosine hydroxylase-positive neurons.
[0103] In some embodiments, the neurons are generated from induced pluripotent stem cells prepared from cells obtained from a subject diagnosed with Parkinson's disease.
[0104] In another aspect, the present disclosure provides a method for treating Parkinson's disease (PD) in a subject having or at risk of developing the PD or inhibiting the onset of the PD, the method comprising administering the gene therapy vector described in the present disclosure, wherein administration of the recombinant gene therapy vector treats the Parkinson's disease in the subject or inhibits the onset of the Parkinson's disease.
[0105] In some embodiments, the PD is early-onset PD, optionally early-onset autosomal recessive PD.
[0106] In some embodiments, the subject comprises a mutation in the PARK2 gene.
[0107] In some embodiments, the PARK2 comprises the amino acid sequence shown in SEQ ID NO:1.
[0108] In some embodiments, the administering step comprises systemic, parenteral, intravenous, cerebral, cerebrospinal, intrathecal, intracisternal, intraputical, intrahippocampal, intrastriatal, or intracerebroventricular administration.
[0109] In some embodiments, the administering step comprises intravenous, brain, cerebrospinal, intrathecal, intracisternal, intraputical, intrahippocampal, intrastriatal, or intracerebroventricular injection.
[0110] In some embodiments, the administering step comprises intrathecal injection using Trendelenburg tilt.
[0111] In some embodiments, the administering step comprises injecting directly into the substantia nigra pars compacta of the brain.
[0112] In some embodiments, the administering step comprises introducing the recombinant gene therapy vector into the brain or cerebrospinal fluid (CSF) of the subject.
[0113] In some embodiments, the subject is administered 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0114] In some embodiments, 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0115] In some embodiments, 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0116] In some embodiments, the subject is administered 1×10 7 -1×10 9 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0117] In some embodiments, the subject is administered 1×10 7 -1×10 11 total vector genomes, for example by direct injection into the putamen or substantia nigra.
[0118] In some embodiments, the subject is an adult.
[0119] In some embodiments, the subject is a child.
[0120] In some embodiments, the number of dopaminergic neurons in the subject after said administering step is greater than the number of dopaminergic neurons in the subject before said administering step.
[0121] In some embodiments, the dopamine level in the subject after said administering step is higher than the dopamine level in the subject before said administering step.
[0122] In some embodiments, the number of dopaminergic neurons in a subject treated by the method is increased compared to the number of dopaminergic neurons in a subject not so treated.
[0123] In some embodiments, dopamine levels in a subject treated by the methods are increased compared to dopamine levels in a subject not so treated.
[0124] In some embodiments, dopamine levels in the substantia nigra of a subject treated by the method are increased compared to dopamine levels in the substantia nigra of a subject not so treated.
[0125] In some embodiments, the level of PRKN in the subject's CSF after said administering step is higher than the level of PRKN in the subject's CSF before said administering step.
[0126] In some embodiments, the subject's Unified Parkinson's Disease Rating Scale (UPDRS) score is improved prior to said administering step compared to the subject's UPDRS score prior to said administering step.
[0127] In some embodiments, PRKN levels in the CSF of a subject treated by the methods are increased compared to PRKN levels in the CSF of a subject not so treated.
[0128] In some embodiments, the UPDRS score of a subject treated by the method is improved compared to the UPDRS score of a subject not so treated.
[0129] In some embodiments, the subject's neurons express reduced amounts of α-synuclein and / or include reduced amounts of Lewy bodies following contact with the recombinant gene therapy vector.
[0130] Other features and advantages of the invention will be apparent from and encompassed by the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0131] This patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication with one or more color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0132] Figure 1 Examples of expression cassettes of the present disclosure are shown.
[0133] Figures 2A-2J The negative control ( Figure 2A ) and positive control ( Figure 2B Representative micrographs of gene expression in SH-SY5Y cells. The expression cassettes were tested in duplicate: WT ( Figure 2C and Figure 2D )、CO1( Figure 2E and Figure 2F )、CO2( Figure 2G and Figure 2H ), and CO3( Figure 2I and Figure 2J ).
[0134] Figure 2K The percentage of GFP+ cells is shown.
[0135] Figure 2L Fluorescence intensity of GFP+ cells is shown.
[0136] Figure 3 Shown is an enzyme-linked immunosorbent assay (ELISA) for Parkin performed on cell lysates from transfected cells.
[0137] Figures 4A-4D The negative control ( Figure 4A )、WT( Figure 4B )、CO1( Figure 4C ) or CO4( Figure 4D ) are representative micrographs of gene expression in SH-SY5Y cells.
[0138] Figure 4E The percentage of GFP+ cells is shown.
[0139] Figure 4F Fluorescence intensity of GFP+ cells is shown.
[0140] Figure 5 Shown is an enzyme-linked immunosorbent assay (ELISA) for Parkin performed on cell lysates from transfected cells.
[0141] Figures 6A-6D The negative control ( Figure 6A )、WT( Figure 6B )、CO1( Figure 6C ) or CO4( Figure 6D Representative micrographs of gene expression in induced pluripotent stem cell (iPSC)-derived Parkin knockout dopaminergic precursor cells.
[0142] Figure 6E The percentage of GFP+ cells and the fluorescence intensity of GFP+ cells are shown. For each of WT, CO1 and CO$, the left bar indicates the % change in GFP intensity relative to WT, and the right bar indicates the % GFP+ cells.
[0143] Figure 7 Examples of AAV vector expression cassettes of the present disclosure are shown.
[0144] Figure 8 A diagram of the transgene cassette and its various elements is shown.
[0145] Figure 9 Parkin transgene expression in SH-SY5Y cells is shown for each of the constructs listed in Table 10.
[0146] Figure 10 Parkin transgene expression in iPSC-derived Parkin knockout dopaminergic precursor cells is shown for each of the constructs listed in Table 11.
[0147] Figures 11A-11D Shown are representative fluorescence micrographs of iPSC-derived Parkin knockout dopaminergic precursor cells transfected with each of the constructs in Table 11, imaged in bright field ( Figure 11A ), or by Parkin immunofluorescence ( Figure 11B ), neuronal marker NeuN ( Figure 11C ) or the astrocyte marker GFAP ( Figure 11D ) imaging.
[0148] Figure 12A Shown Figure 11A Magnified image of .
[0149] Figure 12B Shown Figure 11B Magnified image of .
[0150] Figure 12C Shown Figure 11C Magnified image of .
[0151] Figure 12D Shown Figure 11D Magnified image of .
[0152] Figure 13 Illustrative construct design diagrams are provided. DETAILED DESCRIPTION
[0153] The present disclosure provides, in part, compositions and methods for treating, preventing, inhibiting or delaying central nervous system degeneration (e.g., for treating Parkinson's disease). Specifically, the inventors disclose various embodiments of recombinant gene therapy vectors, comprising Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, α-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene or glucocerebrosidase (GBA) gene or its functional fragment or variant. As used herein, the terms "gene" or "transgene" are used interchangeably and refer to a polynucleotide sequence encoding a polypeptide or protein, such as any of the proteins disclosed in Table 1.
[0154] The present disclosure further includes various embodiments of a gene editing system, comprising a Cas protein, a guide RNA, and a repair template, wherein the repair template comprises Parkinson protein 2, an E3 ubiquitin-protein ligase (PARK2) gene, a PTEN-induced putative kinase 1 (PINK1) gene, a protein deglycosylation enzyme DJ-1 (DJ-1) gene, a leucine-rich repeat kinase 2 (LRRK2) gene, an α-synuclein (SCNA) gene, a proto-oncogene c-Rel (c-Rel) gene, an ubiquitin-like modifier activating enzyme (ATG7) gene, a synaptic vesicle amine transporter (VMAT2) gene, or a glucocerebrosidase (GBA) gene or a functional fragment or variant thereof.
[0155] The present disclosure further includes a method for inhibiting the degeneration or death of dopaminergic neurons with a mutated PARK2 gene and a method for treating the Parkinson's disease in a subject suffering from or at risk of Parkinson's disease or inhibiting the onset or progression of the Parkinson's disease. In a specific embodiment, Parkinson's disease is early-onset or juvenile Parkinson's disease. In certain embodiments, it is associated with or caused by an autosomal recessive mutation in, for example, the subject's PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2 or GBA gene. In some embodiments, a recombinant gene therapy construct is delivered to the subject's body, or more specifically, the brain, using a viral vector (e.g., adeno-associated virus (AAV)). Also provided are recombinant gene therapy vectors or gene editing systems for PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2 or GBA. Table 1 provides protein sequences. These genes are expressed as various isoforms. For example, and without limiting the disclosure to PARK2, Table 2 provides isoforms of PARK2. Table 3 provides polynucleotide sequences. Table 4 provides polynucleotide sequences of isoforms of PARK2. The present disclosure provides compositions and methods comprising or encoding any of the isoforms as proteins or polynucleotides, including codon-optimized polynucleotides and splice or non-splice variants.
[0156] Table 1: Non-limiting examples of genes associated with CNS degeneration
[0157]
[0158]
[0159]
[0160]
[0161] Table 2: PARK2 isoforms
[0162]
[0163]
[0164]
[0165] Table 3: Polynucleotides of non-limiting exemplary genes associated with CNS degeneration
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176] Table 4: Polynucleotides of PARK2 isoforms
[0177]
[0178]
[0179]
[0180]
[0181]
[0182] In a specific embodiment, compositions and methods disclosed herein contemplate the purposes of any functional variant and functional fragment of these proteins or polynucleotide sequences.Functional fragment and variant retain the biological properties or activity of corresponding wild-type protein, although in some cases, compared with wild-type protein, these properties or activity can be reduced to, for example, about 50%, about 60%, about 70% or about 80%, or compared with wild-type protein, increase by, for example, 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times or 5 times. In certain embodiments, the functional fragment or variant of protein have at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity with the corresponding wild-type protein. In certain embodiments, the functional fragment of protein comprises at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% of the corresponding wild-type protein.
[0183] In another aspect, the present disclosure provides a recombinant gene therapy vector comprising a transgenic polynucleotide encoding an E3 ubiquitin protein ligase (PARK2), wherein the transgenic polynucleotide is operably linked to a eukaryotic active promoter sequence. In some embodiments, the transgenic polynucleotide shares at least 95% identity with one of SEQ ID NOs: 35-38.
[0184] In certain embodiments, the present disclosure provides a codon-optimized polynucleotide encoding PARK2. In some cases, the entire transgenic sequence is codon-optimized for expression in mammalian cells. Codon optimization refers to the discovery that the frequency of occurrence of synonymous codons (i.e., codons encoding the same amino acid) in the coding DNA is biased in different species. This codon degeneracy allows the same polypeptide to be encoded by a variety of nucleotide sequences. Various codon optimization methods are known in the art and include, for example, at least the methods disclosed in U.S. Patents 5,786,464 and 6,114,148.
[0185] In some embodiments, the codon-optimized polynucleotide encoding PARK2 comprises fewer CpG islands than the native human polynucleotide sequence encoding human PARK2. For example, in some embodiments, the native human sequence comprises 95 CpG islands, while the codon-optimized polynucleotide comprises less than 95, less than 90, less than 85, less than 80, less than 75, less than 70, less than 65, less than 60, less than 55, less than 50, less than 45, less than 40, less than 35, less than 30, less than 25, less than 20, less than 15, less than 10, less than 5 or no CpG islands. In some embodiments, the codon-optimized polynucleotide sequence comprises 2-20, 5-20, about 5 or about 10 CpG islands. In some embodiments, the codon-optimized polynucleotide sequence comprises one or more CpG islands. In some embodiments, the expression cassette shares at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any one of SEQ ID NOs: 39-58. In some embodiments, the expression cassette comprises, consists essentially of, or consists of a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any one of SEQ ID NOs: 39-58.
[0186] In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the vector includes two AAV inverted terminal repeats (ITRs) flanking the expression cassette. In some embodiments, the AAV has a serotype of AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10, or AAVrh74. In some embodiments, the recombinant gene therapy vector includes a self-complementary AAV. In some embodiments, the recombinant gene therapy vector includes a single-stranded AAV. In some embodiments, the AAV is a wild-type AAV or a modified AAV. In some embodiments, AAV includes a capsid protein having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a wild-type VP1, VP2, or VP3 capsid protein.
[0187] In another aspect, the present disclosure provides a host cell comprising any one of the aforementioned recombinant gene therapy vectors. Exemplary host cells include HEK293, 293T, HeLa, Vero, and Sf9 cells.
[0188] In another aspect, the present disclosure provides a method for inhibiting, reducing, or delaying degeneration or death of dopaminergic neurons, wherein the dopaminergic neurons include a mutation in a gene associated with Parkinson's disease (PD), wherein the mutated gene is the Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene, the method comprising contacting the neurons with a recombinant gene therapy vector of the present disclosure, wherein after contact with the recombinant gene therapy vector, the neurons express the wild-type protein. The method can be performed in vitro or in vivo, for example, in a subject in need thereof.
[0189] In some embodiments, the neurons express reduced amounts of alpha-synuclein and / or include reduced amounts of Lewy bodies after contact with the recombinant gene therapy vector. In some embodiments, alpha-synuclein and / or the inclusion of reduced amounts of Lewy bodies is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or more.
[0190] In some embodiments, the neurons express reduced amounts of monoamine oxidase after contact with the recombinant gene therapy vector. In some implementations, the amount of monoamine oxidase is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or more.
[0191] In some embodiments, the neurons produce and / or release an increased amount of dopamine after contact with the recombinant gene therapy vector. In some embodiments, the amount of dopamine produced and / or released increases by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or more.
[0192] In some embodiments, the neurons experience increased mitophagy after contact with the recombinant gene therapy vector. In some embodiments, mitophagy is increased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or more.
[0193] In some embodiments, the neurons express a lower amount of monoamine oxidase compared to the amount of monoamine oxidase expressed in neurons not contacted with the recombinant gene therapy vector, optionally wherein the lower amount is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% lower than the amount expressed in the neurons not contacted with the recombinant gene therapy vector.
[0194] In some embodiments, the amount of dopamine produced and / or released by the neurons is increased compared to the amount of dopamine produced and / or released by neurons that have not been contacted with the recombinant gene therapy vector, optionally wherein the increase is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least 10-fold greater than the amount produced and / or released by the neurons that have not been contacted with the recombinant gene therapy vector.
[0195] In some embodiments, the amount of autophagy experienced by the neurons is increased compared to the amount of autophagy experienced by neurons not contacted with the recombinant gene therapy vector, optionally wherein the increase is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least 10-fold greater than the amount experienced by the neurons not contacted with the recombinant gene therapy vector.
[0196] In some embodiments, the neurons are primary tyrosine hydroxylase-positive neurons. In some embodiments, the neurons are generated from induced pluripotent stem cells prepared from cells obtained from a subject diagnosed with Parkinson's disease.
[0197] In another aspect, the present disclosure provides a method for treating Parkinson's disease (PD) in a subject having or at risk of developing the PD or inhibiting the onset or progression of the PD, the method comprising administering to the subject a gene therapy vector described in the present disclosure, wherein administration of the recombinant gene therapy vector treats the Parkinson's disease in the subject or inhibits or delays the onset or progression of the Parkinson's disease.
[0198] In some embodiments, the PD is early-onset PD. In some embodiments, the PD is early-onset autosomal recessive PD. In some embodiments, the subject comprises a mutation in the PARK2 gene.
[0199] In some embodiments, the gene therapy vector comprises an expression cassette comprising a transgene encoding PARK2 or a functional fragment or variant thereof. In some embodiments, the PARK2 comprises the amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto. In some embodiments, the transgenic polynucleotide shares at least 95% identity with one of SEQ ID NOs: 35-38.
[0200] In some embodiments, the administering step comprises systemic, parenteral, intravenous, cerebral, cerebrospinal, intrathecal, intracisternal, intraputical, intrahippocampal, intrastriatal, or intracerebroventricular administration.
[0201] In some embodiments, the administering step comprises intravenous, brain, cerebrospinal, intrathecal, intracisternal, intraputical, intrahippocampal, intrastriatal, or intracerebroventricular injection.
[0202] In some embodiments, the administering step comprises intrathecal injection using Trendelenburg tilt.
[0203] In some embodiments, the administering step comprises injecting directly into the substantia nigra pars compacta of the brain.
[0204] In some embodiments, the administering step comprises introducing the recombinant gene therapy vector into the brain or cerebrospinal fluid (CSF) of the subject.
[0205] In some embodiments, the subject is administered 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0206] In some embodiments, 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0207] In some embodiments, 1×10 9 -1×10 14 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0208] In some embodiments, the subject is administered 1×10 7 -1×10 9 vector genomes of the gene therapy vector per kilogram (vg / kg) of the subject's body weight.
[0209] In some embodiments, the subject is an adult or a child.
[0210] In some embodiments, the number of dopaminergic neurons in the subject after said administering step is greater than the number of dopaminergic neurons in the subject before said administering step.
[0211] In some embodiments, the dopamine level in the subject after said administering step is higher than the dopamine level in the subject before said administering step.
[0212] In some embodiments, the number of dopaminergic neurons in a subject treated by the method is increased compared to the number of dopaminergic neurons in a subject not so treated.
[0213] In some embodiments, dopamine levels in a subject treated by the methods are increased compared to dopamine levels in a subject not so treated.
[0214] In some embodiments, dopamine levels in the substantia nigra of a subject treated by the method are increased compared to dopamine levels in the substantia nigra of a subject not so treated.
[0215] In some embodiments, the level of PRKN in the subject's CSF after said administering step is higher than the level of PRKN in the subject's CSF before said administering step.
[0216] In some embodiments, the subject's Unified Parkinson's Disease Rating Scale (UPDRS) score is improved prior to said administering step compared to the subject's UPDRS score prior to said administering step.
[0217] In some embodiments, PRKN levels in the CSF of a subject treated by the methods are increased compared to PRKN levels in the CSF of a subject not so treated.
[0218] In some embodiments, the UPDRS score of a subject treated by the method is improved compared to the UPDRS score of a subject not so treated.
[0219] In some embodiments, the subject's neurons express reduced amounts of α-synuclein and / or include reduced amounts of Lewy bodies following contact with the recombinant gene therapy vector.
[0220] definition
[0221] Unless otherwise defined, the implication of all technical terms and scientific terms used herein is identical with the implication generally understood by those of ordinary skill in the art to which the present invention relates. Although methods and materials similar to or equivalent to those described herein and materials can be used in the practice of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are expressly incorporated by reference in their entirety. In the event of a conflict, this specification sheet (including definitions) shall prevail. In addition, materials, methods and examples described herein are merely illustrative, and not restrictive.
[0222] All publications and patents mentioned herein are incorporated by reference in their entirety to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In the event of a conflict, the present application (including any definitions herein) will control. However, reference to any reference, article, publication, patent, patent disclosure, or patent application cited herein is not, and should not be taken as, an admission or any form of suggestion that it constitutes active prior art or forms part of the common general knowledge in any country in the world.
[0223] In this specification, any concentration range, percentage range, ratio range or integer range should be understood to include the value of any integer in the range, and its fraction (such as one tenth and one hundredth of an integer) when appropriate, unless otherwise stated. When immediately before a number or numerical value, the term "about" means that the range of the number or numerical value is plus or minus 10%. It should be understood that, as used herein, the terms "one" and "a kind of" refer to "one or more" in the listed components, unless otherwise stated. The use of alternatives (for example, "or") should be understood to mean one, two or any combination thereof in the alternatives. The term "and / or" should be understood to mean one or two in the alternatives. As used herein, the terms "comprising" and "including" are used synonymously.
[0224] The abbreviations PRKN and PARK2 are used interchangeably herein.
[0225] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0226] Adeno-associated virus (AAV)
[0227] As used herein, the term "AAV" is a standard abbreviation for adeno-associated virus or its recombinant vector. Adeno-associated virus is a single-stranded DNA parvovirus generated only in cells, in which some functions are provided by co-infection helper viruses. Basic information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169 to 228 and Berns, 1990, Virology, pp. 1743 to 1764, Raven Press, (New York). It is fully expected that the same principles described in these reviews will be applicable to other AAV serotypes characterized after the publication date of the reviews, because it is well known that various serotypes are closely related in structure and function, even at the genetic level. (See, e.g., Blacklowe, 1988, Parvoviruses and Human Disease, ed. JR Pattison, pp. 165-174; and Rose, Comprehensive Virology 3: 1-61 (1974). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all carry three related capsid proteins, such as those expressed in AAV2. The degree of relatedness is further indicated by heteroduplex analysis, which shows extensive cross-hybridization between serotypes along the length of the genome; and the presence of similar self-annealing segments at the termini, which correspond to "inverted terminal repeats (ITRs)." Similar infectivity patterns also suggest that the replication function of each serotype is under similar regulatory control.
[0228] As used herein, "AAV vector" or "rAAV vector" refers to a recombinant vector comprising one or more polynucleotides of interest (or transgenes) flanked by AAV terminal repeats (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in host cells transfected with plasmids encoding and expressing the rep and cap gene products. Alternatively, host cells that have been stably engineered to express the rep and cap genes can be used to package AAV vectors into infectious particles.
[0229] As used herein, "AAV virion" or "AAV virus particle" or "AAV vector particle" refers to a virus particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. As used herein, if the particle includes a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is generally referred to as an "AAV vector particle" or simply as an "AAV vector". Therefore, the production of an AAV vector particle necessarily includes the production of an AAV vector, such that the AAV vector particle contains the vector.
[0230] Adeno-associated virus (AAV) is a replication-deficient parvovirus with a single-stranded DNA genome of approximately 4.7 kb in length containing two 145-nucleotide inverted terminal repeats (ITRs). There are multiple known AAV variants, which are sometimes referred to as serotypes when classified by antigenic epitopes. The nucleotide sequences of the genomes of AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and in Srivastava et al., J. Virol., 45:555-564 {1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the complete genome of AAV-5 is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_00 1862; at least portions of the AAV-7 and AAV-8 genomes are provided in GenBank accession numbers AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., Journal of Virology, 78:6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1):67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2):375-383 (2004); the sequence of the AAVrh.74 genome is provided in U.S. Pat. No. 9,434,928, which is incorporated herein by reference. Cis-acting sequences that direct viral DNA replication (rep), encapsidation / packaging, and host cell chromosomal integration are contained in the AAV ITRs. Three AAV promoters (designated as p5, p19, and p40 relative to their map positions) drive expression of two AAV internal open reading frames encoding the rep and cap genes. Two rep promoters (p5 and p19) coupled to differential splicing of a single AAV intron (at nucleotides 2107 and 2227) result in the production of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. Rep proteins have multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed by the p40 promoter and encodes three capsid proteins, VP1, VP2, and VP3. Alternative splicing and a non-consensus translation start site are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome.The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).
[0231] AAV has unique characteristics, which makes it attractive as a vector for delivering exogenous DNA to cells, for example in gene therapy. AAV infection of cells in culture is non-cytopathic, and natural infection in humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells, thereby allowing the possibility of targeting many different tissues in vivo. Moreover, AAV transduces slowly dividing and non-dividing cells and can substantially last the lifespan of these cells as transcriptionally active nuclear episomes (extrachromosomal elements). The AAV proviral genome is inserted as cloned DNA in a plasmid, which makes it possible to construct a recombinant genome. In addition, since the signal for directing AAV replication and genome encapsidation is contained in the ITR of the AAV genome, some or all of the internal approximately 4.3kb genome (encoding replication and structural capsid proteins, rep-cap) can be replaced with exogenous DNA. In order to produce AAV vectors, rep protein and cap protein can be provided in trans. Another notable feature of AAV is that it is an extremely stable and robust virus. It readily withstands the conditions used to inactivate adenovirus (56°C to 65°C for several hours), making cold storage of AAV less critical. AAV can even be lyophilized. Finally, AAV-infected cells do not tolerate repeated infection.
[0232] The AAV DNA in the rAAV genome can be from any AAV variant or serotype that can be derived from a recombinant virus, including but not limited to AAV variants or serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAVrh10. The generation of pseudotyped rAAVs is disclosed, for example, in WO 01 / 83692. Other types of rAAV variants, such as rAAVs with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art. To promote eye-specific expression, AAV6, AAV8, or AAV9 can be used.
[0233] In some cases, rAAV includes a self-complementary genome. As defined herein, the rAAV including a "self-complementary" or "double-stranded" genome refers to an rAAV that has been engineered so that the coding region of the rAAV is configured to form an intramolecular double-stranded DNA template, such as in McCarty et al., "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis" "Gene Therapy" 8 (16): 1248-54 (2001) as described. In some cases, the present disclosure contemplates the use of rAAV including a self-complementary genome, because when infecting (this transduction) rather than waiting for the cell-mediated synthesis of the second chain of the rAAV genome, the two complementary halves of scAAV will associate to form a double-stranded DNA (dsDNA) unit ready for immediate replication and transcription. It will be appreciated that rAAV comprising a self-complementary genome is likely to retain only about half of this amount (≈2.4 kb), rather than the full coding capacity found in rAAV (4.7-6 kb).
[0234] In other cases, rAAV vectors include single-stranded genomes. As defined herein, "single standard" genomes refer to non-self-complementary genomes. In most cases, non-recombinant AAVs have single-stranded DNA genomes. There are some indications that rAAV should be scAAV to achieve effective transduction of cells (such as eye cells). However, the present disclosure contemplates rAAV vectors that may have single-stranded genomes rather than self-complementary genomes, wherein it is understood that other genetic modifications of rAAV vectors may be beneficial for obtaining optimal gene transcription in target cells. In some cases, the present disclosure relates to single-stranded rAAV vectors that can achieve effective gene transfer to the anterior segment in the mouse eye. See Wang et al., "Single stranded adeno-associated virus achieves efficient gene transfer to the anterior segment in the mouse eye" PLoS ONE 12 (8): e0182473 (2017).
[0235] In some cases, the rAAV vector is serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13 or AAVrh10. The production of pseudotyped rAAV is disclosed in, for example, WO 01 / 83692. Other types of rAAV variants, such as rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). In some cases, the rAAV vector is serotype AAV9. In some embodiments, the rAAV vector is serotype AAV9 and includes a single-stranded genome. In some embodiments, the rAAV vector is serotype AAV9 and includes a self-complementary genome. In some embodiments, the rAAV vector includes an inverted terminal repeat (ITR) sequence of AAV2. In some embodiments, the rAAV vector comprises an AAV2 genome, such that the rAAV vector is an AAV-2 / 9 vector, an AAV-2 / 6 vector, or an AAV-2 / 8 vector.
[0236] The full-length and capsid gene sequences of most known AAVs are provided in U.S. Patent No. 8,524,446, which is incorporated herein by reference in its entirety.
[0237] The AAV vector may include a wild-type AAV sequence, or it may include one or more modifications to a wild-type AAV sequence. In certain embodiments, the AAV vector includes one or more amino acid modifications, such as substitutions, deletions, or insertions, within the capsid protein (e.g., VP1, VP2, and / or VP3). In certain embodiments, the modifications provide reduced immunogenicity when the AAV vector is provided to a subject.
[0238] promoter
[0239] In some embodiments, the polynucleotide sequence encoding wild-type PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2 or GBA protein or its functional variant or fragment is operably linked to a CMV promoter. The present disclosure further contemplates the use of other promoter sequences. Promoters that can be used in the embodiments of the present disclosure include, but are not limited to, cytomegalovirus (CMV) promoter, phosphoglycerate kinase (PGK) promoter, or promoter sequences comprising a CMV enhancer and a chicken β-actin promoter and a portion of the rabbit β-globin gene (CAG). In some cases, the promoter can be a synthetic promoter. Schlabach et al., "Synthetic design of strong promoters," Proc Natl Acad Sci USA, February 9, 2010; 107(6): 2538-2543, provides exemplary synthetic promoters.
[0240] In some cases, the polynucleotide sequence encoding a therapeutic protein or wild-type PARK2, PINK1, LRRK2, SCNA, c-Rel, ATG7, VMAT2 or GBA protein or its functional variant or fragment is operably linked to an inducible promoter. The polynucleotide sequence operably linked to an inducible promoter can be configured to cause the polynucleotide sequence to be transcribed or expressed in response to the addition or accumulation of a medicament or in response to the removal, degradation or dilution of a medicament. The medicament can be a drug. The medicament can be one of tetracycline or its derivatives, including but not limited to doxycycline. In some cases, the inducible promoter is a tet-on promoter, a tet-off promoter, a chemically regulated promoter, a physically regulated promoter (i.e., a promoter that responds to the presence or absence of light or to low or high temperatures). The list of the inducible promoters is non-restrictive.
[0241] As used herein, "eukaryotic active promoter" or "promoter" are used interchangeably and refer to a promoter that can promote the initiation of RNA transcription of a polynucleotide from a eukaryotic cell. In some cases, the promoter is a tissue-specific promoter, such as a promoter that can drive expression to a greater extent in neurons than in non-neuronal cells. In some embodiments, the tissue-specific promoter is selected from a list of neuron-specific promoters consisting of: hSYN1 (human synaptobrevin), INA (α-filament nectin), NES (nestin), tyrosine hydroxylase (TH), forkhead box A2 (FOXA2), calmodulin-dependent protein kinase II (CaMKII), and neuron-specific enolase (NSE). In some cases, the promoter is a ubiquitous promoter. "Ubiquitous promoter" refers to a promoter that is non-tissue-specific under experimental or clinical conditions. In some cases, the ubiquitous promoter is selected from the group consisting of: CMV, CAG, UBC, PGK, EF1-α, GAPDH, SV40, HBV, chicken β-actin, and human β-actin.
[0242] In some embodiments, the promoter sequence is selected from Table 5 and sequences at least 95%, at least 98%, or at least 99% identical thereto.
[0243] Table 5
[0244]
[0245]
[0246] Other illustrative examples of promoters are the SV40 late promoter from simian virus 40, the baculovirus polyhedral enhancer / promoter element, herpes simplex virus thymidine kinase (HSV tk), the immediate early promoter from cytomegalovirus (CMV), and various retroviral promoters containing LTR elements. Inducible promoters include heavy metal ion inducible promoters (such as the mouse mammary tumor virus (mMTV) promoter or various growth hormone promoters) and promoters from T7 phage that are active in the presence of T7 RNA polymerase. By way of example, examples of tissue-specific promoters include various surfactin promoters (for expression in the lung), myosin promoters (for expression in muscle), and albumin promoters (for expression in the liver). A wide variety of other promoters are known and are generally available in the art, and the sequences of many such promoters are available in sequence databases such as the GenBank database.
[0247] In some embodiments, the vector further comprises a CMV enhancer.
[0248] Other regulatory elements
[0249] In some cases, the vectors of the present disclosure further comprise one or more regulatory elements selected from the group consisting of an enhancer, an intron, a poly-A signal, a 2A peptide coding sequence, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), and a hepatitis B posttranscriptional regulatory element (HPRE).
[0250] In certain embodiments, the vector includes one or more enhancers. In a specific embodiment, the enhancer is a CMV enhancer sequence, a GAPDH enhancer sequence, a beta actin enhancer sequence or an EF1-α enhancer sequence. The aforementioned sequence is known in the art. For example, the sequence of the CMV immediate early (IE) enhancer is: CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA
[0251] (SEQ ID NO:79)
[0252] In certain embodiments, the vector comprises one or more introns. In particular embodiments, the intron is a rabbit globin intron sequence, a chicken beta actin intron sequence, a synthetic intron sequence, or an EF1-alpha intron sequence.
[0253] In certain embodiments, the vector comprises a polyA sequence. In specific embodiments, the polyA sequence is a rabbit globin polyA sequence, a human growth hormone polyA sequence, a bovine growth hormone polyA sequence, a PGK polyA sequence, an SV40 polyA sequence, or a TK polyA sequence. In some embodiments, the polyA signal can be a bovine growth hormone polyadenylation signal (bGHpA).
[0254] In certain embodiments, the vector comprises one or more transcription stabilizing elements. In specific embodiments, the transcription stabilizing element is a WPRE sequence, an HPRE sequence, a scaffold attachment region, a 3'UTR, or a 5'UTR. In specific embodiments, the vector comprises both a 5'UTR and a 3'UTR.
[0255] In some embodiments, the vector comprises a 5' untranslated region (UTR) selected from Table 6.
[0256] Table 6
[0257]
[0258]
[0259]
[0260] In some embodiments, the vector comprises a 3' untranslated region selected from Table 7.
[0261] Table 7
[0262]
[0263]
[0264] In some embodiments, the vector comprises a polyadenylation sequence (polyA) selected from Table 8.
[0265] Table 8
[0266]
[0267] An exemplary expression cassette is Figure 13 In some embodiments, the expression cassette comprises, consists essentially of, or consists of a polynucleotide sequence that shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with any one of SEQ ID NOs: 39-58. In some embodiments, the expression cassette comprises, consists essentially of, or consists of a polynucleotide sequence that shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with any one of SEQ ID NOs: 39-58, and does not comprise a sequence encoding a therapeutic gene product. In some embodiments, the sequence encoding the therapeutic gene product is replaced by a sequence encoding a different therapeutic gene product.
[0268] In one embodiment, the expression cassette comprises, in 5' to 3' order, the HuBA promoter, a transgene, WPRE(x), and pA globin-Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0269] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CMV promoter, a TPL-eMLP enhancer, a transgene, WPRE, and pA-globin-Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0270] In one embodiment, the expression cassette comprises, in 5' to 3' order, the Syn promoter, the transgene, WPRE(r), the 3'UTR (globin), and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0271] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CBA promoter, a transgene, and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0272] In one embodiment, the expression cassette comprises, in 5' to 3' order, the EF1α promoter, a transgene, and pA globin-Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0273] In one embodiment, the expression cassette comprises, in 5' to 3' order, the HuBA promoter, a transgene, R2V17, and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0274] In one embodiment, the expression cassette comprises, in 5' to 3' order, the Syn promoter, the transgene, WPRE(x), the 3'UTR (globin), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0275] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CaMKIIa promoter, a transgene, WPRE(r), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0276] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CMV promoter, a TPL-eMLP enhancer, a transgene, WPRE(r), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0277] In one embodiment, the expression cassette comprises, in 5' to 3' order, the HuBA promoter, a transgene, and pAGH-hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0278] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CMV promoter, a TPL / eMLP enhancer, a transgene, R2V17, a 3'UTR (globin), and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0279] In one embodiment, the expression cassette comprises, in 5' to 3' order, the EF1α promoter, a transgene, WPRE(r), and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0280] In one embodiment, the expression cassette comprises, in 5' to 3' order, a Syn promoter, a transgene, R2V17, and pA globin-Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0281] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CaMKIIa promoter, a transgene, R2V17, and pA-globin Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0282] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CBA promoter, a transgene, WPRE(x), a 3'UTR (globin), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0283] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CBA promoter, a transgene, a 3'UTR (globin), and pA-globin-Oc. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0284] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CaMKIIa promoter, a transgene, R2V17, and pAGH-Bt. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0285] In one embodiment, the expression cassette comprises, in 5' to 3' order, the EF1α promoter, the transgene, R2V17, the 3'UTR (globin), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0286] In one embodiment, the expression cassette comprises, in 5' to 3' order, a CMV promoter, a transgene, R2V17, a 3'UTR (globin), and pAGH-Hs. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0287] In one embodiment, the expression cassette comprises a CMV promoter, a transgene, and pAGH-Hs in 5' to 3' order. In certain embodiments, the transgene encodes PARK2, PINK1 (PARK6), DJ-1 (PARK7), LRRK2, α-synuclein, and DJ-1. In specific embodiments, it encodes PARK2, and in certain embodiments, it comprises the sequence set forth in any one of SEQ ID NOs: 27 or 35-38.
[0288] In the foregoing examples, the order of the elements 5' to the transgene was reversed such that the promoter preceded the enhancer element or the enhancer element preceded the promoter element.
[0289] Therapeutic compositions and methods
[0290] As used herein, the term "patient in need" or "subject in need" refers to a patient or subject at risk for or suffering from a disease, disorder or condition that is suitable for treatment or improvement with the recombinant gene therapy vector or gene editing system disclosed herein. For example, a patient or subject in need may be a person diagnosed with a disorder associated with degeneration of the central nervous system. The subject may have a mutation or dysfunction of PARK2, PARK6, PARK7, LRRK2 or α-synuclein, a gene or protein. "Subject" and "patient" are used interchangeably herein. The subject treated by the methods described herein may be an adult or a child. The subject may be of varying ages. The subject may be a person determined to be at risk for Parkinson's disease (e.g., early-onset Parkinson's disease).
[0291] The present invention also contemplates combination therapy. As used herein, combination includes simultaneous treatment or sequential treatment. Specifically contemplated are combinations of the methods of the present invention with standard medical treatments (e.g., corticosteroids or local decompression medications) and combinations with novel therapies. In some cases, the subject can be treated with steroids to prevent or reduce the immune response to the administration of the rAAV described herein. In some cases, the subject can receive local decompression medication before, during, or after administration of the rAAV described herein.
[0292] A therapeutically effective amount of a rAAV vector is in the range of about 1e7 vg / kg to about 5e15 vg / kg, or about 1e7 vg / kg to about 1e14 vg / kg, or about 1e8 vg / kg to about 1e14 vg / kg, or about 1e9 vg / kg to about 1e13 vg / kg, or about 1e9 vg / kg to about 1e12 vg / kg, or about 1e7 vg / kg to about 5e7 vg / kg, or about 1e8 vg / kg to about 5e8 vg / kg, or about 1e9 vg / kg to about 5e9 vg / kg, or about 1e10 vg / kg to about 5e10 vg / kg, or about 1e11 vg / kg to about 5e11 vg / kg, or about 1e12 vg / kg to about 5e12 vg / kg, or about 1e13 vg / kg to about 5e13 vg / kg. The present invention also includes compositions comprising rAAV vectors within these ranges.
[0293] For example, in certain embodiments, the therapeutically effective amount of the rAAV vector is a dose of about 1e10 vg / kg, about 2e10 vg / kg, about 3e10 vg / kg, about 4e10 vg / kg, about 5e10 vg / kg, about 6e10 vg / kg, about 7e10 vg / kg, about 8e10 vg / kg, about 9e10 vg / kg, about 1e12 vg / kg, about 2e12 vg / kg, about 3e12 vg / kg, about 4e12 vg / kg, and 5e12 vg / kg. The present invention also includes compositions comprising these doses of rAAV vectors.
[0294] In some embodiments, for example, where direct injection is performed into the substantia nigra, the therapeutically effective amount of the rAAV vector is a dose ranging from 1e7 vg to 1e11 vg, or about 1e7 vg, about 1e8 vg, about 1e9 vg, about 1e10 vg, or about 1e11 vg.
[0295] In some embodiments, for example, where direct injection into the putamen is performed, the therapeutically effective amount of the rAAV vector is a dose ranging from 1e7 vg to 1e11 vg, or about 1e7 vg, about 1e8 vg, about 1e9 vg, about 1e10 vg, or about 1e11 vg.
[0296] In some cases, the therapeutic composition comprises more than about 1e9, 1e10, or 1e11 rAAV vector genomes per volume of the therapeutic composition injected. In some cases, the therapeutic composition comprises more than about 1e9, 1e10, or 1e11 rAAV vector genomes per volume of the therapeutic composition injected. In some cases, the therapeutic composition comprises more than about 1e10, 1e11, 1e12, or 1e13 rAAV vector genomes per mL. In certain embodiments, the therapeutic composition comprises less than about 1e14, 1e13, or 1e12 rAAV vector genomes per mL.
[0297] Administration of the composition
[0298] An effective dose of the composition can be administered by routes standard in the art, including but not limited to systemic, topical, direct injection, parenteral, intravenous, brain, cerebrospinal, intrathecal, intracisternal, intraputamen, intrahippocampal, intrastriatal, or intraventricular administration. In some cases, administration comprises intravenous, brain, cerebrospinal, intrathecal, intracisternal, intraputamen, intrahippocampal, intrastriatal, or intraventricular injection. Administration can be performed by intrathecal injection with Trendelenburg tilt. Taking into account the condition being treated and the one or more target cells / tissues expressing the repaired and / or exogenously provided genes, one skilled in the art can select and / or match one or more routes of administration and one or more serotypes of the AAV components (particularly AAV ITRs and capsid proteins) of the rAAV of the present invention.
[0299] In certain embodiments, the present disclosure provides for local and systemic administration of effective doses of the rAAV and compositions of the present invention. For example, systemic administration can be administration to the circulatory system, thereby affecting the entire body. Systemic administration includes enteral administration, such as absorption through the gastrointestinal tract, and parenteral administration by injection, infusion, or implantation.
[0300] In particular, the actual administration of the rAAV of the present invention can be accomplished by using any physical method for transporting the rAAV recombinant vector to the target tissue of the animal. Administration according to the present invention includes, but is not limited to, injection into the central nervous system (CNS) or cerebrospinal fluid (CSF) and / or direct injection into the brain.
[0301] The capsid protein of rAAV can be modified so that rAAV targets a specific target tissue of interest, such as neurons or more specifically dopaminergic neurons. See, for example, Albert et al., "AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models." Genes, February 8, 2017; see also U.S. Patent No. 6,180,613 and U.S. Patent Publication No. US20120082650A1, the disclosures of which are incorporated herein by reference. In some embodiments, rAAV is injected directly into the substantia nigra of the subject.
[0302] For the purpose of administration, for example, by injection, various solutions such as sterile aqueous solutions can be used. If necessary, this aqueous solution can be buffered, and the liquid diluent is first isotonic with saline or glucose. An rAAV solution in the form of a free acid (DNA contains an acidic phosphate group) or a pharmaceutically acceptable salt can be prepared in water suitably mixed with surfactants such as hydroxypropyl cellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, and in oil. Under common storage and use conditions, these preparations contain preservatives for preventing microbial growth. In view of this, all sterile aqueous media employed can be easily obtained by standard techniques well known to those skilled in the art.
[0303] Pharmaceutical forms suitable for injectable use include, but are not limited to, sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form is sterile and should have fluidity sufficient to permit easy injection. The composition must be stable under the conditions of manufacture and storage and must be preserved against the contaminating effects of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water; ethanol; a polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.); suitable mixtures thereof; and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the desired particle size in the case of dispersions, and by the use of surfactants. Microbial protection can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In many cases, it will be preferred to include an isotonic agent, such as a sugar or sodium chloride. Absorption of injectable compositions can be prolonged by the use of absorption-retarding agents (e.g., aluminum monostearate and gelatin).
[0304] Sterile injectable solutions are prepared by incorporating the rAAV in the desired amount in an appropriate solvent along with the various other ingredients enumerated above, as needed, followed by filter sterilization. Dispersions are generally prepared by incorporating the sterilized active ingredient into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze drying techniques, which produce a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution thereof.
[0305] Transduction with rAAV can also be performed in vitro. In one embodiment, desired target cells are removed from a subject, transduced with rAAV, and reintroduced into the subject.
[0306] The suitable method of transducing the cells through transduction and reintroducing into the subject is known in the art. In one embodiment, cells can be transduced in vitro by combining rAAV with cells (for example, in suitable culture medium) and using conventional techniques (such as Southern blotting and / or PCR) or by screening those cells containing DNA of interest using selectable markers. Then, the cells through transduction can be formulated into a pharmaceutical composition, and the composition can be introduced into the subject by various techniques, such as by whole body, local, direct injection, parenteral, intravenous, brain, cerebrospinal cord, intrathecal, intracisternal, putamen, hippocampus, striatum or intraventricular administration. In some cases, administration includes intravenous, brain, cerebrospinal cord, intrathecal, intracisternal, putamen, hippocampus, striatum or intraventricular injection. It can be administered by carrying out intrathecal injection with Trendelenburg tilt.
[0307] Transduction of cells with the rAAV of the present invention causes sustained expression of genes of interest, such as PARK2, PARK6, PARK7, LRRK2 or α-synuclein. Therefore, the present invention provides a method for administering or delivering a recombinant gene therapy vector (e.g., rAAV vector) expressing a gene associated with CNS degeneration to a mammalian subject (preferably a human). These methods include transducing tissue (including but not limited to brain tissue) with one or more rAAVs of the present invention. Transduction can be performed with a gene cassette including tissue-specific control elements. For example, one embodiment of the present invention provides a method for transducing neuronal cells and brain tissue directed by neuron-specific control elements, including but not limited to those derived from promoters and other control elements rich in neurons.
[0308] Gene editing system
[0309] As used herein, gene editing system is a system including one or more proteins or polynucleotides capable of editing endogenous target genes or loci in a sequence-specific manner. In certain embodiments, gene editing system is a protein-based gene regulation system, and the protein-based gene regulation system includes a protein comprising one or more zinc finger binding domains and an enzyme domain. In certain embodiments, protein-based gene regulation system includes a protein comprising a transcription activator-like effector nuclease (TALEN) domain and an enzyme domain. Such embodiments are referred to herein as "TALEN".
[0310] 1. Zinc finger-based systems
[0311] The zinc finger-based system includes a fusion protein that includes two protein domains: a zinc finger DNA binding domain and an enzyme domain. A "zinc finger DNA binding domain," "zinc finger protein" or "ZFP" is a domain within a protein or larger protein that binds to DNA in a sequence-specific manner through one or more zinc fingers, wherein the one or more zinc fingers are amino acid sequence regions within the binding domain, and the structure of the binding domain is stabilized by the coordination of zinc ions. The zinc finger domain guides the activity of the enzyme domain to the vicinity of the sequence by binding to the target DNA sequence, and thus induces modification of endogenous target genes near the target sequence. The zinc finger domain can be engineered to bind to almost any desired sequence. Therefore, after identifying a target locus containing a target DNA sequence that is desired to be cut or recombined (e.g., a target locus in a target gene cited in Table 1), one or more zinc finger binding domains can be engineered to bind to one or more target DNA sequences in the target locus. Expression of a fusion protein comprising a zinc finger binding domain and an enzyme domain in a cell affects the modification of the target locus.
[0312] In some embodiments, the zinc finger binding domain includes one or more zinc fingers. Miller et al. (1985) Journal of the European Molecular Biology Association (EMBO J) 4:16010-1714; Rhodes (1993) Scientific American February:56-65; U.S. Patent No. 6,453,242. Typically, the length of a single zinc finger domain is about 30 amino acids. A single zinc finger binds to a trinucleotide (i.e., triplet) sequence (or a tetranucleotide sequence that overlaps one nucleotide with the tetranucleotide binding site of an adjacent zinc finger). Therefore, the length of the sequence to which the zinc finger binding domain is engineered to bind (e.g., the target sequence) will determine the number of zinc fingers in the engineered zinc finger binding domain. For example, for a ZFP whose finger motif does not bind to overlapping subsites, a six-nucleotide target sequence is bound by two finger binding domains; a nine-nucleotide target sequence is bound by a three-finger binding domain, and so on. The binding sites of individual zinc fingers (i.e., subsites) in a target site do not have to be contiguous, but can be separated by one or several nucleotides, depending on the length and nature of the amino acid sequences between the zinc fingers (i.e., interfinger linkers) in the multi-finger binding domain. In some embodiments, the DNA binding domain of an individual ZFN comprises three to six individual zinc finger repeats, each of which can recognize 9 to 18 base pairs.
[0313] Zinc finger binding domains can be engineered to bind to selected sequences. See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann Rev Biochem 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol 12:632-637; Choo et al. (2000) Curr. Opin. Biotechnol 10:411-416. Engineered zinc finger binding domains can have novel binding specificities compared to naturally occurring zinc finger proteins. Engineering approaches include, but are not limited to, rational design and various types of selection.
[0314] The selection of target DNA sequences for binding by zinc finger domains can be achieved, for example, according to the method disclosed in U.S. Patent No. 6,453,242. It will be clear to those skilled in the art that a simple visual inspection of the nucleotide sequence can also be used to select the target DNA sequence. Therefore, any means for selecting a target DNA sequence can be used in the methods described herein. The target site is generally at least 9 nucleotides in length and is therefore bound by a zinc finger binding domain comprising at least three zinc fingers. However, for example, the binding of 4 finger binding domains to 12-nucleotide target sites, 5 finger binding domains to 15-nucleotide target sites, or 6 finger binding domains to 18-nucleotide target sites is also possible. As will be apparent, the binding of larger binding domains (e.g., 7 fingers, 8 fingers, 9 fingers and more) to longer target sites is also possible.
[0315] In some embodiments, the zinc finger binding domain binds to a target DNA sequence that is at least 90% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1. In some embodiments, the zinc finger binding domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1. In some embodiments, the zinc finger binding domain binds to a target DNA sequence that is 100% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1.
[0316] The enzyme domain portion of the zinc finger fusion protein can be obtained from any endonuclease or exonuclease. Exemplary endonucleases from which the enzyme domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, the 2002-2003 catalog, New England Biolabs, Beverly, Massachusetts; and Belfort et al., (1997) Nucleic Acids Res. 25: 3379-3388. Other enzymes that cut DNA are known (e.g., 51 nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; also see Linn et al., (ed.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or their functional fragments) can be used as the source of the cleavage domain.
[0317] Exemplary restriction endonucleases (restriction enzymes) suitable for use as enzymatic domains of the ZFPs described herein are found in many species and are capable of sequence-specific binding to DNA (at a recognition site) and of cleaving DNA at or near the binding site. Certain restriction enzymes (e.g., Type IIS) cleave DNA at a site removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme Fok I catalyzes double-stranded cleavage of DNA at a distance of 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other strand. See, e.g., U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; and Li et al. (1992) Proc. Natl. Acad. Sci. USA 89:4275-4279; Li et al. (1993) Proc. Natl. Acad. Sci. USA 90:2764-2768; Kim et al. (1994a) Proc. Natl. Acad. Sci. USA 91:883-887; Kim et al. (1994b) J. Biol. Chem. 269:31,978-31,982. Thus, in one embodiment, the fusion protein comprises an enzymatic domain from at least one Type IIS restriction enzyme and one or more zinc finger binding domains.
[0318] An exemplary type IIS restriction enzyme is Fok I, whose cleavage domain is separable from the binding domain. This particular enzyme is active as a dimer. Bitinaite et al., (1998) PNAS 95: 10,570-10,575. Thus, for targeted double-stranded DNA cleavage using zinc finger-Fok I fusions, two fusion proteins, each comprising a Fok I enzymatic domain, can be used to reconstitute the catalytically active cleavage domain. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two Fok I enzymatic domains can also be used. An exemplary ZFP comprising a Fok I enzymatic domain is described in U.S. Patent No. 9,782,437.
[0319] 2. TALEN-based systems
[0320] The TALEN-based system includes a protein comprising a TAL effector DNA binding domain and an enzyme domain. It is made by fusing the TAL effector DNA binding domain to a DNA cleavage domain (a nuclease that cuts the DNA chain). The above-mentioned FokI restriction enzyme is an exemplary enzyme domain suitable for use in a TALEN-based gene regulation system.
[0321] TAL effectors are proteins secreted by Xanthomonas bacteria through their type III secretion system when the bacteria infect plants. The DNA binding domain contains a repetitive, highly conserved sequence of 33-34 amino acids, of which the 12th and 13th amino acids are different. These two positions, called repeat variable diresidues (RVDs), are highly variable and are closely related to specific nucleotide recognition. Therefore, the TAL effector domain can be engineered to bind to a specific target DNA sequence by selecting a combination of repeat fragments containing the appropriate RVDs. The nucleic acid specificity of the RVD combination is as follows: HD targets cytosine, NI targets adenine, NG targets thymine, and NN targets guanine (although in some embodiments, NN can also bind to adenine with lower specificity).
[0322] In some embodiments, the TAL effector domain binds to a target DNA sequence that is at least 90% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1. In some embodiments, the TAL effector domain binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1. In some embodiments, the TAL effector domain binds to a target DNA sequence that is 100% identical to a target DNA sequence within a target locus of a target gene selected from those listed in Table 1.
[0323] Methods and compositions for assembling TAL effector repeat sequences are known in the art. See, for example, Cermak et al., Nucleic Acids Research, 39:12, 2011, e82. Plasmids used to construct TAL effector repeat sequences are commercially available from Addgene.
[0324] In some embodiments, the gene editing system is a combined gene regulation system including a site-directed modification polypeptide and a nucleic acid guide molecule. In this article, a "site-directed modification polypeptide" refers to a polypeptide that binds to a nucleic acid guide molecule, targets a target nucleic acid sequence (e.g., a DNA sequence) through a nucleic acid guide molecule bound thereto, and modifies the target DNA sequence (e.g., cutting, mutation, or methylation of the target DNA). The site-directed modification polypeptide includes two parts, namely, a portion that binds to a nucleic acid guide and an active portion. In some embodiments, the site-directed modification polypeptide includes an active portion that exhibits site-directed enzyme activity (e.g., DNA methylation, DNA cutting, histone acetylation, histone methylation, etc.), wherein the enzyme active site is determined by a guide nucleic acid.
[0325] A nucleic acid guide comprises two parts: a first part that is complementary to and capable of binding to an endogenous target DNA sequence (referred to herein as a "DNA-binding segment") and a second part that is capable of interacting with a site-directed modifying polypeptide (referred to herein as a "protein-binding segment"). In some embodiments, the DNA-binding segment and the protein-binding segment of the nucleic acid guide are included in a single polynucleotide molecule. In some embodiments, the DNA-binding segment and the protein-binding segment of the nucleic acid guide are each included in separate polynucleotide molecules, such that the nucleic acid guide comprises two polynucleotide molecules that associate with each other to form a functional guide.
[0326] The nucleic acid guide mediates the target specificity of the bound protein / nucleic acid gene regulation system by specifically hybridizing with the target DNA sequence included in the DNA sequence of the target gene. The target gene mentioned herein covers the full-length DNA sequence of the specific gene, and the full-length DNA sequence of the specific target gene will include multiple target loci, which refer to parts of the specific target gene sequence (e.g., exons or introns). Within each target locus is a shorter DNA sequence extension referred to herein as a "target DNA sequence" or "target sequence", which can be modified by the gene regulation system described herein. Further, each target locus includes a "target modification site", which refers to the precise location of the modification induced by the gene regulation system (e.g., the location of insertion, deletion or mutation, the location of DNA breakage or the location of epigenetic modification). The gene regulation system described herein can include a single nucleic acid guide, or can include multiple nucleic acid guides (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleic acid guides).
[0327] The CRISPR / Cas system described below is an exemplary embodiment of a combined protein / nucleic acid system.
[0328] 3. CRISPR / Cas gene regulation system
[0329] In some embodiments, the gene editing system described herein is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas (CRISPR-associated) nuclease system. In such embodiments, the site-directed modifying polypeptide is a CRISPR-associated nuclease ("Cas" endonuclease), and the nucleic acid guide molecule is a guide RNA (gRNA).
[0330] Cas polypeptides refer to polypeptides that can interact with gRNA molecules and work in conjunction with gRNA molecules to home to or locate target DNA sequences, and include naturally occurring Cas proteins and engineered, altered or otherwise modified Cas proteins that differ in one or more amino acid residues from the naturally occurring Cas sequence.
[0331] In some embodiments, the Cas protein is a Cas9 protein. Cas9 is a multi-domain enzyme that uses an HNH nuclease domain to cut the target strand of DNA and uses a RuvC-like domain to cut the non-target strand. In some embodiments, a mutant of Cas9 can be produced by selective domain inactivation, which enables WT Cas9 to be converted into an enzyme-inactivated mutant (e.g., dCas9) that cannot cut DNA or a nickase mutant that can produce single-stranded DNA breaks by cutting one or the other of the target or non-target strands.
[0332] Guide RNA (gRNA) includes two segments, a DNA binding segment and a protein binding segment. In some embodiments, the protein binding segment of the gRNA is included in one RNA molecule, and the DNA binding segment is included in another separate RNA molecule. These embodiments are referred to herein as "bimolecule gRNA" or "bimolecule gRNA" or "bi-gRNA". In some embodiments, the gRNA is a single RNA molecule and is referred to herein as "single guide RNA" or "sgRNA". The term "guide RNA" or "gRNA" is inclusive and refers to both bimolecule guide RNA and sgRNA.
[0333] The protein-binding segment of the gRNA includes, in part, two complementary stretches of nucleotides that hybridize to each other to form a double-stranded RNA duplex (dsRNA duplex), which promotes binding to the Cas protein.
[0334] The DNA binding segment (or "DNA binding sequence") of the gRNA includes a nucleotide sequence that is complementary to and capable of binding to a specific sequence target DNA sequence. The protein binding segment of the gRNA interacts with the Cas polypeptide, and the interaction of the gRNA molecule with the site-directed modifying polypeptide causes Cas to bind to endogenous DNA and produce one or more modifications in or around the target DNA sequence. The precise location of the target modification site is determined by the following two factors: (i) base pairing complementarity between the gRNA and the target DNA sequence; and (ii) the position of a short motif in the target DNA sequence, which is called a protospacer adjacent motif (PAM). The PAM sequence is essential for Cas to bind to the target DNA sequence. A variety of PAM sequences are known in the art, and are suitable for use with specific Cas endonucleases (e.g., Cas9 endonucleases) are known in the art (see, for example, Nat Methods 2013 Nov; 10(11): 1116-1121 and Sci Rep. 2014; 4: 5405). In certain embodiments, the PAM sequence is positioned within 50 base pairs of the target modification site. In certain embodiments, the PAM sequence is positioned within 10 base pairs of the target modification site. The DNA sequence that can be targeted by this method is only limited by the relative distance between the PAM sequence and the target modification site and the presence of a unique 20 base pair sequence that mediates sequence specificity and gRNA-mediated Cas binding. In certain embodiments, the target modification site is positioned at the 5' end of the target locus. In certain embodiments, the target modification site is positioned at the 3' end of the target locus. In certain embodiments, the target modification site is positioned within an intron or exon of the target locus.
[0335] In some embodiments, the present disclosure provides polynucleotides encoding gRNAs. In some embodiments, the nucleic acid encoding the gRNA is included in an expression vector (e.g., a recombinant expression vector). In some embodiments, the present disclosure provides polynucleotides encoding site-directed modifying polypeptides. In some embodiments, the polynucleotides encoding site-directed modifying polypeptides are included in an expression vector (e.g., a recombinant expression vector).
[0336] a. Cas proteins
[0337] In some embodiments, the site-directed modifying polypeptide is a Cas protein. Cas molecules from various species can be used in the methods and compositions described herein, comprising Cas molecules derived from S. pyogenes, S. aureus, N. meningitidis, S. thermophiles, Acidovorax avenae, Actinobacillus pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces sp., Cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides sp.), Blastopirellulamarina, Bradyrhizobium sp.), Brevibacillus laterospoxus, Campylobacter coli, Campylobacter jejuni, Campylobacter laryngeus, Candidatus puniceispirillum, Clostridium cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheria, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, Gammaproteobacterium, Gluconacetobacter diazoensis diazotrophicus), Haemophilus parainfluenzae, Haemophilus sputomm, Helicobacter canadensis, Helicobacter cinaedi, Helicobacter ferret (Helicobacter ferret), Ilyobacter polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria monocytogenes, Listeriaceae bacterium, Methylocystis sp.), Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis, Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria meningitidis, Neisseria sp., Neisseria wadsworthii, Nitrosomonas sp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris), Rhodovulum sp., Simonsiella muelleri, Sphingomonas sp., Sporolactobacillus vineae, Staphylococcus aureus, Staphylococcus lugdunensis, Streptococcus sp., Subdoligranulum sp., Tistrella mobilis, Treponema sp., or Verminephrobacter eiseniae.
[0338] In some embodiments, the Cas protein is a Cas9 protein or a Cas9 ortholog and is selected from the group consisting of SpCas9, SpCas9-HF1, SpCas9-HF2, SpCas9-HF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9 and NmeCas9. In some embodiments, the endonuclease is selected from the group consisting of: C2C1, C2C3, Cpf1 (also known as Cas12a), Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4. Additional Cas9 orthologs are described in International PCT Publication No. WO 2015 / 071474.
[0339] In some embodiments, the Cas9 protein is a naturally occurring Cas9 protein. Exemplary naturally occurring Cas9 molecules are described in Chylinski et al., RNA Biology, 2013 10:5, 727-737. Such Cas9 molecules include the following Cas9 molecules: Cas9 molecules of cluster 1 bacterial family, cluster 2 bacterial family, cluster 3 bacterial family, cluster 4 bacterial family, cluster 5 bacterial family, cluster 6 bacterial family, cluster 7 bacterial family, cluster 8 bacterial family, cluster 9 bacterial family, cluster 10 bacterial family, cluster 11 bacterial family, cluster 12 bacterial family, cluster 13 bacterial family, cluster 14 bacterial family, cluster 15 bacterial family, cluster 16 bacterial family, cluster 17 bacterial family, cluster 18 bacterial family, cluster 19 bacterial family, cluster 20 bacterial family, cluster 21 bacterial family, cluster 22 bacterial family, cluster 23 bacterial family, cluster 24 bacterial family, cluster 25 bacterial family, cluster 26 bacterial family, cluster 27 bacterial family, cluster 28 bacterial family, cluster 29 bacterial family, cluster 30 bacterial family, cluster 31 bacterial family, cluster 32 bacterial family, cluster 33 bacterial family, cluster 34 bacterial family, cluster 35 bacterial family, cluster 36 bacterial family, cluster 37 bacterial family, and cluster 38 bacterial family. , cluster 39 bacterial family, cluster 40 bacterial family, cluster 41 bacterial family, cluster 42 bacterial family, cluster 43 bacterial family, cluster 44 bacterial family, cluster 45 bacterial family, cluster 46 bacterial family, cluster 47 bacterial family, cluster 48 bacterial family, cluster 49 bacterial family, cluster 50 bacterial family, cluster 51 bacterial family, cluster 52 bacterial family, cluster 53 bacterial family, cluster 54 bacterial family, cluster 55 bacterial family, cluster 56 bacterial family, cluster 57 bacterial family, cluster 58 bacterial family, cluster 59 bacterial family, cluster 60 bacterial family, cluster 61 bacterial family, cluster 62 bacterial family, cluster 63 bacterial family, cluster 64 bacterial family, cluster 65 bacterial family, cluster 66 bacterial family, cluster 67 bacterial family, cluster 68 bacterial family, cluster 69 bacterial family, cluster 70 bacterial family, cluster 71 bacterial family, cluster 72 bacterial family, cluster 73 bacterial family, cluster 74 bacterial family, cluster 75 bacterial family, cluster 76 bacterial family, cluster 77 bacterial family or cluster 78 bacterial family.
[0340] In some embodiments, the Cas9 protein comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the Cas9 amino acid sequence described in Chylinski et al., RNA Biol. 2013 10:5, 727-737; Hou et al., PNAS Early Edition 2013, 1-6.
[0341] In some embodiments, the Cas polypeptide comprises one or more of the following activities:
[0342] a) nickase activity, i.e., the ability to cleave a single strand (e.g., a non-complementary strand or a complementary strand) of a nucleic acid molecule;
[0343] b) double-stranded nuclease activity, i.e., the ability to cleave both strands of a double-stranded nucleic acid and produce a double-strand break, which in one embodiment is the presence of two nickase activities;
[0344] c) endonuclease activity;
[0345] d) exonuclease activity; and / or
[0346] e) Helicase activity, i.e. the ability to unwind the helical structure of double-stranded nucleic acids.
[0347] In some embodiments, Cas9 is a wild-type (WT) Cas9 protein or an ortholog. WT Cas9 includes two catalytically active domains (HNH and RuvC). WT Cas9 causes double-stranded DNA breaks based on the binding of gRNA-specific to DNA, which can be repaired by non-homologous end joining (NHEJ) or homology-directed repair (HDR). In some embodiments, Cas9 is fused to a heterologous protein that recruits DNA damage signaling proteins, exonucleases, or phosphatases to further increase the probability or rate of target sequence repair by one or another repair mechanism. In some embodiments, WT Cas9 is co-expressed with a nucleic acid repair template to promote the incorporation of exogenous nucleic acid sequences by homology-directed repair.
[0348] In some embodiments, it can be advantageous to use different Cas9 proteins (i.e., Cas9 proteins from various species) with the various provided methods in order to take advantage of various enzymatic properties of different Cas9 proteins (e.g., for different PAM sequence preferences; for increased or decreased enzymatic activity; for increased or decreased levels of cytotoxicity; to alter the balance between NHEJ, homology-directed repair, single-strand breaks, double-strand breaks, etc.).
[0349] In some embodiments, the Cas protein is a Cas9 protein derived from Streptococcus pyogenes and recognizes the PAM sequence motifs NGG, NAG, NGA (Mali et al., Science 2013; 339(6121): 823-826). In some embodiments, the Cas protein is a Cas9 protein derived from Streptococcus thermophilus and recognizes the PAM sequence motifs NGGNG and / or NNAGAAW (W=A or T) (see, e.g., Horvath et al., Science 2010; 327(5962): 167-170, and Deveau et al., J BACTERIOL 2008; 190(4): 1390-1400). In some embodiments, the Cas protein is a Cas9 protein derived from Streptococcus mutans and recognizes the PAM sequence motifs NGG and / or NAAR (R=A or G) (see, e.g., Deveau et al., Journal of Bacteriology 2008; 190(4): 1390-1400). In some embodiments, the Cas protein is a Cas9 protein derived from Staphylococcus aureus and recognizes the PAM sequence motifs NNGRR (R=A or G). In some embodiments, the Cas protein is a Cas9 protein derived from Staphylococcus aureus and recognizes the PAM sequence motifs N GRRT (R=A or G). In some embodiments, the Cas protein is a Cas9 protein derived from Staphylococcus aureus and recognizes the PAM sequence motifs N GRRV (R=A or G). In some embodiments, the Cas protein is a Cas9 protein derived from Neisseria meningitidis and recognizes the PAM sequence motifs N GATT or NGCTT (R=A or G, V=A, G or C) (see, e.g., Hou et al., Proceedings of the National Academy of Sciences of the United States of America 2013, 1-6). In the above embodiment, N can be any nucleotide residue, such as any one of A, G, C or T.
[0350] In some embodiments, polynucleotides are provided that encode Cas proteins. In some embodiments, polynucleotides encode Cas proteins that are at least 90% identical to the Cas proteins described in International PCT Publication No. WO 2015 / 071474 or Chylinski et al., RNA Biology 2013 10: 5,727-737. In some embodiments, polynucleotides encode Cas proteins that are at least 95%, 96%, 97%, 98% or 99% identical to the Cas proteins described in International PCT Publication No. WO 2015 / 071474 or Chylinski et al., RNA Biology 2013 10: 5,727-737. In some embodiments, polynucleotides encode Cas proteins that are 100% identical to the Cas proteins described in International PCT Publication No. WO 2015 / 071474 or Chylinski et al., RNA Biology 2013 10: 5,727-737.
[0351] i. Cas mutants
[0352] In some embodiments, the Cas polypeptide is engineered to change one or more properties of the Cas polypeptide. For example, in some embodiments, the Cas polypeptide includes an altered enzymatic property, for example, an altered nuclease activity (compared to a naturally occurring or other reference Cas molecule) or an altered helicase activity. In some embodiments, the engineered Cas polypeptide may have a change that changes its size, for example, a deletion of an amino acid sequence reduces its size without significantly affecting another property of the Cas polypeptide. In some embodiments, the engineered Cas polypeptide includes a change that affects PAM recognition. For example, the engineered Cas polypeptide can be altered to recognize a PAM sequence other than the PAM sequence recognized by the corresponding wild-type Cas protein.
[0353] Cas polypeptides with desired properties can be prepared in a variety of ways, including altering naturally occurring Cas polypeptides or parent Cas polypeptides to provide mutants or altered Cas polypeptides with desired properties. For example, one or more mutations can be introduced into the sequence of a parent Cas polypeptide (e.g., a naturally occurring or engineered Cas polypeptide). Such mutations and differences can include substitutions (e.g., conservative substitutions or substitutions of non-essential amino acids); insertions; or deletions. In some embodiments, the mutant Cas polypeptide includes one or more mutations (e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50 mutations) relative to the parent Cas polypeptide.
[0354] In one embodiment, the mutant Cas polypeptide includes a cutting property different from that of the naturally occurring Cas polypeptide. In some embodiments, Cas is a Cas nickase mutant. The Cas nickase mutant includes only one catalytically active domain (HNH domain or RuvC domain). The Cas nickase mutant retains DNA binding based on gRNA specificity, but is able to cut only one DNA chain, thereby causing single-strand breaks (e.g., "nicks"). In some embodiments, two complementary Cas nickase mutants (e.g., a Cas nickase mutant has an inactivated RuvC domain, and a Cas nickase mutant has an inactivated HNH domain) are expressed in the same cell, wherein the two gRNAs correspond to two corresponding target sequences; one target sequence is on the sense DNA strand, and one is on the antisense DNA strand. This double nickase system causes staggered double-strand breaks and can increase target specificity because it is impossible to produce off-target nicks close enough to produce double-strand breaks. In some embodiments, the Cas nickase mutant is co-expressed with a nucleic acid repair template to promote the incorporation of exogenous nucleic acid sequences by homology-directed repair.
[0355] In some embodiments, the Cas polypeptides described herein can be engineered to change the PAM specificity of the Cas polypeptide. In some embodiments, the PAM specificity of the mutant Cas polypeptide is different from the PAM specificity of the parent Cas polypeptide. For example, the naturally occurring Cas protein can be modified to change the PAM sequence recognized by the mutant Cas polypeptide to reduce off-target sites, improve specificity, or eliminate PAM recognition requirements. In some embodiments, the Cas protein can be modified to increase the length of the PAM recognition sequence. In some embodiments, the length of the PAM recognition sequence is at least 4, 5, 6, 7, 8, 9, 10, or 15 amino acids. Directed evolution can be used to generate Cas polypeptides that recognize different PAM sequences and / or have reduced off-target activity. For example, Esvelt et al., Nature 2011, 472(7344):499-503.
[0356] Exemplary Cas mutants are described in International PCT Publication No. WO 2015 / 161276, which is incorporated herein by reference in its entirety.
[0357] 2. gRNA
[0358] The present disclosure provides a guide RNA (gRNA) that guides a site-directed modified polypeptide to a specific target DNA sequence. The gRNA includes a DNA targeting segment and a protein binding segment. The DNA targeting segment of the gRNA includes a nucleotide sequence that is complementary to the sequence in the target DNA sequence. In this way, the DNA targeting segment of the gRNA interacts with the target DNA in a sequence-specific manner by hybridization (i.e., base pairing), and the nucleotide sequence of the DNA targeting segment determines the position in the target DNA to which the gRNA will bind. The DNA targeting segment of the gRNA can be modified (e.g., by genetic engineering) to hybridize with any desired sequence in the target DNA sequence.
[0359] The protein binding segment of the guide RNA interacts with the site-directed modifying polypeptide (e.g., Cas9 protein) to form a complex. The guide RNA guides the bound polypeptide to a specific nucleotide sequence within the target DNA through the above-mentioned DNA targeting segment. The protein binding segment of the guide RNA includes two nucleotide stretches that are complementary to each other and form a double-stranded RNA duplex.
[0360] In some embodiments, the gRNA comprises two separate RNA molecules. In such embodiments, each of the two RNA molecules comprises a nucleotide stretch that is complementary to each other, such that the complementary nucleotides of the two RNA molecules hybridize to form a double-stranded RNA duplex of the protein-binding segment. In some embodiments, the gRNA comprises a single RNA molecule (sgRNA).
[0361] The specificity of the gRNA for the target locus is mediated by the sequence of the DNA binding segment, which includes about 20 nucleotides that are complementary to the target DNA sequence in the target locus. In some embodiments, the corresponding target DNA sequence is about 20 nucleotides in length. In some embodiments, the DNA binding segment of the gRNA sequence of the present invention is at least 90% complementary to the target DNA sequence in the target locus. In some embodiments, the DNA binding segment of the gRNA sequence of the present invention is at least 95%, 96%, 97%, 98% or 99% complementary to the target DNA sequence in the target locus. In some embodiments, the DNA binding segment of the gRNA sequence of the present invention is 100% complementary to the target DNA sequence in the target locus.
[0362] In some embodiments, the DNA-binding segment of the gRNA sequence binds to a target DNA sequence that is at least 90% identical to a target DNA sequence within the target locus of a target gene selected from those listed in Table 1. In some embodiments, the RNA-binding segment of the gRNA sequence binds to a target DNA sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to a target DNA sequence within the target locus of a target gene selected from those listed in Table 1. In some embodiments, the DNA-binding segment of the gRNA sequence binds to a target DNA sequence that is 100% identical to a target DNA sequence within the target locus of a target gene selected from those listed in Table 1.
[0363] In some embodiments, the DNA binding segments of the gRNA sequences described herein are designed to minimize off-target binding using algorithms known in the art (e.g., Cas-OFF finders) to identify target sequences unique to a particular target locus or target gene.
[0364] In some embodiments, the gRNA described herein may include one or more modified nucleosides or nucleotides that introduce stability to the nuclease. In such embodiments, these modified gRNAs may induce decreased innate immunity compared to unmodified gRNAs. The term "innate immune response" includes cellular responses to exogenous nucleic acids comprising single-stranded nucleic acids typically of viral or bacterial origin that involve the induction of cytokine expression and release, particularly interferon and cell death.
[0365] In some embodiments, the gRNA described herein is modified at or near the 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of its 5' end). In some embodiments, the 5' end of the gRNA is modified by including a eukaryotic mRNA cap structure or cap analog (e.g., G(5')ppp(5')G cap analog, m7G(5')ppp(5')G cap analog, or 3'-O-Me-m7G(5')ppp(5')G anti-reverse cap analog (ARCA)). In some embodiments, the in vitro transcribed gRNA is modified by treatment with a phosphatase (e.g., calf intestinal alkaline phosphatase) to remove the 5' triphosphate group. In some embodiments, the gRNA includes a modification at or near its 3' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of its 3' end). For example, in some embodiments, the 3' end of the gRNA is modified by adding one or more (e.g., 25-200) adenine (A) residues.
[0366] In some embodiments, modified nucleosides and modified nucleotides may be present in gRNA, but may also be present in other gene regulation systems, such as mRNA-, RNAi-, or siRNA-based systems. In some embodiments, modified nucleosides and nucleotides may include one or more of the following:
[0367] a) an alteration, e.g., a substitution, of one or both of the non-linking phosphate oxygens and / or one or more of the linking phosphate oxygens in the phosphodiester backbone linkage;
[0368] b) changes, such as substitutions, of the ribose moiety (e.g., the 2' hydroxyl group on the ribose);
[0369] c) large-scale replacement of phosphate moieties with “dephospho” linkers;
[0370] d) modification or substitution of naturally occurring nucleobases;
[0371] e) substitution or modification of the ribose-phosphate backbone;
[0372] f) modification of the 3' or 5' end of the oligonucleotide, such as removal, modification or replacement of the terminal phosphate group or partial conjugation; and
[0373] g) Sugar modification.
[0374] In some embodiments, the modifications listed above can be combined to provide modified nucleosides and nucleotides that can have two, three, four or more modifications. For example, in some embodiments, modified nucleosides or nucleotides can have modified sugars and modified core bases. In some embodiments, each base of the gRNA is modified. In some embodiments, each of the phosphate groups of the gRNA molecule is replaced by a thiophosphate group.
[0375] In certain embodiments, software tools can be used to optimize the selection of gRNA in the target sequence of the user, for example, to minimize the total off-target activity across the genome. Off-target activity may be activity other than cutting. For example, for each possible gRNA selection using Streptococcus pyogenes Cas9, the software tool can identify all potential off-target sequences (before NAG or NGG PAM) across the genome, and the genome contains up to a certain number (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of mismatched base pairs. The cutting efficiency at each off-target sequence can be predicted using a weighted scheme derived from an experiment. Then, each possible gRNA can be sorted according to its predicted total off-target cutting; the top gRNA represents those gRNAs that may have the maximum on-target cutting and the minimum off-target cutting. The tool can also include other functions, such as automatic reagent design for gRNA vector construction, primer design for on-target measuring instrument (Surveyor) determination, and primer design for high-throughput detection and quantification of off-target cutting by next-generation sequencing.
[0376] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0377] Examples
[0378] Example 1
[0379] Evaluation of Parkin transgenic variants
[0380] A series of plasmid vectors were generated to evaluate the expression of Parkin transgenic variants. Figure 1 ) contains the CMV immediate early (IE) enhancer / promoter and 5'UTR, the Parkin transgene 2A linked to enhanced green fluorescent protein (eGFP), the 3'UTR, and the rabbit globin polyadenylation sequence (polyA) in 5' to 3' order. For the Parkin transgene, the wild-type sequence (WT) of human PRKN or one of four codon-optimized variants (C01 to C04) were tested. The sequences of the wild-type and codon-optimized Parkin transgenes are provided in SEQ ID NOs: 27, 35, 36, 37, and 38.
[0381] One of the considerations in the design of codon-optimized CO1 to CO4 is the number of CpG sites. A CpG island is a region of DNA in which a cytosine nucleotide is followed by a guanine nucleotide in the linear sequence of bases along its 5'→3' direction. It is known that a CpG island (which is generally defined as a polynucleotide sequence of at least 200bp, a GC percentage greater than 50% and a ratio of observed CpG to expected CpG greater than 60%) is associated with vector immunogenicity. Therefore, it is expected that reducing the number of CpG sites will improve vector performance by reducing immunogenicity. The number of CpG sites (5'-CG-3') in each Parkin codon variant is given in Table 9.
[0382] Table 9: CpG sites in exemplary Parkin codon variants
[0383] Construct The number of CpG islands SEQ ID NO: Wild type (WT) 95 27 Construct 1 (CO1) 0 35 Construct 2 (CO2) 0 36 Construct 3 (CO3) 0 37 Construct 4 (CO4) 10 38
[0384] SH-SY5Y cells, a human neuroblastoma cell line, were used to assess gene expression in cells of the neuronal lineage. SH-SY5Y cells were cultured in 96-well plates at a seeding density of 10,000 cells per well. After 24 hours, the cells were transfected with 0.10 μg of WT, CO1, CO2, or CO3 plasmids in complex with 4 μL of Fugene HD per μg of plasmid. The cells were cultured for an additional 48 hours, and then eGFP expression was measured by fluorescence microscopy.
[0385] Figures 2A-2J Representative micrographs are shown in FIG. The control is non-transfected cells ( Figure 2A ) and a known plasmid as a positive control ( Figure 2B ). The expression cassettes were tested in duplicate: WT ( Figures 2C-2D )、CO1( Figures 2E-2F )、CO2( Figures 2G-2H ) and CO3( Figures 2I-2J ). The percentage of GFP+ cells and the fluorescence intensity of GFP+ cells are plotted on Figure 2H and Figure 2K Seven days after transfection, cell lysates were collected and assayed for Parkin by enzyme-linked immunosorbent assay (ELISA). Figure 3 These experiments demonstrate that CO1 to CO3 do not increase Parkin expression but do decrease the percentage of cells expressing Parkin and the overall level of Parkin expression.
[0386] Codon variant CO4 was subsequently tested against WT and CO1. Figure 4A )、WT( Figure 4B )、CO1( Figure 4C ) or CO4( Figure 4D ) of SH-SY5Y cells, and the percentage of GFP+ ( Figure 4E ) and intensity ( Figure 4F ) was quantified. Cell lysates were assayed for Parkin expression by ELISA ( Figure 5 In SH-SY5Y cells, CO4 expression was similar to that of WT and CO1.
[0387] iPSC-derived Parkin knockout dopaminergic precursor cells were cultured in 96-well plates at a seeding density of 10,000 cells per well. After 7 days, the cells were transfected with 0.15 μg of WT, CO1, and CO4 plasmids, which were complexed with 4 μL of ViaFect per μg of plasmid. Seven days after transfection, cells were transfected in untransfected wells ( Figure 6A )、WT( Figure 6B )、CO1( Figure 6C ) or CO4( Figure 6D ) wells to assess transgene expression. Figure 6E As shown, the three transgenes (WT, CO1 and CO4) gave rise to similar percentages of GFP+ cells, but surprisingly, CO4 increased GFP intensity by 20% compared to WT.
[0388] Example 2
[0389] Selection of CO4 Parkin transgenic expression cassette
[0390] To evaluate other regulatory elements, various AAV expression cassettes were constructed as transfer plasmids for use in helper-free AAV packaging systems. Figure 7 ) contains, in 5' to 3' order, the 5' ITR of AAV2, the CMV enhancer (Enh) or no enhancer, a promoter selected from Table 5, a 5' untranslated region (UTR) selected from Table 6, a Parkin transgene variant CO4 (SEQ ID NO: 38), a 3' untranslated region selected from Table 7, a polyadenylation sequence (polyA) selected from Table 8, and the 3' ITR of AAV2. A diagram of the cassette and various elements is provided in Figure 8 To detect transgene expression in in vitro assays, a polynucleotide sequence (SEQ ID NO: 80) encoding an N-terminal FLAG / HA-tag (SEQ ID NO: 81) was inserted after the start codon on the Parkin transgene in each of the sequences listed in Table 10.
[0391] SH-SY5Y cells were cultured in 24-well plates at a seeding density of 50,000 cells per well. After 24 hours, the cells were transfected with 0.75 μg of plasmid complexed with 4 μL Fugene6 per μg of plasmid. The cells were cultured for another 48 hours, and Parkin expression was determined by performing ELISA on cell lysates using an anti-Parkin primary antibody. The results for each construct are shown in Table 10 and plotted in Table 10. Figure 9 Notably, the protein expression of neural-specific promoters (Syn and CaMKIIa) was low.
[0392] Table 10Parkin expression in SH-SY5Y cells (average value of replicates)
[0393]
[0394] iPSC-derived Parkin knockout dopaminergic precursor cells were cultured in 96-well plates at a seeding density of 10,000 cells per well. After 15 days, the cells were transfected with 0.15 μg of plasmid complexed with 4 μL of ViaFect per μg of plasmid. Two days later, Parkin expression was determined by ELISA of cell lysates using an anti-Parkin primary antibody. The results for each construct are shown in Table 11 and plotted in Table 12. Figure 10 (three replicates are shown for each construct).
[0395] Table 11Parkin expression in iPSC-derived cells (average value of replicates)
[0396]
[0397]
[0398] For fluorescence microscopy, transfected cells were fixed, stained, and imaged in bright field 8 days after transfection ( Figure 11A and Figure 12A ), or by Parkin immunofluorescence ( Figure 11B and Figure 12B ), neuronal marker NeuN ( Figure 11C and Figure 12C ) or the astrocyte marker GFAP ( Figure 11D and Figure 12D ) for imaging. Figures 12A-12D Shown Figures 11A-11D Magnified image of .
[0399] Example 3
[0400] In vivo and clinical testing of Parkin AAV gene therapy
[0401] AAV vectors were produced by packaging AAV vector genomes from constructs 1 to 20 in Example 2, specifically constructs 1, 7, 11, and 15 from Table 11. Testing was performed in rats, and one or more constructs were selected for testing in non-human primates (NHPs). Dose-finding studies were performed, and the starting dose for clinical trials was determined by measuring protein expression and observed toxicity.
[0402] The clinical trial was conducted in subjects identified as having a recessive mutation in the PRKN gene (also known as PRK2). Protein expression and observed toxicity were used to determine the optimal dose. Efficacy was assessed using a modification of the Unified Parkinson's Disease Rating Scale (UPDRS).
[0403] Example 4
[0404] In vitro testing
[0405] The recombination cassette was tested in a human neuroblastoma cell line (SH-SY5Y). (See Jiang et al., "Extracellular dopamine induces the oxidative toxicity of SH-SY5Y cells." Synapse. 2008 Nov;62(11):797-803. doi:10.1002 / syn.20554.) The genes of interest tested were parkin 2, E3 ubiquitin-protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, alpha-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene, or glucocerebrosidase (GBA) gene.
[0406] Each cell line was treated with a recombinant gene therapy vector for each gene of interest. Expression of the gene of interest was increased. The function of the gene of interest was improved. In some cases, improved mitophagy, reduced cytotoxicity, and / or reduced oxidative stress were observed.
[0407] Example 5
[0408] In vivo testing
[0409] Rodents or non-human primates with a combination of one or more known mutations in the genes of interest are treated with recombinant gene therapy vectors directed against the genes of interest. The genes of interest tested are Parkinson 2, E3 ubiquitin-protein ligase (PARK2) gene, PTEN-induced putative kinase 1 (PINK1) gene, protein deglycosylation enzyme DJ-1 (DJ-1) gene, leucine-rich repeat kinase 2 (LRRK2) gene, alpha-synuclein (SCNA) gene, proto-oncogene c-Rel (c-Rel) gene, ubiquitin-like modifier activating enzyme (ATG7) gene, synaptic vesicle amine transporter (VMAT2) gene, or glucocerebrosidase (GBA) gene.
[0410] Test subjects have one or more of the following features: dopamine (DA) loss, ≥20% nigral cell loss, movement disorders, Lewy bodies, signs of mitochondrial dysfunction, ROS, inflammation, other motor behavioral deficits, and neurodegenerative symptoms.
[0411] Animals tested for the methods of the present disclosure include non-diseased and diseased animals as well as mutant carrier animals and non-carrier animals. Animal models and illustrative motor behavior readouts for testing the methods of the present disclosure are provided in Table 12.
[0412] Table 12
[0413]
[0414]
[0415] Test subjects exhibit improvements in any one of the following features in motor behavior readouts: increased DA in the striatum, increased nigral cells, decreased Lewy bodies, improved behavioral or other motor deficits, improved mitochondrial function, decreased inflammatory markers, increased lifespan.
[0416] Example 6
[0417] Clinical trials
[0418] It is considered that parkin-type early-onset Parkinson's disease is diagnosed mainly in individuals with early-onset Parkinson's syndrome (age <40 years old), especially when it is suspected that the individual has autosomal recessive inheritance. The gene PRKN (formerly known as PARK2) that encodes the protein parkin is the main gene for which pathogenic variants are known to cause parkin-type early-onset Parkinson's disease. Parkin-type early-onset Parkinson's disease can only be diagnosed when pathogenic variants are identified on both alleles of PRKN (i.e., the individual is homozygous for the same pathogenic allele, or is compound heterozygous for two different pathogenic alleles). The frequency of variant detection varies depending on family history and age of onset.
[0419] Additional mutants associated with Parkinson's disease are provided in Table 13.
[0420] Table 13
[0421]
[0422] Human subjects with one or more Parkinson's disease-associated mutations are treated with recombinant gene therapy vectors encoding wild-type or functional variants of the mutant genes. The subjects exhibit an improvement in any of the motor behavior readouts listed in Table 12 or any of the following features: increased dopamine in the brain (particularly the substantia nigra), an increase in the number of dopaminergic neurons, increased expression of genes of interest including PRKN, or an improvement in the Unified Parkinson's Disease Rating Scale (UPDRS).
[0423] All of the above-mentioned U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety.
[0424] The present invention may be implemented in other specific forms without departing from the structure, method or other essential characteristics of the present invention as broadly described herein and claimed below. The described embodiments are considered to be merely illustrative and non-restrictive in all respects. Therefore, the scope of the present invention is indicated by the appended claims rather than by the foregoing description. All changes that fall within the meaning and scope of the equivalents of the claims will be encompassed within the scope of the claims. Sequence Listing <110> Rocket Pharmaceuticals, Inc. Keravala, Annahita Battiprolu, Pavan Prabhakar, Raj Wong, Roderick Pratumsuwan, Piratip Yalamanchi, Naveen <120> Gene therapy for CNS degeneration <130> ROPA-009 / 01WO 329952-2067 <150> US 62 / 664,006 <151> 2018-04-27 <160> 81 <170> PatentIn Version 3.5 <210> 1 <211> 465 <212> PRT <213> Homo sapiens <400> 1 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln 50 55 60 Ser Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met 65 70 75 80 Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu 85 90 95 Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu 100 105 110 Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg 115 120 125 Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn 130 135 140 Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly 145 150 155 160 Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu 165 170 175 Thr Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met 180 185 190 Ser Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu Phe 195 200 205 Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser Val 210 215 220 Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile Thr 225 230 235 240 Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser Arg 245 250 255 His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu 260 265 270 Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu Pro 275 280 285 Cys Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe 290 295 300 Arg Ile Leu Gly Glu Glu Gln Tyr Asn Arg Tyr Gln Gln Tyr Gly Ala 305 310 315 320 Glu Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly 325 330 335 Cys Gly Ala Gly Leu Leu Pro Glu Pro Asp Gln Arg Lys Val Thr Cys 340 345 350 Glu Gly Gly Asn Gly Leu Gly Cys Gly Phe Ala Phe Cys Arg Glu Cys 355 360 365 Lys Glu Ala Tyr His Glu Gly Glu Cys Ser Ala Val Phe Glu Ala Ser 370 375 380 Gly Thr Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg Ala Ala Glu Gln 385 390 395 400 Ala Arg Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys 405 410 415 Pro Cys Pro Arg Cys His Val Pro Val Glu Lys Asn Gly Gly Cys Met 420 425 430 His Met Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu Trp Cys Trp Asn 435 440 445 Cys Gly Cys Glu Trp Asn Arg Val Cys Met Gly Asp His Trp Phe Asp 450 455 460 Val 465 <210> 2 <211> 581 <212> PRT <213> Homo sapiens <400> 2 Met Ala Val Arg Gln Ala Leu Gly Arg Gly Leu Gln Leu Gly Arg Ala 1 5 10 15 Leu Leu Leu Arg Phe Thr Gly Lys Pro Gly Arg Ala Tyr Gly Leu Gly 20 25 30 Arg Pro Gly Pro Ala Ala Gly Cys Val Arg Gly Glu Arg Pro Gly Trp 35 40 45 Ala Ala Gly Pro Gly Ala Glu Pro Arg Arg Val Gly Leu Gly Leu Pro 50 55 60 Asn Arg Leu Arg Phe Phe Arg Gln Ser Val Ala Gly Leu Ala Ala Arg 65 70 75 80 Leu Gln Arg Gln Phe Val Val Arg Ala Trp Gly Cys Ala Gly Pro Cys 85 90 95 Gly Arg Ala Val Phe Leu Ala Phe Gly Leu Gly Leu Gly Leu Ile Glu 100 105 110 Glu Lys Gln Ala Glu Ser Arg Arg Ala Val Ser Ala Cys Gln Glu Ile 115 120 125 Gln Ala Ile Phe Thr Gln Lys Ser Lys Pro Gly Pro Asp Pro Leu Asp 130 135 140 Thr Arg Arg Leu Gln Gly Phe Arg Leu Glu Glu Tyr Leu Ile Gly Gln 145 150 155 160 Ser Ile Gly Lys Gly Cys Ser Ala Ala Val Tyr Glu Ala Thr Met Pro 165 170 175 Thr Leu Pro Gln Asn Leu Glu Val Thr Lys Ser Thr Gly Leu Leu Pro 180 185 190 Gly Arg Gly Pro Gly Thr Ser Ala Pro Gly Glu Gly Gln Glu Arg Ala 195 200 205 Pro Gly Ala Pro Ala Phe Pro Leu Ala Ile Lys Met Met Trp Asn Ile 210 215 220 Ser Ala Gly Ser Ser Ser Glu Ala Ile Leu Asn Thr Met Ser Gln Glu 225 230 235 240 Leu Val Pro Ala Ser Arg Val Ala Leu Ala Gly Glu Tyr Gly Ala Val 245 250 255 Thr Tyr Arg Lys Ser Lys Arg Gly Pro Lys Gln Leu Ala Pro His Pro 260 265 270 Asn Ile Ile Arg Val Leu Arg Ala Phe Thr Ser Ser Val Pro Leu Leu 275 280 285 Pro Gly Ala Leu Val Asp Tyr Pro Asp Val Leu Pro Ser Arg Leu His 290 295 300 Pro Glu Gly Leu Gly His Gly Arg Thr Leu Phe Leu Val Met Lys Asn 305 310 315 320 Tyr Pro Cys Thr Leu Arg Gln Tyr Leu Cys Val Asn Thr Pro Ser Pro 325 330 335 Arg Leu Ala Ala Met Met Leu Leu Gln Leu Leu Glu Gly Val Asp His 340 345 350 Leu Val Gln Gln Gly Ile Ala His Arg Asp Leu Lys Ser Asp Asn Ile 355 360 365 Leu Val Glu Leu Asp Pro Asp Gly Cys Pro Trp Leu Val Ile Ala Asp 370 375 380 Phe Gly Cys Cys Leu Ala Asp Glu Ser Ile Gly Leu Gln Leu Pro Phe 385 390 395 400 Ser Ser Trp Tyr Val Asp Arg Gly Gly Asn Gly Cys Leu Met Ala Pro 405 410 415 Glu Val Ser Thr Ala Arg Pro Gly Pro Arg Ala Val Ile Asp Tyr Ser 420 425 430 Lys Ala Asp Ala Trp Ala Val Gly Ala Ile Ala Tyr Glu Ile Phe Gly 435 440 445 Leu Val Asn Pro Phe Tyr Gly Gln Gly Lys Ala His Leu Glu Ser Arg 450 455 460 Ser Tyr Gln Glu Ala Gln Leu Pro Ala Leu Pro Glu Ser Val Pro Pro 465 470 475 480 Asp Val Arg Gln Leu Val Arg Ala Leu Leu Gln Arg Glu Ala Ser Lys 485 490 495 Arg Pro Ser Ala Arg Val Ala Ala Asn Val Leu His Leu Ser Leu Trp 500 505 510 Gly Glu His Ile Leu Ala Leu Lys Asn Leu Lys Leu Asp Lys Met Val 515 520 525 Gly Trp Leu Leu Gln Gln Ser Ala Ala Thr Leu Leu Ala Asn Arg Leu 530 535 540 Thr Glu Lys Cys Cys Val Glu Thr Lys Met Lys Met Leu Phe Leu Ala 545 550 555 560 Asn Leu Glu Cys Glu Thr Leu Cys Gln Ala Ala Leu Leu Leu Cys Ser 565 570 575 Trp Arg Ala Ala Leo 580 <210> 3 <211> 189 <212> PRT <213> Homo sapiens <400> 3 Met Ala Ser Lys Arg Ala Leu Val Ile Leu Ala Lys Gly Ala Glu Glu 1 5 10 15 Met Glu Thr Val Ile Pro Val Asp Val Met Arg Arg Ala Gly Ile Lys 20 25 30 Val Thr Val Ala Gly Leu Ala Gly Lys Asp Pro Val Gln Cys Ser Arg 35 40 45 Asp Val Val Ile Cys Pro Asp Ala Ser Leu Glu Asp Ala Lys Lys Glu 50 55 60 Gly Pro Tyr Asp Val Val Val Leu Pro Gly Gly Asn Leu Gly Ala Gln 65 70 75 80 Asn Leu Ser Glu Ser Ala Ala Val Lys Glu Ile Leu Lys Glu Gln Glu 85 90 95 Asn Arg Lys Gly Leu Ile Ala Ala Ile Cys Ala Gly Pro Thr Ala Leu 100 105 110 Leu Ala His Glu Ile Gly Phe Gly Ser Lys Val Thr Thr His Pro Leu 115 120 125 Ala Lys Asp Lys Met Met Asn Gly Gly His Tyr Thr Tyr Ser Glu Asn 130 135 140 Arg Val Glu Lys Asp Gly Leu Ile Leu Thr Ser Arg Gly Pro Gly Thr 145 150 155 160 Ser Phe Glu Phe Ala Leu Ala Ile Val Glu Ala Leu Asn Gly Lys Glu 165 170 175 Val Ala Ala Gln Val Lys Ala Pro Leu Val Leu Lys Asp 180 185 <210> 4 <211> 2527 <212> PRT <213> Homo sapiens <400> 4 Met Ala Ser Gly Ser Cys Gln Gly Cys Glu Glu Asp Glu Glu Thr Leu 1 5 10 15 Lys Lys Leu Ile Val Arg Leu Asn Asn Val Gln Glu Gly Lys Gln Ile 20 25 30 Glu Thr Leu Val Gln Ile Leu Glu Asp Leu Leu Val Phe Thr Tyr Ser 35 40 45 Glu Arg Ala Ser Lys Leu Phe Gln Gly Lys Asn Ile His Val Pro Leu 50 55 60 Leu Ile Val Leu Asp Ser Tyr Met Arg Val Ala Ser Val Gln Gln Val 65 70 75 80 Gly Trp Ser Leu Leu Cys Lys Leu Ile Glu Val Cys Pro Gly Thr Met 85 90 95 Gln Ser Leu Met Gly Pro Gln Asp Val Gly Asn Asp Trp Glu Val Leu 100 105 110 Gly Val His Gln Leu Ile Leu Lys Met Leu Thr Val His Asn Ala Ser 115 120 125 Val Asn Leu Ser Val Ile Gly Leu Lys Thr Leu Asp Leu Leu Leu Thr 130 135 140 Ser Gly Lys Ile Thr Leu Leu Ile Leu Asp Glu Glu Ser Asp Ile Phe 145 150 155 160 Met Leu Ile Phe Asp Ala Met His Ser Phe Pro Ala Asn Asp Glu Val 165 170 175 Gln Lys Leu Gly Cys Lys Ala Leu His Val Leu Phe Glu Arg Val Ser 180 185 190 Glu Glu Gln Leu Thr Glu Phe Val Glu Asn Lys Asp Tyr Met Ile Leu 195 200 205 Leu Ser Ala Leu Thr Asn Phe Lys Asp Glu Glu Glu Ile Val Leu His 210 215 220 Val Leu His Cys Leu His Ser Leu Ala Ile Pro Cys Asn Asn Val Glu 225 230 235 240 Val Leu Met Ser Gly Asn Val Arg Cys Tyr Asn Ile Val Val Glu Ala 245 250 255 Met Lys Ala Phe Pro Met Ser Glu Arg Ile Gln Glu Val Ser Cys Cys 260 265 270 Leu Leu His Arg Leu Thr Leu Gly Asn Phe Phe Asn Ile Leu Val Leu 275 280 285 Asn Glu Val His Glu Phe Val Val Lys Ala Val Gln Gln Tyr Pro Glu 290 295 300 Asn Ala Ala Leu Gln Ile Ser Ala Leu Ser Cys Leu Ala Leu Leu Thr 305 310 315 320 Glu Thr Ile Phe Leu Asn Gln Asp Leu Glu Glu Lys Asn Glu Asn Gln 325 330 335 Glu Asn Asp Asp Glu Gly Glu Glu Asp Lys Leu Phe Trp Leu Glu Ala 340 345 350 Cys Tyr Lys Ala Leu Thr Trp His Arg Lys Asn Lys His Val Gln Glu 355 360 365 Ala Ala Cys Trp Ala Leu Asn Asn Leu Leu Met Tyr Gln Asn Ser Leu 370 375 380 His Glu Lys Ile Gly Asp Glu Asp Gly His Phe Pro Ala His Arg Glu 385 390 395 400 Val Met Leu Ser Met Leu Met His Ser Ser Ser Lys Glu Val Phe Gln 405 410 415 Ala Ser Ala Asn Ala Leu Ser Thr Leu Leu Glu Gln Asn Val Asn Phe 420 425 430 Arg Lys Ile Leu Leu Ser Lys Gly Ile His Leu Asn Val Leu Glu Leu 435 440 445 Met Gln Lys His Ile His Ser Pro Glu Val Ala Glu Ser Gly Cys Lys 450 455 460 Met Leu Asn His Leu Phe Glu Gly Ser Asn Thr Ser Leu Asp Ile Met 465 470 475 480 Ala Ala Val Val Pro Lys Ile Leu Thr Val Met Lys Arg His Glu Thr 485 490 495 Ser Leu Pro Val Gln Leu Glu Ala Leu Arg Ala Ile Leu His Phe Ile 500 505 510 Val Pro Gly Met Pro Glu Glu Ser Arg Glu Asp Thr Glu Phe His His 515 520 525 Lys Leu Asn Met Val Lys Lys Gln Cys Phe Lys Asn Asp Ile His Lys 530 535 540 Leu Val Leu Ala Ala Leu Asn Arg Phe Ile Gly Asn Pro Gly Ile Gln 545 550 555 560 Lys Cys Gly Leu Lys Val Ile Ser Ser Ile Val His Phe Pro Asp Ala 565 570 575 Leu Glu Met Leu Ser Leu Glu Gly Ala Met Asp Ser Val Leu His Thr 580 585 590 Leu Gln Met Tyr Pro Asp Asp Gln Glu Ile Gln Cys Leu Gly Leu Ser 595 600 605 Leu Ile Gly Tyr Leu Ile Thr Lys Lys Asn Val Phe Ile Gly Thr Gly 610 615 620 His Leu Leu Ala Lys Ile Leu Val Ser Ser Leu Tyr Arg Phe Lys Asp 625 630 635 640 Val Ala Glu Ile Gln Thr Lys Gly Phe Gln Thr Ile Leu Ala Ile Leu 645 650 655 Lys Leu Ser Ala Ser Phe Ser Lys Leu Leu Val His His Ser Phe Asp 660 665 670 Leu Val Ile Phe His Gln Met Ser Ser Asn Ile Met Glu Gln Lys Asp 675 680 685 Gln Gln Phe Leu Asn Leu Cys Cys Lys Cys Phe Ala Lys Val Ala Met 690 695 700 Asp Asp Tyr Leu Lys Asn Val Met Leu Glu Arg Ala Cys Asp Gln Asn 705 710 715 720 Asn Ser Ile Met Val Glu Cys Leu Leu Leu Leu Gly Ala Asp Ala Asn 725 730 735 Gln Ala Lys Glu Gly Ser Ser Leu Ile Cys Gln Val Cys Glu Lys Glu 740 745 750 Ser Ser Pro Lys Leu Val Glu Leu Leu Leu Asn Ser Gly Ser Arg Glu 755 760 765 Gln Asp Val Arg Lys Ala Leu Thr Ile Ser Ile Gly Lys Gly Asp Ser 770 775 780 Gln Ile Ile Ser Leu Leu Leu Arg Arg Leu Ala Leu Asp Val Ala Asn 785 790 795 800 Asn Ser Ile Cys Leu Gly Gly Phe Cys Ile Gly Lys Val Glu Pro Ser 805 810 815 Trp Leu Gly Pro Leu Phe Pro Asp Lys Thr Ser Asn Leu Arg Lys Gln 820 825 830 Thr Asn Ile Ala Ser Thr Leu Ala Arg Met Val Ile Arg Tyr Gln Met 835 840 845 Lys Ser Ala Val Glu Glu Gly Thr Ala Ser Gly Ser Asp Gly Asn Phe 850 855 860 Ser Glu Asp Val Leu Ser Lys Phe Asp Glu Trp Thr Phe Ile Pro Asp 865 870 875 880 Ser Ser Met Asp Ser Val Phe Ala Gln Ser Asp Asp Leu Asp Ser Glu 885 890 895 Gly Ser Glu Gly Ser Phe Leu Val Lys Lys Lys Ser Asn Ser Ile Ser 900 905 910 Val Gly Glu Phe Tyr Arg Asp Ala Val Leu Gln Arg Cys Ser Pro Asn 915 920 925 Leu Gln Arg His Ser Asn Ser Leu Gly Pro Ile Phe Asp His Glu Asp 930 935 940 Leu Leu Lys Arg Lys Arg Lys Ile Leu Ser Ser Asp Asp Ser Leu Arg 945 950 955 960 Ser Ser Lys Leu Gln Ser His Met Arg His Ser Asp Ser Ile Ser Ser 965 970 975 Leu Ala Ser Glu Arg Glu Tyr Ile Thr Ser Leu Asp Leu Ser Ala Asn 980 985 990 Glu Leu Arg Asp Ile Asp Ala Leu Ser Gln Lys Cys Cys Ile Ser Val 995 1000 1005 His Leu Glu His Leu Glu Lys Leu Glu Leu His Gln Asn Ala Leu 1010 1015 1020 Thr Ser Phe Pro Gln Gln Leu Cys Glu Thr Leu Lys Ser Leu Thr 1025 1030 1035 His Leu Asp Leu His Ser Asn Lys Phe Thr Ser Phe Pro Ser Tyr 1040 1045 1050 Leu Leu Lys Met Ser Cys Ile Ala Asn Leu Asp Val Ser Arg Asn 1055 1060 1065 Asp Ile Gly Pro Ser Val Val Leu Asp Pro Thr Val Lys Cys Pro 1070 1075 1080 Thr Leu Lys Gln Phe Asn Leu Ser Tyr Asn Gln Leu Ser Phe Val 1085 1090 1095 Pro Glu Asn Leu Thr Asp Val Val Glu Lys Leu Glu Gln Leu Ile 1100 1105 1110 Leu Glu Gly Asn Lys Ile Ser Gly Ile Cys Ser Pro Leu Arg Leu 1115 1120 1125 Lys Glu Leu Lys Ile Leu Asn Leu Ser Lys Asn His Ile Ser Ser 1130 1135 1140 Leu Ser Glu Asn Phe Leu Glu Ala Cys Pro Lys Val Glu Ser Phe 1145 1150 1155 Ser Ala Arg Met Asn Phe Leu Ala Ala Met Pro Phe Leu Pro Pro 1160 1165 1170 Ser Met Thr Ile Leu Lys Leu Ser Gln Asn Lys Phe Ser Cys Ile 1175 1180 1185 Pro Glu Ala Ile Leu Asn Leu Pro His Leu Arg Ser Leu Asp Met 1190 1195 1200 Ser Ser Asn Asp Ile Gln Tyr Leu Pro Gly Pro Ala His Trp Lys 1205 1210 1215 Ser Leu Asn Leu Arg Glu Leu Leu Phe Ser His Asn Gln Ile Ser 1220 1225 1230 Ile Leu Asp Leu Ser Glu Lys Ala Tyr Leu Trp Ser Arg Val Glu 1235 1240 1245 Lys Leu His Leu Ser His Asn Lys Leu Lys Glu Ile Pro Pro Glu 1250 1255 1260 Ile Gly Cys Leu Glu Asn Leu Thr Ser Leu Asp Val Ser Tyr Asn 1265 1270 1275 Leu Glu Leu Arg Ser Phe Pro Asn Glu Met Gly Lys Leu Ser Lys 1280 1285 1290 Ile Trp Asp Leu Pro Leu Asp Glu Leu His Leu Asn Phe Asp Phe 1295 1300 1305 Lys His Ile Gly Cys Lys Ala Lys Asp Ile Ile Arg Phe Leu Gln 1310 1315 1320 Gln Arg Leu Lys Lys Ala Val Pro Tyr Asn Arg Met Lys Leu Met 1325 1330 1335 Ile Val Gly Asn Thr Gly Ser Gly Lys Thr Thr Leu Leu Gln Gln 1340 1345 1350 Leu Met Lys Thr Lys Lys Ser Asp Leu Gly Met Gln Ser Ala Thr 1355 1360 1365 Val Gly Ile Asp Val Lys Asp Trp Pro Ile Gln Ile Arg Asp Lys 1370 1375 1380 Arg Lys Arg Asp Leu Val Leu Asn Val Trp Asp Phe Ala Gly Arg 1385 1390 1395 Glu Glu Phe Tyr Ser Thr His Pro His Phe Met Thr Gln Arg Ala 1400 1405 1410 Leu Tyr Leu Ala Val Tyr Asp Leu Ser Lys Gly Gln Ala Glu Val 1415 1420 1425 Asp Ala Met Lys Pro Trp Leu Phe Asn Ile Lys Ala Arg Ala Ser 1430 1435 1440 Ser Ser Pro Val Ile Leu Val Gly Thr His Leu Asp Val Ser Asp 1445 1450 1455 Glu Lys Gln Arg Lys Ala Cys Met Ser Lys Ile Thr Lys Glu Leu 1460 1465 1470 Leu Asn Lys Arg Gly Phe Pro Ala Ile Arg Asp Tyr His Phe Val 1475 1480 1485 Asn Ala Thr Glu Glu Ser Asp Ala Leu Ala Lys Leu Arg Lys Thr 1490 1495 1500 Ile Ile Asn Glu Ser Leu Asn Phe Lys Ile Arg Asp Gln Leu Val 1505 1510 1515 Val Gly Gln Leu Ile Pro Asp Cys Tyr Val Glu Leu Glu Lys Ile 1520 1525 1530 Ile Leu Ser Glu Arg Lys Asn Val Pro Ile Glu Phe Pro Val Ile 1535 1540 1545 Asp Arg Lys Arg Leu Leu Gln Leu Val Arg Glu Asn Gln Leu Gln 1550 1555 1560 Leu Asp Glu Asn Glu Leu Pro His Ala Val His Phe Leu Asn Glu 1565 1570 1575 Ser Gly Val Leu Leu His Phe Gln Asp Pro Ala Leu Gln Leu Ser 1580 1585 1590 Asp Leu Tyr Phe Val Glu Pro Lys Trp Leu Cys Lys Ile Met Ala 1595 1600 1605 Gln Ile Leu Thr Val Lys Val Glu Gly Cys Pro Lys His Pro Lys 1610 1615 1620 Gly Ile Ile Ser Arg Arg Asp Val Glu Lys Phe Leu Ser Lys Lys 1625 1630 1635 Arg Lys Phe Pro Lys Asn Tyr Met Ser Gln Tyr Phe Lys Leu Leu 1640 1645 1650 Glu Lys Phe Gln Ile Ala Leu Pro Ile Gly Glu Glu Tyr Leu Leu 1655 1660 1665 Val Pro Ser Ser Leu Ser Asp His Arg Pro Val Ile Glu Leu Pro 1670 1675 1680 His Cys Glu Asn Ser Glu Ile Ile Ile Arg Leu Tyr Glu Met Pro 1685 1690 1695 Tyr Phe Pro Met Gly Phe Trp Ser Arg Leu Ile Asn Arg Leu Leu 1700 1705 1710 Glu Ile Ser Pro Tyr Met Leu Ser Gly Arg Glu Arg Ala Leu Arg 1715 1720 1725 Pro Asn Arg Met Tyr Trp Arg Gln Gly Ile Tyr Leu Asn Trp Ser 1730 1735 1740 Pro Glu Ala Tyr Cys Leu Val Gly Ser Glu Val Leu Asp Asn His 1745 1750 1755 Pro Glu Ser Phe Leu Lys Ile Thr Val Pro Ser Cys Arg Lys Gly 1760 1765 1770 Cys Ile Leu Leu Gly Gln Val Val Asp His Ile Asp Ser Leu Met 1775 1780 1785 Glu Glu Trp Phe Pro Gly Leu Leu Glu Ile Asp Ile Cys Gly Glu 1790 1795 1800 Gly Glu Thr Leu Leu Lys Lys Trp Ala Leu Tyr Ser Phe Asn Asp 1805 1810 1815 Gly Glu Glu His Gln Lys Ile Leu Leu Asp Asp Leu Met Lys Lys 1820 1825 1830 Ala Glu Glu Gly Asp Leu Leu Val Asn Pro Asp Gln Pro Arg Leu 1835 1840 1845 Thr Ile Pro Ile Ser Gln Ile Ala Pro Asp Leu Ile Leu Ala Asp 1850 1855 1860 Leu Pro Arg Asn Ile Met Leu Asn Asn Asp Glu Leu Glu Phe Glu 1865 1870 1875 Gln Ala Pro Glu Phe Leu Leu Gly Asp Gly Ser Phe Gly Ser Val 1880 1885 1890 Tyr Arg Ala Ala Tyr Glu Gly Glu Glu Val Ala Val Lys Ile Phe 1895 1900 1905 Asn Lys His Thr Ser Leu Arg Leu Leu Arg Gln Glu Leu Val Val 1910 1915 1920 Leu Cys His Leu His His Pro Ser Leu Ile Ser Leu Leu Ala Ala 1925 1930 1935 Gly Ile Arg Pro Arg Met Leu Val Met Glu Leu Ala Ser Lys Gly 1940 1945 1950 Ser Leu Asp Arg Leu Leu Gln Gln Asp Lys Ala Ser Leu Thr Arg 1955 1960 1965 Thr Leu Gln His Arg Ile Ala Leu His Val Ala Asp Gly Leu Arg 1970 1975 1980 Tyr Leu His Ser Ala Met Ile Ile Tyr Arg Asp Leu Lys Pro His 1985 1990 1995 Asn Val Leu Leu Phe Thr Leu Tyr Pro Asn Ala Ala Ile Ile Ala 2000 2005 2010 Lys Ile Ala Asp Tyr Gly Ile Ala Gln Tyr Cys Cys Arg Met Gly 2015 2020 2025 Ile Lys Thr Ser Glu Gly Thr Pro Gly Phe Arg Ala Pro Glu Val 2030 2035 2040 Ala Arg Gly Asn Val Ile Tyr Asn Gln Gln Ala Asp Val Tyr Ser 2045 2050 2055 Phe Gly Leu Leu Leu Tyr Asp Ile Leu Thr Thr Gly Gly Arg Ile 2060 2065 2070 Val Glu Gly Leu Lys Phe Pro Asn Glu Phe Asp Glu Leu Glu Ile 2075 2080 2085 Gln Gly Lys Leu Pro Asp Pro Val Lys Glu Tyr Gly Cys Ala Pro 2090 2095 2100 Trp Pro Met Val Glu Lys Leu Ile Lys Gln Cys Leu Lys Glu Asn 2105 2110 2115 Pro Gln Glu Arg Pro Thr Ser Ala Gln Val Phe Asp Ile Leu Asn 2120 2125 2130 Ser Ala Glu Leu Val Cys Leu Thr Arg Arg Ile Leu Leu Pro Lys 2135 2140 2145 Asn Val Ile Val Glu Cys Met Val Ala Thr His His Asn Ser Arg 2150 2155 2160 Asn Ala Ser Ile Trp Leu Gly Cys Gly His Thr Asp Arg Gly Gln 2165 2170 2175 Leu Ser Phe Leu Asp Leu Asn Thr Glu Gly Tyr Thr Ser Glu Glu 2180 2185 2190 Val Ala Asp Ser Arg Ile Leu Cys Leu Ala Leu Val His Leu Pro 2195 2200 2205 Val Glu Lys Glu Ser Trp Ile Val Ser Gly Thr Gln Ser Gly Thr 2210 2215 2220 Leu Leu Val Ile Asn Thr Glu Asp Gly Lys Lys Arg His Thr Leu 2225 2230 2235 Glu Lys Met Thr Asp Ser Val Thr Cys Leu Tyr Cys Asn Ser Phe 2240 2245 2250 Ser Lys Gln Ser Lys Gln Lys Asn Phe Leu Leu Val Gly Thr Ala 2255 2260 2265 Asp Gly Lys Leu Ala Ile Phe Glu Asp Lys Thr Val Lys Leu Lys 2270 2275 2280 Gly Ala Ala Pro Leu Lys Ile Leu Asn Ile Gly Asn Val Ser Thr 2285 2290 2295 Pro Leu Met Cys Leu Ser Glu Ser Thr Asn Ser Thr Glu Arg Asn 2300 2305 2310 Val Met Trp Gly Gly Cys Gly Thr Lys Ile Phe Ser Phe Ser Asn 2315 2320 2325 Asp Phe Thr Ile Gln Lys Leu Ile Glu Thr Arg Thr Ser Gln Leu 2330 2335 2340 Phe Ser Tyr Ala Ala Phe Ser Asp Ser Asn Ile Ile Thr Val Val 2345 2350 2355 Val Asp Thr Ala Leu Tyr Ile Ala Lys Gln Asn Ser Pro Val Val 2360 2365 2370 Glu Val Trp Asp Lys Lys Thr Glu Lys Leu Cys Gly Leu Ile Asp 2375 2380 2385 Cys Val His Phe Leu Arg Glu Val Met Val Lys Glu Asn Lys Glu 2390 2395 2400 Ser Lys His Lys Met Ser Tyr Ser Gly Arg Val Lys Thr Leu Cys 2405 2410 2415 Leu Gln Lys Asn Thr Ala Leu Trp Ile Gly Thr Gly Gly Gly His 2420 2425 2430 Ile Leu Leu Leu Asp Leu Ser Thr Arg Arg Leu Ile Arg Val Ile 2435 2440 2445 Tyr Asn Phe Cys Asn Ser Val Arg Val Met Met Thr Ala Gln Leu 2450 2455 2460 Gly Ser Leu Lys Asn Val Met Leu Val Leu Gly Tyr Asn Arg Lys 2465 2470 2475 Asn Thr Glu Gly Thr Gln Lys Gln Lys Glu Ile Gln Ser Cys Leu 2480 2485 2490 Thr Val Trp Asp Ile Asn Leu Pro His Glu Val Gln Asn Leu Glu 2495 2500 2505 Lys His Ile Glu Val Arg Lys Glu Leu Ala Glu Lys Met Arg Arg 2510 2515 2520 Thr Ser Val Glu 2525 <210> 5 <211> 140 <212> PRT <213> Homo sapiens <400> 5 Met Asp Val Phe Met Lys Gly Leu Ser Lys Ala Lys Glu Gly Val Val 1 5 10 15 Ala Ala Ala Glu Lys Thr Lys Gln Gly Val Ala Glu Ala Ala Gly Lys 20 25 30 Thr Lys Glu Gly Val Leu Tyr Val Gly Ser Lys Thr Lys Glu Gly Val 35 40 45 Val His Gly Val Ala Thr Val Ala Glu Lys Thr Lys Glu Gln Val Thr 50 55 60 Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala Val Ala Gln Lys 65 70 75 80 Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Ala Thr Gly Phe Val Lys 85 90 95 Lys Asp Gln Leu Gly Lys Asn Glu Glu Gly Ala Pro Gln Glu Gly Ile 100 105 110 Leu Glu Asp Met Pro Val Asp Pro Asp Asn Glu Ala Tyr Glu Met Pro 115 120 125 Ser Glu Glu Gly Tyr Gln Asp Tyr Glu Pro Glu Ala 130 135 140 <210> 6 <211> 619 <212> PRT <213> Homo sapiens <400> 6 Met Ala Ser Gly Ala Tyr Asn Pro Tyr Ile Glu Ile Ile Glu Gln Pro 1 5 10 15 Arg Gln Arg Gly Met Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala 20 25 30 Gly Ser Ile Pro Gly Glu His Ser Thr Asp Asn Asn Arg Thr Tyr Pro 35 40 45 Ser Ile Gln Ile Met Asn Tyr Tyr Gly Lys Gly Lys Val Arg Ile Thr 50 55 60 Leu Val Thr Lys Asn Asp Pro Tyr Lys Pro His Pro His Asp Leu Val 65 70 75 80 Gly Lys Asp Cys Arg Asp Gly Tyr Tyr Glu Ala Glu Phe Gly Gln Glu 85 90 95 Arg Arg Pro Leu Phe Phe Gln Asn Leu Gly Ile Arg Cys Val Lys Lys 100 105 110 Lys Glu Val Lys Glu Ala Ile Ile Thr Arg Ile Lys Ala Gly Ile Asn 115 120 125 Pro Phe Asn Val Pro Glu Lys Gln Leu Asn Asp Ile Glu Asp Cys Asp 130 135 140 Leu Asn Val Val Arg Leu Cys Phe Gln Val Phe Leu Pro Asp Glu His 145 150 155 160 Gly Asn Leu Thr Thr Ala Leu Pro Pro Val Val Ser Asn Pro Ile Tyr 165 170 175 Asp Asn Arg Ala Pro Asn Thr Ala Glu Leu Arg Ile Cys Arg Val Asn 180 185 190 Lys Asn Cys Gly Ser Val Arg Gly Gly Asp Glu Ile Phe Leu Leu Cys 195 200 205 Asp Lys Val Gln Lys Asp Asp Ile Glu Val Arg Phe Val Leu Asn Asp 210 215 220 Trp Glu Ala Lys Gly Ile Phe Ser Gln Ala Asp Val His Arg Gln Val 225 230 235 240 Ala Ile Val Phe Lys Thr Pro Pro Tyr Cys Lys Ala Ile Thr Glu Pro 245 250 255 Val Thr Val Lys Met Gln Leu Arg Arg Pro Ser Asp Gln Glu Val Ser 260 265 270 Glu Ser Met Asp Phe Arg Tyr Leu Pro Asp Glu Lys Asp Thr Tyr Gly 275 280 285 Asn Lys Ala Lys Lys Gln Lys Thr Thr Leu Leu Phe Gln Lys Leu Cys 290 295 300 Gln Asp His Val Glu Thr Gly Phe Arg His Val Asp Gln Asp Gly Leu 305 310 315 320 Glu Leu Leu Thr Ser Gly Asp Pro Pro Thr Leu Ala Ser Gln Ser Ala 325 330 335 Gly Ile Thr Val Asn Phe Pro Glu Arg Pro Arg Pro Gly Leu Leu Gly 340 345 350 Ser Ile Gly Glu Gly Arg Tyr Phe Lys Lys Glu Pro Asn Leu Phe Ser 355 360 365 His Asp Ala Val Val Arg Glu Met Pro Thr Gly Val Ser Ser Gln Ala 370 375 380 Glu Ser Tyr Tyr Pro Ser Pro Gly Pro Ile Ser Ser Gly Leu Ser His 385 390 395 400 His Ala Ser Met Ala Pro Leu Pro Ser Ser Ser Trp Ser Ser Val Ala 405 410 415 His Pro Thr Pro Arg Ser Gly Asn Thr Asn Pro Leu Ser Ser Phe Ser 420 425 430 Thr Arg Thr Leu Pro Ser Asn Ser Gln Gly Ile Pro Pro Phe Leu Arg 435 440 445 Ile Pro Val Gly Asn Asp Leu Asn Ala Ser Asn Ala Cys Ile Tyr Asn 450 455 460 Asn Ala Asp Asp Ile Val Gly Met Glu Ala Ser Ser Met Pro Ser Ala 465 470 475 480 Asp Leu Tyr Gly Ile Ser Asp Pro Asn Met Leu Ser Asn Cys Ser Val 485 490 495 Asn Met Met Thr Thr Ser Ser Asp Ser Met Gly Glu Thr Asp Asn Pro 500 505 510 Arg Leu Leu Ser Met Asn Leu Glu Asn Pro Ser Cys Asn Ser Val Leu 515 520 525 Asp Pro Arg Asp Leu Arg Gln Leu His Gln Met Ser Ser Ser Ser Met 530 535 540 Ser Ala Gly Ala Asn Ser Asn Thr Thr Val Phe Val Ser Gln Ser Asp 545 550 555 560 Ala Phe Glu Gly Ser Asp Phe Ser Cys Ala Asp Asn Ser Met Ile Asn 565 570 575 Glu Ser Gly Pro Ser Asn Ser Thr Asn Pro Asn Ser His Gly Phe Val 580 585 590 Gln Asp Ser Gln Tyr Ser Gly Ile Gly Ser Met Gln Asn Glu Gln Leu 595 600 605 Ser Asp Ser Phe Pro Tyr Glu Phe Phe Gln Val 610 615 <210> 7 <211> 698 <212> PRT <213> Homo sapiens <400> 7 Met Gly Asp Pro Gly Leu Ala Lys Leu Gln Phe Ala Pro Phe Asn Ser 1 5 10 15 Ala Leu Asp Val Gly Phe Trp His Glu Leu Thr Gln Lys Lys Leu Asn 20 25 30 Glu Tyr Arg Leu Asp Glu Ala Pro Lys Asp Ile Lys Gly Tyr Tyr Tyr 35 40 45 Asn Gly Asp Ser Ala Gly Leu Pro Thr Arg Leu Thr Leu Glu Phe Ser 50 55 60 Ala Phe Asp Met Ser Ala Ser Thr Pro Ala His Cys Cys Pro Ala Met 65 70 75 80 Gly Thr Leu His Asn Thr Asn Thr Leu Glu Ala Phe Lys Thr Ala Asp 85 90 95 Lys Lys Leu Leu Leu Glu Gln Ser Ala Asn Glu Ile Trp Glu Ala Ile 100 105 110 Lys Ser Gly Ala Ala Leu Glu Asn Pro Met Leu Leu Asn Lys Phe Leu 115 120 125 Leu Leu Thr Phe Ala Asp Leu Lys Lys Tyr His Phe Tyr Tyr Trp Phe 130 135 140 Cys Cys Pro Ala Leu Cys Leu Pro Glu Ser Ile Pro Leu Ile Arg Gly 145 150 155 160 Pro Val Ser Leu Asp Gln Arg Leu Ser Pro Lys Gln Ile Gln Ala Leu 165 170 175 Glu His Ala Tyr Asp Asp Leu Cys Arg Ala Glu Gly Val Thr Ala Leu 180 185 190 Pro Tyr Phe Leu Phe Lys Tyr Asp Asp Asp Thr Val Leu Val Ser Leu 195 200 205 Leu Lys His Tyr Ser Asp Phe Phe Gln Gly Gln Arg Thr Lys Ile Thr 210 215 220 Val Gly Val Tyr Asp Pro Cys Asn Leu Ala Gln Tyr Pro Gly Trp Pro 225 230 235 240 Leu Arg Asn Phe Leu Val Leu Ala Ala His Arg Trp Ser Gly Ser Phe 245 250 255 Gln Ser Val Glu Val Leu Cys Phe Arg Asp Arg Thr Met Gln Gly Ala 260 265 270 Arg Asp Val Thr His Ser Ile Ile Phe Glu Val Lys Leu Pro Glu Met 275 280 285 Ala Phe Ser Pro Asp Cys Pro Lys Ala Val Gly Trp Glu Lys Asn Gln 290 295 300 Lys Gly Gly Met Gly Pro Arg Met Val Asn Leu Ser Gly Cys Met Asp 305 310 315 320 Pro Lys Arg Leu Ala Glu Ser Ser Val Asp Leu Asn Leu Lys Leu Met 325 330 335 Cys Trp Arg Leu Val Pro Thr Leu Asp Leu Asp Lys Val Val Ser Val 340 345 350 Lys Cys Leu Leu Leu Gly Ala Gly Thr Leu Gly Cys Asn Val Ala Arg 355 360 365 Thr Leu Met Gly Trp Gly Val Arg His Val Thr Phe Val Asp Asn Ala 370 375 380 Lys Ile Ser Tyr Ser Asn Pro Val Arg Gln Pro Leu Tyr Glu Phe Glu 385 390 395 400 Asp Cys Leu Gly Gly Gly Lys Pro Lys Ala Leu Ala Ala Ala Glu Arg 405 410 415 Leu Gln Lys Ile Phe Pro Gly Val Asn Ala Arg Gly Phe Asn Met Ser 420 425 430 Ile Pro Met Pro Gly His Pro Val Asn Phe Ser Asp Val Thr Met Glu 435 440 445 Gln Ala Arg Arg Asp Val Glu Gln Leu Glu Gln Leu Ile Asp Asn His 450 455 460 Asp Val Ile Phe Leu Leu Met Asp Thr Arg Glu Ser Arg Trp Leu Pro 465 470 475 480 Thr Val Ile Ala Ala Ser Lys Arg Lys Leu Val Ile Asn Ala Ala Leu 485 490 495 Gly Phe Asp Thr Phe Val Val Met Arg His Gly Leu Lys Lys Pro Lys 500 505 510 Gln Gln Gly Ala Gly Asp Leu Cys Pro Ser His Leu Val Ala Pro Ala 515 520 525 Asp Leu Gly Ser Ser Leu Phe Ala Asn Ile Pro Gly Tyr Lys Leu Gly 530 535 540 Cys Tyr Phe Cys Asn Asp Val Val Ala Pro Gly Asp Ser Thr Arg Asp 545 550 555 560 Arg Thr Leu Asp Gln Gln Cys Thr Val Ser Arg Pro Gly Leu Ala Val 565 570 575 Ile Ala Gly Ala Leu Ala Val Glu Leu Met Val Ser Val Leu Gln His 580 585 590 Pro Glu Gly Gly Tyr Ala Ile Ala Ser Ser Ser Asp Asp Arg Met Asn 595 600 605 Glu Pro Pro Thr Ser Leu Gly Leu Val Pro His Gln Ile Arg Gly Phe 610 615 620 Leu Ser Arg Phe Asp Asn Val Leu Pro Val Ser Leu Ala Phe Asp Lys 625 630 635 640 Cys Thr Ala Cys Ser Pro Lys Val Leu Asp Gln Tyr Glu Arg Glu Gly 645 650 655 Phe Thr Phe Leu Ala Lys Val Phe Asn Ser Ser His Ser Phe Leu Glu 660 665 670 Asp Leu Thr Gly Leu Thr Leu Leu His Gln Glu Thr Gln Ala Ala Glu 675 680 685 Ile Trp Asp Met Ser Asp Glu Glu Thr Val 690 695 <210> 8 <211> 514 <212> PRT <213> Homo sapiens <400> 8 Met Ala Leu Ser Glu Leu Ala Leu Val Arg Trp Leu Gln Glu Ser Arg 1 5 10 15 Arg Ser Arg Lys Leu Ile Leu Phe Ile Val Phe Leu Ala Leu Leu Leu 20Tyr Ser Ile Lys His Glu Lys Asn Ala Thr Glu Ile Gln Thr Ala Arg 50 55 60 Pro Val His Thr Ala Ser Ile Ser Asp Ser Phe Gln Ser Ile Phe Ser 65 70 75 80 Tyr Tyr Asp Asn Ser Thr Met Val Thr Gly Asn Ala Thr Arg Asp Leu 85 90 95 Thr Leu His Gln Thr Ala Thr Gln His Met Val Thr Asn Ala Ser Ala 100 105 110 Val Pro Ser Asp Cys Pro Ser Glu Asp Lys Asp Leu Leu Asn Glu Asn 115 120 125 Val Gln Val Gly Leu Leu Phe Ala Ser Lys Ala Thr Val Gln Leu Ile 130 135 140 Thr Asn Pro Phe Ile Gly Leu Leu Thr Asn Arg Ile Gly Tyr Pro Ile 145 150 155 160 Pro Ile Phe Ala Gly Phe Cys Ile Met Phe Val Ser Thr Ile Met Phe 165 170 175 Ala Phe Ser Ser Ser Tyr Ala Phe Leu Leu Ile Ala Arg Ser Leu Gln 180 185 190 Gly Ile Gly Ser Ser Cys Ser Ser Val Ala Gly Met Gly Met Leu Ala 195 200 205 Ser Val Tyr Thr Asp Asp Glu Glu Arg Gly Asn Val Met Gly Ile Ala 210 215 220 Leu Gly Gly Leu Ala Met Gly Val Leu Val Gly Pro Pro Phe Gly Ser 225 230 235 240 Val Leu Tyr Glu Phe Val Gly Lys Thr Ala Pro Phe Leu Val Leu Ala 245 250 255 Ala Leu Val Leu Leu Asp Gly Ala Ile Gln Leu Phe Val Leu Gln Pro 260 265 270 Ser Arg Val Gln Pro Glu Ser Gln Lys Gly Thr Pro Leu Thr Thr Leu 275 280 285 Leu Lys Asp Pro Tyr Ile Leu Ile Ala Ala Gly Ser Ile Cys Phe Ala 290 295 300 Asn Met Gly Ile Ala Met Leu Glu Pro Ala Leu Pro Ile Trp Met Met 305 310 315 320 Glu Thr Met Cys Ser Arg Lys Trp Gln Leu Gly Val Ala Phe Leu Pro 325 330 335 Ala Ser Ile Ser Tyr Leu Ile Gly Thr Asn Ile Phe Gly Ile Leu Ala 340 345 350 His Lys Met Gly Arg Trp Leu Cys Ala Leu Leu Gly Met Ile Ile Val 355 360 365 Gly Val Ser Ile Leu Cys Ile Pro Phe Ala Lys Asn Ile Tyr Gly Leu 370 375 380 Ile Ala Pro Asn Phe Gly Val Gly Phe Ala Ile Gly Met Val Asp Ser 385 390 395 400 Ser Met Met Pro Ile Met Gly Tyr Leu Val Asp Leu Arg His Val Ser 405 410 415 Val Tyr Gly Ser Val Tyr Ala Ile Ala Asp Val Ala Phe Cys Met Gly 420 425 430 Tyr Ala Ile Gly Pro Ser Ala Gly Gly Ala Ile Ala Lys Ala Ile Gly 435 440 445 Phe Pro Trp Leu Met Thr Ile Ile Gly Ile Ile Asp Ile Leu Phe Ala 450 455 460 Pro Leu Cys Phe Phe Leu Arg Ser Pro Pro Ala Lys Glu Glu Lys Met 465 470 475 480 Ala Ile Leu Met Asp His Asn Cys Pro Ile Lys Thr Lys Met Tyr Thr 485 490 495 Gln Asn Asn Ile Gln Ser Tyr Pro Ile Gly Glu Asp Glu Glu Ser Glu 500 505 510 Ser Asp <210> 9 <211> 536 <212> PRT <213> Homo sapiens <400> 9 Met Glu Phe Ser Ser Pro Ser Arg Glu Glu Cys Pro Lys Pro Leu Ser 1 5 10 15 Arg Val Ser Ile Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln 20 25 30 Ala Val Ser Trp Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe 35 40 45 Gly Tyr Ser Ser Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser 50 55 60 Phe Asp Pro Pro Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu 65 70 75 80 Ser Thr Arg Ser Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln 85 90 95 Ala Asn His Thr Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln 100 105 110 Lys Phe Gln Lys Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala 115 120 125 Ala Leu Asn Ile Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Leu 130 135 140 Lys Ser Tyr Phe Ser Glu Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val 145 150 155 160 Pro Met Ala Ser Cys Asp Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp 165 170 175 Thr Pro Asp Asp Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp 180 185 190 Thr Lys Leu Lys Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln 195 200 205 Arg Pro Val Ser Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu 210 215 220 Lys Thr Asn Gly Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro 225 230 235 240 Gly Asp Ile Tyr His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu 245 250 255 Asp Ala Tyr Ala Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu 260 265 270 Asn Glu Pro Ser Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu 275 280 285 Gly Phe Thr Pro Glu His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly 290 295 300 Pro Thr Leu Ala Asn Ser Thr His His Asn Val Arg Leu Leu Met Leu 305 310 315 320 Asp Asp Gln Arg Leu Leu Leu Pro His Trp Ala Lys Val Val Leu Thr 325 330 335 Asp Pro Glu Ala Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr 340 345 350 Leu Asp Phe Leu Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg 355 360 365 Leu Phe Pro Asn Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly Ser 370 375 380 Lys Phe Trp Glu Gln Ser Val Arg Leu Gly Ser Trp Asp Arg Gly Met 385 390 395 400 Gln Tyr Ser His Ser Ile Ile Thr Asn Leu Leu Tyr His Val Val Gly 405 410 415 Trp Thr Asp Trp Asn Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp 420 425 430 Val Arg Asn Phe Val Asp Ser Pro Ile Ile Val Asp Ile Thr Lys Asp 435 440 445 Thr Phe Tyr Lys Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys 450 455 460 Phe Ile Pro Glu Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys 465 470 475 480 Asn Asp Leu Asp Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val 485 490 495 Val Val Val Leu Asn Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys 500 505 510 Asp Pro Ala Val Gly Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser Ile 515 520 525 His Thr Tyr Leu Trp Arg Arg Gln 530 535 <210> 10 <211> 464 <212> PRT <213> Homo sapiens <400> 10 Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu Val 1 5 10 15 Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys Arg 20 25 30 Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys Glu 35 40 45 Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln Ser 50 55 60 Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met Asn 65 70 75 80 Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu Arg 85 90 95 Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu Pro 100 105 110 Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg Lys 115 120 125 Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn Ser 130 135 140 Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly Lys 145 150 155 160 Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu Thr 165 170 175 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser 180 185 190 Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu Phe Phe 195 200 205 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser Val Ala 210 215 220 Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile Thr Cys 225 230 235 240 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser Arg His 245 250 255 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn 260 265 270 Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu Pro Cys 275 280 285 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg 290 295 300 Ile Leu Gly Glu Glu Gln Tyr Asn Arg Tyr Gln Gln Tyr Gly Ala Glu 305 310 315 320 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys 325 330 335 Gly Ala Gly Leu Leu Pro Glu Pro Asp Gln Arg Lys Val Thr Cys Glu 340 345 350 Gly Gly Asn Gly Leu Gly Cys Gly Phe Ala Phe Cys Arg Glu Cys Lys 355 360 365 Glu Ala Tyr His Glu Gly Glu Cys Ser Ala Val Phe Glu Ala Ser Gly 370 375 380 Thr Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg Ala Ala Glu Gln Ala 385 390 395 400 Arg Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro 405 410 415 Cys Pro Arg Cys His Val Pro Val Glu Lys Asn Gly Gly Cys Met His 420 425 430 Met Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu Trp Cys Trp Asn Cys 435 440 445 Gly Cys Glu Trp Asn Arg Val Cys Met Gly Asp His Trp Phe Asp Val 450 455 460 <210> 11 <211> 437 <212> PRT <213> Homo sapiens <400> 11 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln 50 55 60 Ser Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met 65 70 75 80 Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu 85 90 95 Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu 100 105 110 Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg 115 120 125 Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn 130 135 140 Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly 145 150 155 160 Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu 165 170 175 Thr Gln Glu Phe Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys 180 185 190 Glu Thr Ser Val Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile 195 200 205 Thr Cys Ile Thr Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln 210 215 220 Cys Asn Ser Arg His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys 225 230 235 240 Val Thr Arg Leu Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly 245 250 255 Tyr Ser Leu Pro Cys Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu 260 265 270 Leu His His Phe Arg Ile Leu Gly Glu Glu Gln Tyr Asn Arg Tyr Gln 275 280 285 Gln Tyr Gly Ala Glu Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys 290 295 300 Pro Arg Pro Gly Cys Gly Ala Gly Leu Leu Pro Glu Pro Asp Gln Arg 305 310 315 320 Lys Val Thr Cys Glu Gly Gly Asn Gly Leu Gly Cys Gly Phe Ala Phe 325 330 335 Cys Arg Glu Cys Lys Glu Ala Tyr His Glu Gly Glu Cys Ser Ala Val 340 345 350 Phe Glu Ala Ser Gly Thr Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg 355 360 365 Ala Ala Glu Gln Ala Arg Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys 370 375 380 Lys Thr Thr Lys Pro Cys Pro Arg Cys His Val Pro Val Glu Lys Asn 385 390 395 400 Gly Gly Cys Met His Met Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu 405 410 415 Trp Cys Trp Asn Cys Gly Cys Glu Trp Asn Arg Val Cys Met Gly Asp 420 425 430 His Trp Phe Asp Val 435 <210> 12 <211> 218 <212> PRT <213> Homo sapiens <400> 12 Met Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys 1 5 10 15 Glu Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val 20 25 30 Leu Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser 35 40 45 Arg Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr 50 55 60 Asn Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro 65 70 75 80 Gly Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr 85 90 95 Leu Thr Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg 100 105 110 Met Ser Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu 115 120 125 Phe Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser 130 135 140 Val Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile 145 150 155 160 Thr Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser 165 170 175 Arg His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg 180 185 190 Leu Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu 195 200 205 Pro Cys Val Val Cys Leu Leu Pro Gly Met 210 215 <210> 13 <211> 274 <212> PRT <213> Homo sapiens <400> 13 Met Ser Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu 1 5 10 15 Phe Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser 20 25 30 Val Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile 35 40 45 Thr Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser 50 55 60 Arg His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg 65 70 75 80 Leu Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu 85 90 95 Pro Cys Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His 100 105 110 Phe Arg Ile Leu Gly Glu Glu Gln Tyr Asn Arg Tyr Gln Gln Tyr Gly<O002063>115 120 125 Ala Glu Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro 130 135 140 Gly Cys Gly Ala Gly Leu Leu Pro Glu Pro Asp Gln Arg Lys Val Thr 145 150 155 160 Cys Glu Gly Gly Asn Gly Leu Gly Cys Gly Phe Ala Phe Cys Arg Glu 165 170 175 Cys Lys Glu Ala Tyr His Glu Gly Glu Cys Ser Ala Val Phe Glu Ala 180 185 190 Ser Gly Thr Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg Ala Ala Glu 195 200 205 Gln Ala Arg Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr 210 215 220 Lys Pro Cys Pro Arg Cys His Val Pro Val Glu Lys Asn Gly Gly Cys 225 230 235 240 Met His Met Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu Trp Cys Trp 245 250 255<00,02080>Asn Cys Gly Cys Glu Trp Asn Arg Val Cys Met Gly Asp His Trp Phe 260 265 270 Asp Val <210> 14 <211> 387 <212> PRT <213> Homo sapiens <400> 14 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln 50 55 60 Ser Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met 65 70 75 80 Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu 85 90 95 Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu 100 105 110 Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg 115 120 125 Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn 130 135 140 Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly 145 150 155 160 Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu 165 170 175 Thr Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met 180 185 190 Ser Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu Phe 195 200 205 Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser Val 210 215 220 Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile Thr 225 230 235 240 Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser Arg 245 250 255 His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu 260 265 270 Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu Pro 275 280 285 Cys Val Gly Thr Gly Asp Thr Val Val Leu Arg Gly Ala Leu Gly Gly 290 295 300 Phe Arg Arg Gly Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu 305 310 315 320 His His Phe Arg Ile Leu Gly Glu Glu Gln Tyr Asn Arg Tyr Gln Gln 325 330 335 Tyr Gly Ala Glu Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro 340 345 350 Arg Pro Gly Cys Gly Ala Gly Leu Leu Pro Glu Pro Asp Gln Arg Lys 355 360 365 Val Thr Cys Glu Gly Gly Asn Gly Leu Gly Cys Gly Tyr Gly Gln Arg 370 375 380 Arg Thr Lys 385 <210> 15 <211> 316 <212> PRT <213> Homo sapiens <400> 15 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Glu Phe Phe Phe Lys Cys Gly 50 55 60 Ala His Pro Thr Ser Asp Lys Glu Thr Ser Val Ala Leu His Leu Ile 65 70 75 80 Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile Thr Cys Thr Asp Val Arg 85 90 95 Ser Pro Val Leu Val Phe Gln Cys Asn Ser Arg His Val Ile Cys Leu 100 105 110 Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn Asp Arg Gln Phe 115 120 125 Val His Asp Pro Gln Leu Gly Tyr Ser Leu Pro Cys Val Ala Gly Cys 130 135 140 Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg Ile Leu Gly Glu 145 150 155 160 Glu Gln Tyr Asn Arg Tyr Gln Gln Tyr Gly Ala Glu Glu Cys Val Leu 165 170 175 Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys Gly Ala Gly Leu 180 185 190 Leu Pro Glu Pro Asp Gln Arg Lys Val Thr Cys Glu Gly Gly Asn Gly 195 200 205 Leu Gly Cys Gly Phe Ala Phe Cys Arg Glu Cys Lys Glu Ala Tyr His 210 215 220 Glu Gly Glu Cys Ser Ala Val Phe Glu Ala Ser Gly Thr Thr Thr Gln 225 230 235 240 Ala Tyr Arg Val Asp Glu Arg Ala Ala Glu Gln Ala Arg Trp Glu Ala 245 250 255 Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro Cys Pro Arg Cys 260 265 270 His Val Pro Val Glu Lys Asn Gly Gly Cys Met His Met Lys Cys Pro 275 280 285 Gln Pro Gln Cys Arg Leu Glu Trp Cys Trp Asn Cys Gly Cys Glu Trp 290 295 300 Asn Arg Val Cys Met Gly Asp His Trp Phe Asp Val 305 310 315 <210> 16 <211> 387 <212> PRT <213> Homo sapiens <400> 16 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln 50 55 60 Ser Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met 65 70 75 80 Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu 85 90 95 Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu 100 105 110 Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg 115 120 125 Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn 130 135 140 Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly 145 150 155 160 Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu 165 170 175 Thr Gln Glu Phe Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys 180 185 190 Glu Thr Ser Val Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile 195 200 205 Thr Cys Ile Thr Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln 210 215 220 Cys Asn Ser Arg His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys 225 230 235 240 Val Thr Arg Leu Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly 245 250 255 Tyr Ser Leu Pro Cys Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu 260 265 270 Leu His His Phe Arg Ile Leu Gly Glu Glu Gln Phe Ala Phe Cys Arg 275 280 285 Glu Cys Lys Glu Ala Tyr His Glu Gly Glu Cys Ser Ala Val Phe Glu 290 295 300 Ala Ser Gly Thr Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg Ala Ala 305 310 315 320 Glu Gln Ala Arg Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys Lys Thr 325 330 335 Thr Lys Pro Cys Pro Arg Cys His Val Pro Val Glu Lys Asn Gly Gly 340 345 350 Cys Met His Met Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu Trp Cys 355 360 365 Trp Asn Cys Gly Cys Glu Trp Asn Arg Val Cys Met Gly Asp His Trp 370 375 380 Phe Asp Val 385 <210> 17 <211> 415 <212> PRT <213> Homo sapiens <400> 17 Met Ile Val Phe Val Arg Phe Asn Ser Ser His Gly Phe Pro Val Glu 1 5 10 15 Val Asp Ser Asp Thr Ser Ile Phe Gln Leu Lys Glu Val Val Ala Lys 20 25 30 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys 35 40 45 Glu Leu Arg Asn Asp Trp Thr Val Gln Asn Cys Asp Leu Asp Gln Gln 50 55 60 Ser Ile Val His Ile Val Gln Arg Pro Trp Arg Lys Gly Gln Glu Met 65 70 75 80 Asn Ala Thr Gly Gly Asp Asp Pro Arg Asn Ala Ala Gly Gly Cys Glu 85 90 95 Arg Glu Pro Gln Ser Leu Thr Arg Val Asp Leu Ser Ser Ser Val Leu 100 105 110 Pro Gly Asp Ser Val Gly Leu Ala Val Ile Leu His Thr Asp Ser Arg 115 120 125 Lys Asp Ser Pro Pro Ala Gly Ser Pro Ala Gly Arg Ser Ile Tyr Asn 130 135 140 Ser Phe Tyr Val Tyr Cys Lys Gly Pro Cys Gln Arg Val Gln Pro Gly 145 150 155 160 Lys Leu Arg Val Gln Cys Ser Thr Cys Arg Gln Ala Thr Leu Thr Leu 165 170 175 Thr Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met 180 185 190 Ser Gly Glu Cys Gln Ser Pro His Cys Pro Gly Thr Ser Ala Glu Phe 195 200 205 Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Glu Thr Ser Val 210 215 220 Ala Leu His Leu Ile Ala Thr Asn Ser Arg Asn Ile Thr Cys Ile Thr 225 230 235 240 Cys Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn Ser Arg 245 250 255 His Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu 260 265 270 Asn Asp Arg Gln Phe Val His Asp Pro Gln Leu Gly Tyr Ser Leu Pro 275 280 285 Cys Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe 290 295 300 Arg Ile Leu Gly Glu Glu Gln Phe Ala Phe Cys Arg Glu Cys Lys Glu 305 310 315 320 Ala Tyr His Glu Gly Glu Cys Ser Ala Val Phe Glu Ala Ser Gly Thr 325 330 335 Thr Thr Gln Ala Tyr Arg Val Asp Glu Arg Ala Ala Glu Gln Ala Arg 340 345 350 Trp Glu Ala Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro Cys 355 360 365 Pro Arg Cys His Val Pro Val Glu Lys Asn Gly Gly Cys Met His Met 370 375 380 Lys Cys Pro Gln Pro Gln Cys Arg Leu Glu Trp Cys Trp Asn Cys Gly 385 390 395 400 Cys Glu Trp Asn Arg Val Cys Met Gly Asp His Trp Phe Asp Val 405 410 415 <210> 18 <211> 1398 <212> DNA <213> Homo sapiens <400> 18 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccagggtcca 540 tcttgctggg atgatgtttt aattccaaac cggatgagtg gtgaatgcca atccccacac 600 tgccctggga ctagtgcaga atttttcttt aaatgtggag cacaccccac ctctgacaag 660 gaaacatcag tagctttgca cctgatcgca acaaatagtc ggaacatcac ttgcattacg 720 tgcacagacg tcaggagccc cgtcctggtt ttccagtgca actcccgcca cgtgatttgc 780 ttagactgtt tccacttata ctgtgtgaca agactcaatg atcggcagtt tgttcacgac 840 cctcaacttg gctactccct gccttgtgtg gctggctgtc ccaactcctt gattaaagag 900 ctccatcact tcaggattct gggagaagag cagtacaacc ggtaccagca gtatggtgca 960 gaggagtgtg tcctgcagat ggggggcgtg ttatgccccc gccctggctg tggagcgggg 1020 ctgctgccgg agcctgacca gaggaaagtc acctgcgaag ggggcaatgg cctgggctgt 1080 gggtttgcct tctgccggga atgtaaagaa gcgtaccatg aaggggagtg cagtgccgta 1140 tttgaagcct caggaacaac tactcaggcc tacagagtcg atgaaagagc cgccgagcag 1200 gctcgttggg aagcagcctc caaagaaacc atcaagaaaa ccaccaagcc ctgtccccgc 1260 tgccatgtac cagtggaaaa aaatggaggc tgcatgcaca tgaagtgtcc gcagccccag 1320 tgcaggctcg agtggtgctg gaactgtggc tgcgagtgga accgcgtctg catgggggac 1380 cactggttcg acgtgtag 1398 <210> 19 <211> 1746 <212> DNA <213> Homo sapiens <400> 19 atggcggtgc gacaggcgct gggccgcggc ctgcagctgg gtcgagcgct gctgctgcgc 60 ttcacgggca agcccggccg ggcctacggc ttggggcggc cgggcccggc ggcgggctgt 120 gtccgcgggg agcgtccagg ctgggccgca ggaccgggcg cggagcctcg cagggtcggg 180 ctcgggctcc ctaaccgtct ccgcttcttc cgccagtcgg tggccgggct ggcggcgcgg 240 ttgcagcggc agttcgtggt gcgggcctgg ggctgcgcgg gcccttgcgg ccgggcagtc 300 tttctggcct tcgggctagg gctgggcctc atcgaggaaa aacaggcgga gagccggcgg 360 gcggtctcgg cctgtcagga gatccaggca atttttaccc agaaaagcaa gccggggcct 420 gacccgttgg acacgagacg cttgcagggc tttcggctgg aggagtatct gatagggcag 480 tccattggta agggctgcag tgctgctgtg tatgaagcca ccatgcctac attgccccag 540 aacctggagg tgacaaagag caccgggttg cttccaggga gaggcccagg taccagtgca 600 ccaggagaag ggcaggagcg agctccgggg gcccctgcct tccccttggc catcaagatg 660 atgtggaaca tctcggcagg ttcctccagc gaagccatct tgaacacaat gagccaggag 720 ctggtcccag cgagccgagt ggccttggct ggggagtatg gagcagtcac ttacagaaaa 780 tccaagagag gtcccaagca actagcccct caccccaaca tcatccgggt tctccgcgcc 840 ttcacctctt ccgtgccgct gctgccaggg gccctggtcg actaccctga tgtgctgccc 900 tcacgcctcc accctgaagg cctgggccat ggccggacgc tgttcctcgt tatgaagaac 960 tatccctgta ccctgcgcca gtacctttgt gtgaacacac ccagcccccg cctcgccgcc 1020 atgatgctgc tgcagctgct ggaaggcgtg gaccatctgg ttcaacaggg catcgcgcac 1080 agagacctga aatccgacaa catccttgtg gagctggacc cagacggctg cccctggctg 1140 gtgatcgcag attttggctg ctgcctggct gatgagagca tcggcctgca gttgcccttc 1200 agcagctggt acgtggatcg gggcggaaac ggctgtctga tggccccaga ggtgtccacg 1260 gcccgtcctg gccccagggc agtgattgac tacagcaagg ctgatgcctg ggcagtggga 1320 gccatcgcct atgaaatctt cgggcttgtc aatcccttct acggccaggg caaggcccac 1380 cttgaaagcc gcagctacca agaggctcag ctacctgcac tgcccgagtc agtgcctcca 1440 gacgtgagac agttggtgag ggcactgctc cagcgagagg ccagcaagag accatctgcc 1500 cgagtagccg caaatgtgct tcatctaagc ctctggggtg aacatattct agccctgaag 1560 [[ID=VIII]]aatctgaagt tagacaagat ggttggctgg ctcctccaac aatcggccgc cactttgttg 1620 gccaacaggc tcacagagaa gtgttgtgtg gaaacaaaaa tgaagatgct ctttctggct 1680 aacctggagt gtgaaacgct ctgccaggca gccctcctcc tctgctcatg gagggcagcc 1740 ctgtga 1746 <210> 20 <211> 570 <212> DNA <213> Homo sapiens <400> 20 atggcttcca aaagagctct ggtcatcctg gctaaaggag cagaggaaat ggagacggtc 60 atccctgtag atgtcatgag gcgagctggg attaaggtca ccgttgcagg cctggctgga 120 aaagacccag tacagtgtag ccgtgatgtg gtcatttgtc ctgatgccag ccttgaagat 180 It should be noted that there seems to be a typo in the original text where "VIII" is used instead of "ID=8" in one place. This has been corrected in the translation.gcaaaaaaag agggaccata tgatgtggtg gttctaccag gaggtaatct gggcgcacag 240 aatttatctg agtctgctgc tgtgaaggag atactgaagg agcaggaaaa ccggaagggc 300 ctgatagccg ccatctgtgc aggtcctact gctctgttgg ctcatgaaat aggttttgga 360 agtaaagtta caacacaccc tcttgctaaa gacaaaatga tgaatggagg tcattacacc 420 tactctgaga atcgtgtgga aaaagacggc ctgattctta caagccgggg gcctgggacc 480 agcttcgagt ttgcgcttgc aattgttgaa gccctgaatg gcaaggaggt ggcggctcaa 540 gtgaaggctc cacttgttct taaagactag 570 <210> 21 <211> 7583 <212> DNA <213> Homo sapiens <400> 21 atggctagtg gcagctgtca ggggtgcgaa gaggacgagg aaactctgaa gaagttgata 60 gtcaggctga acaatgtcca ggaaggaaaa cagatagaaa cgctggtcca aatcctggag 120 gatctgctgg tgttcacgta ctccgagcac gcctccaagt tatttcaagg caaaaatatc 180 catgtgcctc tgttgatcgt cttggactcc tatatgagag tcgcgagtgt gcagcaggtg 240 ggttggtcac ttctgtgcaa attack gtctgtccag gtacaatgca aagcttaatg ggaccccagg atgttggaa tgattggga gtccttggtg ttcaccaatt gattcttaa atgctaacag ttcataatgc cagtgtaaac ttgtcagtga ttggactgaa gaccttagat ctcctcctaa cttcaggtaa aatcaccttg ctgatattgg atgaagaaag tgatattttc atgttaattt ttgatgccat gcactcattt ccagccaatg atgaagtcca gaaacttgga tgcaaagctt tacatgtgct gtttgagaga gtctcagagg agcaactgac tgaatttgtt gagaacaaag attatatgat attgttaagt gcgttaacaa attttaaga tgaagagga attgtgcttc atgtgctgca ttgtttacat tccctagcga ttccttgcaa taatgtggaa 720. gtcctcatga gtggcaatgt caggtgttat aatattgtgg tggaagctat gaaagcattc cctatgagtg aaagaattca agaagtgagt tgctgtttgc tccataggct tacattaggt aattttttca atatcctggt attaacgaa gtccatgagt ttgtggtgaa agctgtgcag cagtacccag agaatgcagc attgcagatc tcagcgctca gctgtttggc cctcctcact gagactattt tctttaatca agattagag gaaagaatg agaatcaga gagagatgat 1020 gagggggaag agaataattt gttttggctg gaagcctgtt aaagcatt aacgtggcat 1080 agaaagaaca agcacgtgca ggaggccgca tgctgggcac taaataatct ccttatgtac 1140 caaaacagtt tacatgagaa gattgagat gagatggcc atttcccagc tcatagggaa 1200 gtgatgctct ccatgctgat gcattctca tcaaggag ttttccaggc atctgcgaat 1260 gcattgtcaa ctctcttaga aaaatgtt aatttcagaa aaatactgtt atcaaagga 1320 atacacctga atgttttgga gttaatgcag aagcatatac attctcctga agtggctgaa 1380 agtggctgta aaatgctaaa tcatctttt gaaggaagca acacttccct ggatataatg 1440 gcagcagtgg tccccaaaat actaacagtt atgaacgtc atgagacaatc attackagtg 1500 cagctggagg cgcttcgagc tattttacat ttatagtgc ctggcatgcc agagaatcc 1560 agggaggata cagaatttca tcataagcta atatggtta aaaaacagtg ttcaagaat 1620 gatattcaca aactggtcct agcagctttg aacaggttca ttggaatcc tgggattcag 1680 1740 tccctggaag gtgctatgga ttcagtgctt cacacactgc agatgtatcc agatgaccaa 1800 gaaattcagt gtctgggttt aagtcttata ggatacttga ttaacaagaa gaatgtgttc 1860 ataggaactg gacatctgct ggcaaaaatt ctggtttcca gcttataccg atttaaggat 1920 gttgctgaaa tacagaactaa aggatttcag acaatcttag caatcctcaa attgtcagca 1980 tcttttcta agctgctggt gcatcattca tttgacttag taatattcca tcaaatgtct 2040 tccaatatca tggaaaaaa ggatcaacag tttctaaacc tctgttgcaa gtgttttgca 2100 aaagtagcta tggatgattc ttaaaaaatg tgatgctaga gagagcgtgt gatcagaata 2160 acagcatcat ggttgaatgc ttgcttctat tgggagcaga tgccaatcaa gcaaaggagg 2220 gatcttcttt aatttgtcag gtatgtgaga aagagagcag tcccaaattg gtggaactct 2280 tactgaatag tggatctcgt gaacaagatg tacgaaaagc gttgacgata agcattggga 2340 aaggtgacag ccagatcatc agcttgctct taaggaggct ggccctggat gtggccaaca 2400 atagcatttg ccttggagga ttttgtatag gaaaagttga accttcttgg cttggtcctt 2460 tatttccaga taagacttct aatttaagga aaaaaaa tatagcatct acactagcaa 2520 gaatggtgat cagatatcag atgaaaagtg ctgtggaaga aggaacagcc tcaggcagcg 2580 atggaaattt ttctgaagat gtgctgtcta aatttgatga atggaccttt attcctgact 2640 cttctatgga cagtgtgttt gctcaaagtg atgacctgga tagtgaagga agtgaaggct 2700 cattctttgt gaaaaagaaa tctaattcaa ttagtgtagg agaattttac cgagatgccg 2760 tattacagcg ttgctcacca aatttgcaaa gacattccaa ttccttgggg cccatttttg 2820 atcatgaaga tttactgaag cgaaaaagaa aaattatc ttcagatgat tcactcaggt 2880 catcaaaact tcaatcccat atgaggcatt cagacagcat ttcttctctg gcttctgaga 2940 gagaatatat tacatcacta gacctttcag caaatgaact aagagatatt gatgccctaa 3000 gccagaaatg ctgtataagt gttcatttgg agcatcttga aaagctggag cttcaccaga 3060 atgcactcac gagctttcca caacagctat gtgaaactct gaagagtttg acacatttgg 3120 acttgcacag tataaattt acatcatttc cttcttattt gttgaaaatg agttgtattg 3180 ctaatcttga tgtctctcga aatgacattg gaccctcagt ggttttagat cctacagtga 3240 aatgtccaac tctgaaacag tttaacctgt catataacca gctgtctttt gtacctgaga 3300 acctcactga tgtggtagag aaactggagc agctcatttt agaaggaaat aaaatatcag 3360 ggatatgctc ccccttgaga ctgaaggaac tgaagatttt aaaccttagt aagaaccaca 3420 tttcatccct atcagagaac tttcttgagg cttgtcctaa agtggagagt ttcagtgcca 3480 gaatgaattt tcttgctgct atgccttct tgcctccttc tatgacaatc ctaaaattat 3540 ctcagaacaa atttcctgt attccagaag caattttaaa tcttccacac ttgcggtct 3600 tagatatgag cagcaatgat attcagtacc taccaggtcc cgcacactgg aaatctttga 3660 acttaaggga actcttattt agccataatc agatcagcat cttggacttg agtgaaaaag 3720 catatttatg gtctagagta gagaaactgc atctttctca caataaactg aaagagattc 3780 ctcctgagat tggctgtctt gaaaatctga catctctgga tgtcagttac aacttggaac 3840 taagatcctt tcccaatgaa atggggaaat taagcaaaat atgggatctt cctttggatg 3900 aactgcatct taactttgat tttaaacata taggatgtaa agccaaagac atcataaggt 3960 ttcttcaaca gcgattaaaa aaggctgtgc cttataaccg aatgaaactt atgattgtgg 4020 gaaatactgg gagtggtaaa accaccttat tgcagcaatt aatgaaaacc aagaaatcag 4080 atcttggaat gcaaagtgcc acagttggca tagatgtgaa agactggcct atccaaataa 4140 gagacaaaag aaagagagat ctcgtcctaa atgtgtggga ttttgcaggt cgtgaggaat 4200 tctatagtac tcatccccat tttatgacgc agcgagcatt gtaccttgct gtctatgacc 4260 tcagcaaggg acaggctgaa gttgatgcca tgaagccttg gctcttcaat ataaaggctc 4320 gcgcttcttc ttcccctgtg attctcgttg gcacacattt ggatgtttct gatgagaagc 4380 aacgcaaagc ctgcatgagt aaaatcacca aggaactcct gaataagcga gggttccctg 4440 ccatacgaga ttaccacttt gtgaatgcca ccgaggaatc tgatgctttg gcaaaacttc 4500 ggaaaaccat cataaacgag agccttaatt tcaagatccg agatcagctt gttgttggac 4560 agctgattcc agactgctat gtagaacttg aaaaaatcat tttacggag cgtaaaaatg 4620 tgccaattga atttcccgta attgaccgga aacgattatt acaactg agagaaaatc 4680 agctgcagtt agatgaaat gagcttccctc acgcagttca ctttctaaat gatcaggag 4740 tccttcttca ttttcagac ccagcactgc agttaagtga cttgtacttt gtggaaccca 4800 agtggctttg taaaatcatg gcacagattt tgacagtgaa agtggaggt tgtccaaac 4860 accctaaggg cattattcg cgtagagatg tggaaaatt tcttcaaa aaaaggaaat 4920 ttccaaagaa ctacatgtca cagtatttta agctcctaga aaaattccag attgctttgc 4980 caataggaga agaatattg ctggttccaa gcagtttgtc tgaccacagg cctgtgatag 5040 agcttcccca tgtgagaac tctgaatta tcatccgact attgaatg ccttattttc 5100 caatgggatt ttggtcaaga ttaatcaatc gattacttga gatttcacct tacatgcttt 5160 cagggagaga acgagcactt cgcccaaaca gatgtattg gcgacaaggc attackta 5220 attggtctcc tgaagcttat tgtctgtag gatctgaagt cttagacaat catccagaga 5280 gttctttaaa aattacagtt ccttcttgta gaaaaggctg tattcttttg ggccaagttg 5340 tggaccacat tgattctctc atggaagaat ggtttcctgg gttgctggag attgatattt 5400 gtggtgaagg agaaactctg ttgaagaaat gggcattata tagttttaat gatggtgaag 5460 aacatcaaaa aatcttactt gatgacttga tgaagaaagc agaggaagga gatctcttag 5520 taaatccaga tcaaccaagg ctcaccattc caatatctca gattgcccct gacttgattt 5580 tggctgacct gcctagaaat attatgttga ataatgatga gttggaattt gaacaagctc 5640 cagagtttct cctaggtgat ggcagttttg gatcagttta ccgagcagcc tatgaaggag 5700 aagaagtggc tgtgaagatt tttaataaac atacatcact caggctgtta agacaagagc 5760 ttgtggtgct ttgccacctc caccacccca gtttgatatc tttgctggca gctgggattc 5820 gtccccggat gttggtgatg gagttagcct ccaagggttc cttggatcgc ctgcttcagc 5880 aggacaaagc cagcctcact agaaccctac agcacaggat tgcactccac gtagctgatg 5940 gtttgagata cctccactca gccatgatta tataccgaga cctgaaaccc cacaatgtgc 6000 tgcttttcac actgtatccc aatgctgcca tcattgcaaa gattgctgac tacggcattg 6060 ctcagtactg ctgtagaatg gggataaaaa catcagaggg cacaccaggg tttcgtgcac 6120 ctgaagttgc cagaggaaat gtcatttata accaacaggc tgatgtttat tcatttggtt 6180 tactactcta tgacattttg acaactggag gtagaatagt agagggtttt aagtttccaa 6240 atgagtttga tgaattagaa atacaaggaa aattacctga tccagttaaa gaatatggtt 6300 gtgccccatg gcctatggtt gagaaattaa ttaaacagtg tttgaaagaa aatcctcaag 6360 aaaggcctac ttctgcccag gtctttgaca ttttgaattc agctgaatta gtctgtctga 6420 cgagacgcat tttattacct aaaaacgtaa ttgttgaatg catggttgct acacatcaca 6480 acagcaggaa tgcaagcatt tggctggggct gtggcacac cgacagagga cagctctcat 6540 ttcttgactt aaatactgaa ggatacactt ctgaggaagt tgctgatagt agaatattgt 6600 gcttagcctt ggtgcatctt cctgttgaaa aggaaagctg gattgtgtct gggacacagt 6660 ctggtactct cctggtcatc aataccgaag atgggaaaaa gagacatacc ctagaaaaga 6720 tgactgattc tgtcacttgt ttgtattgca attccttttc caagcaaagc aaacaaaaaa 6780 attttctttt ggttggaacc gctgatggca agttagcaat ttttgaagat aagactgtta 6840 agcttaaagg agctgctcct ttgaagatac taaatatagg aaatgtcagt actccattga 6900 tgtgtttgag tgaatccaca aattcaacgg aaagaaatgt aatgtgggga ggatgtggca 6960 caaagatttt ctccttttct aatgatttca ccattcagaa actcattgag acaagaacaa 7020 gccaactgtt ttcttatgca gctttcagtg attccaacat cataacagtg gtggtagaca 7080 ctgctctcta tattgctaag caaaatagcc ctgttgtgga agtgtgggat aagaaaactg 7140 aaaaactctg tggactaata gactgcgtgc actttttaag ggaggtaatg gtaaaagaaa 7200 acaaggaatc aaaacacaaa atgtcttatt ctgggagagt gaaaaccctc tgccttcaga 7260 agaacactgc tctttggata ggaactggag gaggccatat tttactcctg gatctttcaa 7320 ctcgtcgact tatacgtgta atttacaact tttgtaattc ggtcagagtc atgatgacag 7380 cacagctagg aagccttaaa aatgtcatgc tggtattggg ctacaaccgg aaaaatactg 7440 aaggtacaca aaagcagaaa gagatacaat cttgcttgac cgttttgggac atcaatctc 7500 cacatgaagt gcaaattta gaaaaacaca tgaagtgag aaagaatta gctgaaaaaaa 7560 tgagacgac atctgttgag taa 7583 <210> 22 <211> 423 <212> DNA <213> Humans (Homo sapiens) <400> 22 atggatgtat tcatgaaagg acttcaag gccaaggagg gagttgtgc tgctgctgag 60 aaaaaccaaac agggtgtggc agaagcagca ggaagacaa aagaggtgt tctctatgta 120 ggctccaaaa ccaaggagggg agtggtgcat ggtgtggcaa cagtggctga gagaccaaa 180 gagcaagtga caatgttgg aggagcagtg gtgacgggtg tgacagcagt agcccagaag 240 acagtggagg gagcagggag cattgcagca gccactggct tgtcaaaa ggaccagttg 300 ggcaagaatg aagaaggagc cccacaggaa ggaattctgg agatatgcc tgtggatcct 360 gatagagg cttatgaat gccttctgag gaagggtatc aagactacga acctgaagcc 420 there are 423 <210> 23 <211> 1860 <212> DNA <213> Homo sapiens <400> 23 atggcctccg gtgcgtataa cccgtatata gagataattg aacaacccag gcagagggga 60 atgcgtttta gatacaaatg tgaagggcga tcagcaggca gcattccagg ggagcacagc 120 acagacaaca accgaacata cccttctatc cagattatga actattatgg aaaaggaaaa 180 gtgagaatta cattagtaac aaagaatgac ccatataaac ctcatcctca tgatttagtt 240 ggaaaagact gcagagacgg ctactatgaa gcagaatttg gacaagaacg cagacctttg 300 tttttccaaa atttgggtat tcgatgtgtg aagaaaaaag aagtaaaaga agctattatt 360 acaagaataa aggcaggaat caatccattc aatgtccctg aaaaacagct gaatgatatt 420 gaagattgtg acctcaatgt ggtgagactg tgttttcaag tttttctccc tgatgaacat 480 ggtaatttga cgactgctct tcctcctgtt gtctcgaacc caatttatga caaccgtgct 540 ccaaatactg cagaattaag gatttgtcgt gtaaacaaga attgtggaag tgtcagagga 600 ggagatgaaa tatttctact ttgtgacaaa gttcagaaag atgacataga agttcgtttt 660 gtgttgaacg attgggaagc aaaaggcatc ttttcacaag ctgatgtaca ccgtcaagta 720 gccattgttt tcaaaactcc accatattgc aaagctatca cagaacccgt aacagtaaaa 780 atgcagttgc ggagaccttc tgaccaggaa gttagtgaat ctatggattt tagatatctg 840 ccagatgaaa aagatactta cggcaataaa gcaaagaaac aaaagacaac tctgcttttc 900 cagaaactgt gccaggatca cgtagaaaca gggttcgcc atgttgacca ggatggtctt 960 gaactcctga catcaggtga tccacccacc ttggcctccc aaagtgctgg gattacagtt 1020 aatttctctg agagaccaag acctggtctc ctcggttcaa ttggagaagg aagatacttc 1080 aaaaaagaac caaacttgtt ttctcatgat gcagttgtga gagaaatgcc tacaggggtt 1140 tcaagtcaag cagaatccta ctatccctca cctgggccca tctcaagtgg attgtcacat 1200 catgcctcaa tggcacctct gccttcttca agctggtcat cagtggccca ccccacccca 1260 cgctcaggca atacaaaccc actgagtagt tttcaacaa ggacacttcc ttctaattcg 1320 caaggtatcc caccattcct gagaatacct gttgggaatg atttaaatgc ttctaatgct 1380 tgcatttaca acatgccga tgacatagtc ggaatggaag cgtcatccat gccatcagca 1440 gatttatatg gtatttctga tccacatg ctgtctaatt gttctgtgaa tatgatgaca 1500 accagcagtg acaccatggg agagactgat aatccagac ttctgagcat gatcttgaa 1560 aacccctcat gtattcagt gttagaccca agagacttga gagagctcca tcagatgtcc 1620 tcttccagta tgtcagcagg cgccaattcc atactactg ttttgttc acatcagat 1680 gcatttgagg gatctgactt cagttgtgca gatacagca tgataaatga gtcgggacca 1740 tcaacagta ctaatccaaa cagtcatggt ttgttcag atagtcagta tcaggtatt 1800 ggcagtatgc aaatgagca attgagtgac tcctttccat atgaattttt tcaagtataa 1860 <210> 24 <211> 2097 <212> DNA <213> Humans (Homo sapiens) <400> 24 atgggggacc ctggactggc caagttgcag ttcgccccct ttaatagtgc cctggacgtt 60 ggcttctggc acgaacgac ccagagaag ttgaacgagt accgcctgga cgaggcaccc 120 aaagacatca agggctatta ctacaatggt gactctgctg gtctgcccac ccgcttgacg ttggagttca gtgcttttga catgagtgcc tccacgcctg cccactgctg cccggccatg 240 ggaaccctgc acaacaccaa cacacttgag gcttttaaga cagcagacaa gaagctcctt ctggagcagt cagcaatga gatctggga gccataagt caggtgctgc tctcgaaaac cccatgctcc tcaacaagtt tctgctcctg accttcgcgg acctaaaga gtaccacttc 420 tactactggt tttgctgccc cgccctctgt cttcctgaga gcatccctct aatccgggga 480 cctgtgagct tggatcaaag gctttcacca aaacagatcc aggccctgga gcatgcctat 540 gatgatctgt gtcgagccga aggcgtcacg gccctgccct acttcttatt caagtacgat 660. gacgacactg ttctggtctc cttgctcaaa cactacagtg atttcttcca aggtcaaagg acaaagataa cagttggtgt gtacgatccc tgtaacctag cccagtaccc tggatggcct 720 ttgaggaatt ttttggtcct ggcagcccac agatggagcg gcagtttcca gtccgttgaa gtcctctgct ttcgggaccg caccatgcag ggagctagag acgtgacaca tagcatcatc 840 tttgaagtga aacttccaga aatggcattt agcccagatt gtcctaagc tgttggctgg gagaagaacc agaaaggagg catgggtccg aggatggtga acctcagtgg atgtatggac cccaaaaggc tggctgagtc atctgtggat ctgaatctca agctgatgtg ctggcgattg gtccccacct tggacttgga caaggtcgtg tctgtcaagt gcctgctgct gggagctggt 1080 accttggggt gtaatgtggc taggacactg atgggctggg gcgtcagaca tgtcaccttt 1140 gtggataacg ccaagatctc ctactccaat cccgtgaggc agcctctgta tgaatttgaa gattgtctag ggggtggcaa gcccaaggcc ctggctgcag cagagcggct acagaaaata tttcccggag tgaatgccag agggttcaac atgagcatcc ccatgccagg acaccctgtg aacttctctg acgtcacgat ggagcaggcc cgcagagatg tggagcagct ggagcagctc attgataacc atgatgtcat cttcctgcta atggacacca gggagagccg gtggcttcct 1440 actgttattg cagccagcaa gcgaaagctg gtcatcaacg ctgccttggg gtttgatacc tttgttgtca tgagacatgg cctgaagaaa cccaagcagc agggagccgg agacctctgc ccaagccatc ttgtagcacc tgctgacctg ggctcctcac tttttgccaa catccctgga 1620 tacaagcttg gctgctactt ctgcaatgat gtggtggctc caggagattc aaccagagac 1680 cggactctgg accagcagtg cacagtgagc cgcccaggcc tggccgtgat tgcaggtgcc 1740 ctggctgtgg agctgatggt ctctgtcctg cagcatcctg aggggggcta cgccatcgcc 1800 agcagcagtg atgaccgcat gaatgagcct cccacctcgc tgggacttgt gcctcaccag 1860 atccggggtt ttctgtcacg gttcgataat gttcttcctg tcagcctggc atttgataaa 1920 tgtacagcct gttcacccaa agttcttgat cagtacgagc gagaaggatt caccttccta 1980 gcgaaggttt ttaactcctc acattccttc ttagaagact tgaccggtct taccctgctc 2040 catcaagaga cccaagctgc tgagatctgg gacatgagtg acgaggagac tgtctga 2097 <210> 25 <211> 1545 <212> DNA <213> Homo sapiens <400> 25 atggccctga gcgagctggc gctggtccgc tggctgcagg agagccgccg ctcgcggaag 60 ctcatcctgt tcatcgtgtt cctggcgctg ctgctggaca acatgctgct cactgtcgtg 120 gtccccatca tcccaagtta tctgtacagc attaagcatg agaagaatgc tacagaaatc 180 cagacggcca ggccagtgca cactgcctcc atctcagaca gcttccagag catcttctcc 240 tattatgata actcgactat ggtcaccggg aatgctacca gagacctgac acttcatcag 300 accgccacac agcacatggt gaccaacgcg tccgctgttc cttccgactg tcccagtgaa 360 gacaaagacc tcctgaatga aaacgtgcaa gttggtctgt tgtttgcctc gaaagccacc 420 gtccagctca tcaccaaccc tttcatagga ctactgacca acagaattgg ctatccaatt 480 cccatatttg cgggattctg catcatgttt gtctcaacaa ttatgtttgc cttctccagc 540 agctatgcct tctgctgat tgccaggtcg ctgcagggca tcggctcgtc ctgctcctct 600 gtggctggga tgggcatgct tgccagtgtc tacacagatg atgaagagag aggcaacgtc 660 atgggaatcg ccttgggagg cctggccatg ggggtcttag tgggcccccc cttcggggagt 720 gtgctctatg agttgtggg gaagacggct ccgttcctgg tgctggccgc cctggtactc 780 ttggatggag ctattcagct ctttgtgctc cagccgtccc gggtgcagcc agagagtcag 840 aaggggacac ccctaaccac gctgctgaag gacccgtaca tcctcattgc tgcaggctcc 900 atctgctttg caaacatggg catcgccatg ctggagccag ccctgcccat ctggatgatg 960 gagaccatgt gttcccgaaa gtggcagctg ggcgttgcct tcttgccagc tagtatctct 1020 tatctcattg gaaccaatat ttttgggata cttgcacaca aaatggggag gtggctttgt 1080 gctcttctgg gaatgataat tgttggagtc agcattttat gtattccatt tgcaaaaaac 1140 atttatggac tcatagctcc gaactttgga gttggttttg caattggaat ggtggattcg 1200 tcaatgatgc ctatcatggg ctacctcgta gacctgcggc acgtgtccgt ctatgggagt 1260 gtgtacgcca ttgcggatgt ggcattttgt atggggtatg ctataggtcc ttctgctggt 1320 ggtgctattg caaaggcaat tggatttcca tggctcatga caattattgg gataattgat 1380 attctttttg cccctctctg cttttttctt cgaagtccac ctgccaaaga agaaaaaatg 1440 gctattctca tggatcacaa ctgccctatt aaaacaaaaa tgtacactca gaataatatc 1500 cagtcatatc cgataggtga agatgaagaa tctgaaagtg actga 1545 <210> 26 <211> 2324 <212> DNA <213> Homo sapiens <400> 26 atcacatgac ccatccacat cgggaagccg gaattacttg cagggctaac ctagtgccta 60 tagctaaggc aggtacctgc atccttgttt ttgtttagtg gatcctctat ccttcagaga 120 ctctggaacc cctgtggtct tctcttcatc taatgaccct gaggggatgg agttttcaag 180 tccttccaga gaggaatgtc ccaagccttt gagtagggta agcatcatgg ctggcagcct 240 cacaggattg cttctacttc aggcagtgtc gtgggcatca ggtgcccgcc cctgcatccc 300 taaaagcttc ggctacagct cggtggtgtg tgtctgcaat gccacatact gtgactcctt 360 tgaccccccg acctttcctg cccttggtac cttcagccgc tatgagagta cacgcagtgg 420 gcgacggatg gagctgagta tggggcccat ccaggctaat cacacgggca caggcctgct 480 actgaccctg cagccagaac agaagttcca gaaagtgaag ggatttggag gggccatgac 540 agatgctgct gctctcaaca tccttgccct gtcaccccct gcccaaaatt tgctacttaa 600 atcgtacttc tctgaagaag gaatcggata taacatcatc cgggtaccca tggccagctg 660 tgacttctcc atccgcacct acacctatgc agacacccct gatgatttcc agttgcacaa 720 cttcagcctc ccagaggaag ataccaagct caagataccc ctgattcacc gagccctgca 780 gttggcccag cgtcccgttt cactccttgc cagcccctgg acatcaccca cttggctcaa 840 gaccaatgga gcggtgaatg ggaaggggtc actcaaggga cagcccggag acatctacca 900 ccagacctgg gccagatact ttgtgaagtt cctggatgcc tatgctgagc acaagttaca 960 gttctgggca gtgacagctg aaaatgagcc ttctgctggg ctgttgagtg gatacccctt 1020 ccagtgcctg ggcttcaccc ctgaacatca gcgagacttc attgcccgtg acctaggtcc 1080 taccctcgcc aacagtactc accacaatgt ccgcctactc atgctggatg accaacgctt 1140 gctgctgccc cactgggcaa aggtggtact gacagaccca gaagcagcta aatatgttca 1200 tggcattgct gtacattggt acctggactt tctggctcca gccaaagcca ccctagggga 1260 gacacaccgc ctgttcccca acaccatgct ctttgcctca gaggcctgtg tgggctccaa 1320 gttctgggag cagagtgtgc ggctaggctc ctgggatcga gggatgcagt acagccacag 1380 catcatcacg aacctcctgt accatgtggt cggctgggacc gactggaacc ttgccctgaa 1440 ccccgaagga ggacccaatt gggtgcgtaa ctttgtcgac agtcccatca ttgtagacat 1500 caccaaggac acgttttaca aacagcccat gttctaccac cttggccact tcagcaagtt 1560 cattcctgag ggctcccaga gagtggggct ggttgccagt cagaagaacg acctggacgc 1620 agtggcactg atgcatcccg atggctctgc tgttgtggtc gtgctaaacc gctcccttaa 1680 ggatgtgcct cttaccatca aggatcctgc tgtgggcttc ctggagacaa tctcacctgg 1740 ctactccatt cacacctacc tgtggcgtcg ccagtgatgg agcagatact caaggaggca 1800 ctgggctcag cctgggcatt aagggacag agtcagctca cacgctgtct gtgactaaag 1860 agggcacagc agggccagtg tgagcttaca gcgacgtaag cccaggggca atggtttggg 1920 tgactcactt tcccctctag gtggtgccag gggctggagg cccctagaaa aagatcagta 1980 agccccagtg tccccccagc ccccatgctt atgtgaacat gcgctgtgtg ctgcttgctt 2040 tggaaactgg gcctgggtcc aggcctaggg tgagctcact gtccgtacaa acacaagatc 2100 agggctgagg gtaaggaaaa gaagagacta ggaaagctgg gcccaaaact ggagactgtt 2160 tgtctttcct ggagatgcag aactgggccc gtggagcagc agtgtcagca tcagggcgga 2220 agccttaaag cagcagcggg tgtgcccagg cacccagatg attcctatgg caccagccag 2280 gaaaaatggc agctcttaaa ggagaaaatg tttgagccca gtca 2324 <210> 27 <211> 1398 <212> DNA <213> Homo sapiens <400> 27 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccagggtcca 540 tcttgctggg atgatgtttt aattccaaac cggatgagtg gtgaatgcca atccccacac 600 tgccctggga ctagtgcaga atttttcttt aaatgtggag cacaccccac ctctgacaag 660 gaaacatcag tagctttgca cctgatcgca acaaatagtc ggaacatcac ttgcattacg 720 tgcacagacg tcaggagccc cgtcctggtt ttccagtgca actcccgcca cgtgatttgc 780 ttagactgtt tccacttata ctgtgtgaca agactcaatg atcggcagtt tgttcacgac 840 cctcaacttg gctactccct gccttgtgtg gctggctgtc ccaactcctt gattaaagag 900 ctccatcact tcaggattct gggagaagag cagtacaacc ggtaccagca gtatggtgca 960 gaggagtgtg tcctgcagat ggggggcgtg ttatgccccc gccctggctg tggagcgggg 1020 ctgctgccgg agcctgacca gaggaaagtc acctgcgaag ggggcaatgg cctgggctgt 1080 gggtttgcct tctgccggga atgtaaagaa gcgtaccatg aaggggagtg cagtgccgta 1140 tttgaagcct caggaacaac tactcaggcc tacagagtcg atgaaagagc cgccgagcag 1200 gctcgttggg aagcagcctc caaagaaacc atcaagaaaa ccaccaagcc ctgtccccgc 1260 tgccatgtac cagtggaaaa aaatggaggc tgcatgcaca tgaagtgtcc gcagccccag 1320 tgcaggctcg agtggtgctg gaactgtggc tgcgagtgga accgcgtctg catgggggac 1380 cactggttcg acgtgtag 1398 <210> 28 <211> 1314 <212> DNA <213> Homo sapiens <400> 28 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccaggaattt 540 ttctttaaat gtggagcaca ccccacctct gacaaggaaa catcagtagc tttgcacctg 600 atcgcaacaa atagtcggaa catcacttgc attacgtgca cagacgtcag gagccccgtc 660 ctggttttcc agtgcaactc ccgccacgtg atttgcttag actgtttcca cttatactgt 720 gtgacaagac tcaatgatcg gcagtttgtt cacgaccctc aacttggcta ctccctgcct 780 tgtgtggctg gctgtcccaa ctccttgatt aaagagctcc atcacttcag gattctggga 840 gaagagcagt acaaccggta ccagcagtat ggtgcagagg agtgtgtcct gcagatgggg 900 ggcgtgttat gcccccgccc tggctgtgga gcggggctgc tgccggagcc tgaccagagg 960 aaagtcacct gcgaaggggg caatggcctg ggctgtgggt ttgccttctg ccgggaatgt 1020 aaagaagcgt accatgaagg ggagtgcagt gccgtatttg aagcctcagg aacaactact 1080 caggcctaca gagtcgatga aagagccgcc gagcaggctc gttgggaagc agcctccaaa 1140 gaaaccatca agaaaaccac caagccctgt ccccgctgcc atgtaccagt ggaaaaaaat 1200 ggaggctgca tgcacatgaa gtgtccgcag ccccagtgca ggctcgagtg gtgctggaac 1260 tgtggctgcg agtggaaccg cgtctgcatg ggggaccact ggttcgacgt gtag 1314 <210> 29 <211> 657 <212> DNA <213> Homo sapiens <400> 29 atgaatgcaa ctggaggcga cgaccccaga aacgcggcgg gaggctgtga gcgggagccc 60 cagagcttga ctcgggtgga cctcagcagc tcagtcctcc caggagactc tgtggggctg 120 gctgtcattc tgcacactga cagcaggaag gactcaccac cagctggaag tccagcaggt 180 agatcaatct acaacagctt ttatgtgtat tgcaaaggcc cctgtcaaag agtgcagccg 240 ggaaaactca gggtacagtg cagcacctgc aggcaggcaa cgctcacctt gacccagggt 300 ccatcttgct gggatgatgt tttaattcca aaccggatga gtggtgaatg ccaatcccca 360 cactgccctg ggactagtgc agaatttttc tttaaatgtg gagcacaccc cacctctgac 420 aaggaaacat cagtagcttt gcacctgatc gcaacaaata gtcggaacat cacttgcatt 480 acgtgcacag acgtcaggag ccccgtcctg gttttccagt gcaactcccg ccacgtgatt 540 tgcttagact gtttccactt atactgtgtg acaagactca atgatcggca gtttgttcac 600 gaccctcaac ttggctactc cctgccttgt gtggtttgcc ttctgccggg aatgtaa 657 <210> 30 <211> 825 <212> DNA <213> Homo sapiens <400> 30 atgagtggtg aatgccaatc cccacactgc cctgggacta gtgcagaatt tttctttaaa 60 tgtggagcac accccacctc tgacaaggaa acatcagtag ctttgcacct gatcgcaaca 120 aatagtcgga acatcacttg cattacgtgc acagacgtca ggagccccgt cctggttttc 180 cagtgcaact cccgccacgt gatttgctta gactgtttcc acttatactg tgtgacaaga 240 ctcaatgatc ggcagtttgt tcacgaccct caacttggct actccctgcc ttgtgtggct 300 ggctgtccca actccttgat taaagagctc catcacttca ggattctggg agaagagcag 360 tacaaccggt accagcagta tggtgcagag gagtgtgtcc tgcagatggg gggcgtgtta 420 tgcccccgcc ctggctgtgg agcggggctg ctgccggagc ctgaccagag gaaagtcacc 480 tgcgaagggg gcaatggcct gggctgtggg tttgccttct gccgggaatg taaagaagcg 540 taccatgaag gggagtgcag tgccgtattt gaagcctcag gaacaactac tcaggcctac 600 agagtcgatg aaagagccgc cgagcaggct cgttgggaag cagcctccaa agaaaccatc 660 aagaaaacca ccaagccctg tccccgctgc catgtaccag tggaaaaaaa tggaggctgc 720 atgcacatga agtgtccgca gccccagtgc aggctcgagt ggtgctggaa ctgtggctgc 780 gagtggaacc gcgtctgcat gggggaccac tggttcgacg tgtag 825 <210> 31 <211> 1161 <212> DNA <213> Homo sapiens <400> 31 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccagggtcca 540 tcttgctggg atgatgtttt aattccaaac cggatgagtg gtgaatgcca atccccacac 600 tgccctggga ctagtgcaga atttttcttt aaatgtggag cacaccccac ctctgacaag 660 gaaacatcag tagctttgca cctgatcgca acaaatagtc ggaacatcac ttgcattacg 720 tgcacagacg tcaggagccc cgtcctggtt ttccagtgca actcccgcca cgtgatttgc 780 ttagactgtt tccacttata ctgtgtgaca agactcaatg atcggcagtt tgttcacgac 840 cctcaacttg gctactccct gccttgtgtg ggaactggag acacagtggt gcttagagga 900 gctctggggg gattcaggag aggagtcgct ggctgtccca actccttgat taaagagctc 960 catcacttca ggattctggg agaagagcag tacaaccggt accagcagta tggtgcagag 1020 gagtgtgtcc tgcagatggg gggcgtgtta tgcccccgcc ctggctgtgg agcggggctg 1080 ctgccggagc ctgaccagag gaaagtcacc tgcgaagggg gcaatggcct gggctgtggg 1140 tatggacaac gaagaacaaa a 1161 <210> 32 <211> 951 <212> DNA <213> Homo sapiens <400> 32 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca ggaatttttc 180 tttaaatgtg gagcacaccc cacctctgac aaggaaacat cagtagcttt gcacctgatc 240 gcaacaaata gtcggaacat cacttgcatt acgtgcacag acgtcaggag ccccgtcctg 300 gttttccagt gcaactcccg ccacgtgatt tgcttagact gtttccactt atactgtgtg 360 acaagactca atgatcggca gtttgttcac gaccctcaac ttggctactc cctgccttgt 420 gtggctggct gtcccaactc cttgattaaa gagctccatc acttcaggat tctgggagaa 480 gagcagtaca accggtacca gcagtatggt gcagaggagt gtgtcctgca gatggggggc 540 gtgttatgcc cccgccctgg ctgtggagcg gggctgctgc cggagcctga ccagaggaaa 600 gtcacctgcg aagggggcaa tggcctgggc tgtgggtttg ccttctgccg ggaatgtaaa 660 gaagcgtacc atgaagggga gtgcagtgcc gtatttgaag cctcaggaac aactactcag 720 gcctacagag tcgatgaaag agccgccgag caggctcgtt gggaagcagc ctccaaagaa 780 accatcaaga aaaccaccaa gccctgtccc cgctgccatg taccagtgga aaaaaatgga 840 ggctgcatgc acatgaagtg tccgcagccc cagtgcaggc tcgagtggtg ctggaactgt 900 ggctgcgagt ggaaccgcgt ctgcatgggg gaccactggt tcgacgtgta g 951 <210> 33 <211> 1164 <212> DNA <213> Homo sapiens <400> 33 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccaggaattt 540 ttctttaaat gtggagcaca ccccacctct gacaaggaaa catcagtagc tttgcacctg 600 atcgcaacaa atagtcggaa catcacttgc attacgtgca cagacgtcag gagccccgtc 660 ctggttttcc agtgcaactc ccgccacgtg atttgcttag actgtttcca cttatactgt 720 gtgacaagac tcaatgatcg gcagtttgtt cacgaccctc aacttggcta ctccctgcct 780 tgtgtggctg gctgtcccaa ctccttgatt aaagagctcc atcacttcag gattctggga 840 gaagagcagt ttgccttctg ccgggaatgt aaagaagcgt accatgaagg ggagtgcagt 900 gccgtatttg aagcctcagg aacaactact caggcctaca gagtcgatga aagagccgcc 960 gagcaggctc gttgggaagc agcctccaaa gaaaccatca agaaaaccac caagccctgt 1020 ccccgctgcc atgtaccagt ggaaaaaaat ggaggctgca tgcacatgaa gtgtccgcag 1080 ccccagtgca ggctcgagtg gtgctggaac tgtggctgcg agtggaaccg cgtctgcatg 1140 ggggaccact ggttcgacgt gtag 1l64 <210> 34 <211> 1248 <212> DNA <213> Homo sapiens <400> 34 atgatagtgt ttgtcaggtt caactccagc catggtttcc cagtggaggt cgattctgac 60 accagcatct tccagctcaa ggaggtggtt gctaagcgac agggggttcc ggctgaccag 120 It should be noted that there might be some errors in the original text as "1l64" in seems incorrect. It might be "1164". This translation is based on the given text with the best attempt to maintain the integrity of the original content.ttgcgtgtga ttttcgcagg gaaggagctg aggaatgact ggactgtgca gaattgtgac 180 ctggatcagc agagcattgt tcacattgtg cagagaccgt ggagaaaagg tcaagaaatg 240 aatgcaactg gaggcgacga ccccagaaac gcggcgggag gctgtgagcg ggagccccag 300 agcttgactc gggtggacct cagcagctca gtcctcccag gagactctgt ggggctggct 360 gtcattctgc acactgacag caggaaggac tcaccaccag ctggaagtcc agcaggtaga 420 tcaatctaca acagctttta tgtgtattgc aaaggcccct gtcaaagagt gcagccggga 480 aaactcaggg tacagtgcag cacctgcagg caggcaacgc tcaccttgac ccagggtcca 540 tcttgctggg atgatgtttt aattccaaac cggatgagtg gtgaatgcca atccccacac 600 tgccctggga ctagtgcaga atttttcttt aaatgtggag cacaccccac ctctgacaag 660 gaaacatcag tagctttgca cctgatcgca acaaatagtc ggaacatcac ttgcattacg 720 tgcacagacg tcaggagccc cgtcctggtt ttccagtgca actcccgcca cgtgatttgc 780 ttagactgtt tccacttata ctgtgtgaca agactcaatg atcggcagtt tgttcacgac 840 cctcaacttg gctactccct gccttgtgtg gctggctgtc ccaactcctt gattaaagag 900 ctccatcact tcaggattct gggagaagag cagtttgcct tctgccggga atgtaaagaa 960 gcgtaccatg aaggggagtg cagtgccgta tttgaagcct caggaacaac tactcaggcc 1020 tacagagtcg atgaaagagc cgccgagcag gctcgttggg aagcagcctc caaagaaacc 1080 atcaagaaaa ccaccaagcc ctgtccccgc tgccatgtac cagtggaaaa aaatggaggc 1140 tgcatgcaca tgaagtgtcc gcagccccag tgcaggctcg agtggtgctg gaactgtggc 1200 tgcgagtgga accgcgtctg catgggggac cactggttcg acgtgtag 1248 <210> 35 <211> 1398 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - codon-optimized PRKN variant CO1 <400> 35 atgattgtgt ttgtcagatt caactcctcc catggcttcc ctgtggaagt ggactcagat 60 acctccatct tccaactgaa ggaggtggtg gccaagagac agggggtgcc tgcagatcag 120 cttagggtca tctttgctgg aaaggagctg agaaatgact ggactgtgca gaactgtgac 180 ctggaccagc agagcatagt gcacattgtc caacggccct ggaggaaagg acaggagatg 240 aatgccactg gaggagatga cccccgcaat gctgcgggtg gctgtgaaag agaacctcag 300 tccctgacca gagtggacct gtccagctca gtgctcccag gagactcagt ggggcttgct 360 gtgattctgc acactgactc caggaaggac tccccccctg ctggaagccc agcgggcaga 420 agcatctaca actccttcta tgtgtactgc aagggcccct gccagagagt gcagcctgga 480 aagctgaggg tgcagtgctc cacctgtcgc caagccactc tcaccctgac ccagggccca 540 tcctgctggg atgatgtctt gatccccaac aggatgtcgg gagaatgtca gtcaccacac 600 tgccctggaa cctcggcaga gttcttcttc aaatgtggtg cccaccctac ctccgacaag 660 gaaacctcag tggccctgca tctcattgcc accaacagca ggaacatcac ctgtatcact 720 tgcactgatg tcaggtcacc tgtgctggtg ttccagtgca actccagaca tgtgatctgc 780 ctggactgct tccacctgta ctgtgtgact aggctcaatg acagacaatt tgtccatgac 840 ccccagctgg gctactccct gccctgtgtg gctggatgcc ctaactccct gatcaaggaa 900 ctccaccact tccgcatcct gggagaagaa cagtacaaca ggtaccagca gtacggtgca 960 gaagagtgtg tgctccaaat ggggggagtg ctgtgccccc ggccgggctg tggagctggc 1020 ctgctgcctg aacctgatca gagaaaggtc acttgcgagg gtggaaacgg tcttggttgt 1080 gggtttgcct tctgccggga gtgcaaggag gcctaccacg aaggagagtg ctctgcagtg 1140 ttcgaggcct ctggcactac cacccaagcc tatagagtgg atgagcgggc agcagaacag 1200 gccagatggg aagctgccag caaggaaacc attaagaaaa ccaccaagcc atgcccccgg 1260 tgccacgtgc cagtggagaa gaatggaggg tgcatgcaca tgaagtgccc ccagccccag 1320 tgccgcttgg agtggtgctg gaactgtggt tgtgaatgga acagggtctg tatgggggac 1380 cactggtttg atgtgtaa 1398 <210> 36 <211> 1398 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - codon-optimized PRKN variant CO2 <400> 36 atgattgtgt ttgtcagatt caactcctcc catggcttcc ctgtggaagt ggactcggac 60 accagcatct tccagctgaa ggaagtggtg gccaagagac agggagtgcc agcagatcag 120 ctccgggtca tttttgctgg aaaggaactg aggaatgact ggactgtcca gaactgtgac 180 ctggaccagc agtccattgt ccacattgtg cagaggcctt ggaggaaggg ccaagagatg 240 aatgccactg ggggggatga ccctagaaat gcggctggag gctgtgaacg ggagcctcag 300 tccctcacta gagtggacct gagctcctca gtcctccctg gagactcagt gggcctggct 360 gtgatcctcc acactgactc ccgcaaggac agccccccag cgggcagccc tgcaggccgg 420 tccatctaca actccttcta tgtgtactgc aagggaccct gccagagagt ccagcctggc 480 aaactgaggg tgcagtgctc cacctgtcgc caagccaccc tgaccctgac ccaaggaccc 540 tcctgctggg atgatgtgct gatccccaac cggatgtcag gagaatgtca aagcccgcat 600 tgcccaggga cctctgcaga gttcttcttc aagtgtggag cccaccccac ctcggacaag 660 gaaacctcag tggccctgca cctgattgcc acaaactccc ggaacatcac ctgtatcacc 720 tgtactgatg tgcgctcacc agtgctggtg ttccagtgca actcccgcca tgtgatctgc 780 ctggattgct tccacttgta ctgtgtgact agactgaatg acaggcagtt tgtgcatgat 840 ccccagctgg gttacagctt gccctgtgtg gctggttgcc ccaactccct gatcaaggag 900 ctgcaccact tccgcatttt gggggaggag caatacaaca gataccagca gtatggagca 960 gaagaatgtg tgctgcagat ggggggggtg ctctgcccga ggccaggatg tggtgcaggc 1020 ctgctccctg aacctgacca gagaaaagtg acctgtgaag ggggcaacgg acttggttgt 1080 ggattgcct tctgccggga gtgcaaggag gcctaccacg agggagaatg ctctgctgtc 1140 tttgaggcct caggaaccac tacccaggcc tacagagtgg atgaaagggc tgctgagcaa 1200 gccagatggg aagcagcctc caaggaaacc atcaagaaaa ccactaagcc ctgccccgc 1260 tgccatgtgc ctgtggagaa gaatggtgga tgcatgcaca tgaagtgccc ccaacctcag 1320 tgcaggcttg aatggtgctg gaactgtggc tgtgaatgga acagagtctg catgggggac 1380 cactggtttg atgtctaa 1398 <210> 37 <211> 1398 <212> DNA <213> Artificial Sequence <220> <223> Preparation in the laboratory - Codon-optimized PRKN variant CO3 <400> 37 atgattgtgt ttgtgagatt caactcctcc catggcttcc cagtggaagt ggattctgac 60 acctccatct tccaattaaa ggaggtggtg gccaagcgtc agggagtccc agcagaccag 120 ctgagggtga tctttgctgg caaagaactt agaaatgact ggactgtgca gaactgtgac 180 ctggaccagc agagcattgt gcatattgtc caacggccct ggcggaaggg ccaggagatg 240 aatgccactg ggggggatga cccccggaat gccgcggggg gctgtgagag ggaacctcaa 300 tccctgacca gagtggacct gagctcctcg gtgttgccag gagacagcgt gggcctggct 360 gtgatcctgc acactgactc caggaaggac agcccccctg ctggaagccc agctggccgc 420 tccatctaca actccttcta tgtctactgc aagggcccct gccagagagt gcagcctgga 480 aagctgagag tgcagtgctc cacctgtcgc caggccaccc tgaccctgac ccaaggaccg 540 tcctgctggg atgatgtcct catccccaac aggatgtcag gagaatgcca atccccccac 600 tgtcctggca cttcagcgga gttcttcttc aagtgtggag ctcaccccac ttctgacaag 660 gaaacctcag tggccctcca cctgattgcc accaactcca gaaacatcac atgcattact 720 tgcactgatg tcaggtcccc tgtgttggtg ttccagtgca actcaagaca tgtgatctgc 780 ctggactgct tccatctcta ctgtgtgact agacttaacg agacagtt tgtccatgac 840 ccacagcttg gatacagcct cccctgtgtg gctgggtgcc ccaactccct gattaaggaa 900 ctgcaccact tcaggatcct gggagagaa footcaaca ggtaccagca atatggggct 960 gaggagtgtg tgctccagat gggggagtc ctgtgccccc ggccgggatg tggtgcaggc 1020 ctgctccctg agcctgacca gcgcaaagtg acctgtgaag gtggcaacgg tctgggttgt 1080 ggttttgcct tctgccggga gtgcaaggaa gcctaccacg aaggggaatg ctcagctgtg 1140 tttgaggcct caggaaccac cacccaggcc tacagggtgg atgagcgagc agcagagcag 1200 gccagatggg aggcagcctc caaggaaacc atcaagaaaa ccactaagcc ttgccctcgg 1260 tgccatgtgc ctgtggagaa gaatggaggg tgcatgcaca tgaagtgccc ccagcctcag 1320 tgcaggctgg aatggtgctg gaactgtggc tgtgaatgga acagggtctg catgggagat 1380 cactggtttg atgtctaa 1398 <210> 38 <211> 1398 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - codon-optimized PRKN variant CO4 <400> 38 atgattgtgt ttgtccggtt caactcctcc catggtttcc cggtggaagt ggactcagac 60 accagcatct tccaactgaa ggaagtggtg gccaagcgtc agggggtccc ggcagaccag 120 ttgagagtga tcttcgctgg aaaggaactg agaaacgact ggactgtgca gaactgtgac 180 ctggaccaac agtccattgt gcacattgtc cagcggcctt ggcggaaagg tcaagagatg 240 aacgccactg gtggagatga ccccaggaat gcagctgggg gctgtgaacg ggaacctcag 300 agcctgacca gagtggacct cagctcctct gtcctcccgg gagactccgt gggactggca 360 gtcattctgc acactgacag ccgcaaggat tccccccctg cgggttcacc agctggacgg 420 tccatctaca actccttcta tgtgtactgc aagggaccct gccagagggt gcagccggga 480 aagctcagag tgcagtgcag cacttgcaga caagccaccc tgaccctgac ccagggccca 540 tcctgctggg atgatgtcct gatccccaac cggatgtcag gggaatgcca aagccctcac 600 tgccctggaa cctcggccga gttcttcttc aaatgtggag cccaccccac ctcggacaag 660 gaaacctcgg tggcccttca cctcattgcc accaactccc gcaacatcac ctgtatcact 720 tgcactgatg ttcgctctcc ggtgctggtg ttccagtgca actcccgaca cgtgatctgc 780 ctggactgct tccacctgta ctgtgtgacc agactgaatg acaggcagtt tgtccacgac 840 ccccaactgg gctactcctt gccttgtgtg gctggctgcc ccaactccct gatcaaggag 900 ttgcaccact tccggatcct ggggagagaa footcaaca gataccagca gtacggggca 960 gaggaatgtg tcctccaaat gggggagtg ctgtgccccc ggcctggttg tggagctggc 1020 ctcctgccgg aacctgacca gcggaaggtc acttgcgagg gtggaaacgg cctgggctgt 1080 ggcttcgcct tctgtcggga gtgcaaggag gcctaccacg aaggaatg ctccgcggtg 1140 tttgaagcct cagggaccac cacaagcc tacagagtgg atgagagggc agcggagcag 1200 gcccgctggg aagcggctc caaggagact atcaagaaaa ccaccaagcc atgccctagg 1260 tgccatgtgc ctgtggaaaa gaatggaggc tgcatgcaca tgaagtgccc ccagccacag 1320 tgccgccttg aatggtgctg gaactgtggc tgcgagtgga acagagtgtg tatgggggac 1380 cactggtttg atgtgtga 1398 <210> 39 <211> 4187 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 39 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccagcccagc accccaaggc ggccaacgcc aaaactctcc ctcctcctct 360 tcctcaatct cgctctcgct cttttttttt ttcgcaaaag gaggggagag ggggtaaaaa 420 aatgctgcac tgtgcggcga agccggtgag tgagcggcgc ggggccaatc agcgtgcgcc 480 gttccgaaag ttgcctttta tggctcgagc ggccgcggcg gcgccctata aaacccagcg 540 gcgcgacgcg ccaccaccgc cgagtccgcg tccgcccgcg agcacagagc ctcgcctttg 600 ccgatccgcc gcccgtccac acccgccgcc aggtaagccc ggccagccga ccggggcatg 660 cggccgcggc ccttcgcccg tgcagagccg ccgtctgggc cgcagcgggg ggcgcatggg 720 gcggaaccgg accgccgtgg ggggcgcggg agaagcccct gggcctccgg agatggggga 780 caccccacgc cagttcgcag gcgcgaggcc gcgctcgggc gggcgcgctc cgggggtgcc 840 gctctcgggg cgggggcaac cggcggggtc tttgtctgag ccgggctctt gccaatgggg 900 atcgcacggt gggcgcggcg tagccccgt caggcccggt gggggctggg gcgccatgcg 960 cgtgcgcgct ggtcctttgg gcgctaactg cgtgcgcgct gggaattggc gctaattgcg cgtgcgcgct gggactcaat ggcgctaatc gcgcgtgcgt tctggggccc gggcgcttgc 1080 gccacttcct gcccgagccg ctggcgcccg agggtgtggc cgctgcgtgc gcgcgcgcga 1140 cccggtcgct gtttgaaccg ggcggaggcg gggctggcgc ccggttggga gggggttggg 1200 gcctggcttc ctgccgcgcg ccgcggggac gcctccgacc agtgtttgcc ttttatggta 1260 ataacgcggc cggcccggct tcctttgtcc ccaatctggg cgcgcgccgg cgccccctgg 1320 cggcctaagg actcggcgcg ccggaagtgg ccagggcggc agcggctgct cttggcggcc 1380 ccgaggtgac tatagccttc ttttgtgtct tgatagttcg ccagcctctg ctaaccatgt 1440 tcatgccttc ttctttttcc tacagctcct gggcaacgtg ctggttattg tgctgtctca 1500 tcattttggc aaagaattcg gcttgatcga agccgtctca ggggaattca aagcaagccg 1560 ccaccatgat tgtgtttgtc cggttcaact cctcccatgg tttcccggtg gaagtggact 1620 cagacaccag catcttccaa ctgaaggaag tggtggccaa gcgtcagggg gtcccggcag 1680 accagttgag agtgatcttc gctggaaagg aactgagaaa cgactggact gtgcagaact 1740 gtgacctgga ccaacagtcc attgtgcaca ttgtccagcg gccttggcgg aaaggtcaag 1800 agatgaacgc cactggtgga gatgacccca ggaatgcagc tgggggctgt gaacgggaac 1860 ctcagagcct gaccagagtg gacctcagct cctctgtcct cccgggagac tccgtgggac 1920 tggcagtcat tctgcacact gacagccgca aggattcccc ccctgcgggt tcaccagctg 1980 gacggtccat ctacaactcc ttctatgtgt actgcaaggg accctgccag agggtgcagc 2040 cgggaaagct cagagtgcag tgcagcactt gcagacaagc caccctgacc ctgacccagg 2100 gcccatcctg ctgggatgat gtcctgatcc ccaaccggat gtcaggggaa tgccaaagcc 2160 ctcactgccc tggaacctcg gccgagttct tcttcaaatg tggagcccac cccacctcgg 2220 acaaggaaac ctcggtggcc cttcacctca ttgccaccaa ctcccgcaac atcacctgta 2280 tcacttgcac tgatgttcgc tctccggtgc tggtgttcca gtgcaactcc cgacacgtga 2340 tctgcctgga ctgcttccac ctgtactgtg tgaccagact gaatgacagg cagtttgtcc 2400 acgaccccca actgggctac tccttgcctt gtgtggctgg ctgccccaac tccctgatca 2460 aggagttgca ccacttccgg atcctgggag aggaacagta caacagatac cagcagtacg 2520 gggcagagga atgtgtcctc caaatggggg gagtgctgtg cccccggcct ggttgtggag 2580 ctggcctcct gccggaacct gaccagcgga aggtcacttg cgagggtgga aacggcctgg 2640 gctgtggctt cgccttctgt cgggagtgca aggaggccta ccacgaagga gaatgctccg 2700 cggtgtttga agcctcaggg accaccacac aagcctacag agtggatgag agggcagcgg 2760 agcaggcccg ctgggaagcg gcctccaagg agactatcaa gaaaaccacc aagccatgcc 2820 ctaggtgcca tgtgcctgtg gaaaagaatg gaggctgcat gcacatgaag tgcccccagc 2880 cacagtgccg ccttgaatgg tgctggaact gtggctgcga gtggaacaga gtgtgtatgg 2940 gggaccactg gtttgatgtg tgataatgga ttcctgttaa tcaacctctg gattacaaaa 3000 tttgtgaaag attgactggt attcttaact atgttgctcc ttttacgcta tgtggatacg 3060 ctgctttaat gcctttgtat catgctattg cttcccgtat ggctttcatt ttctcctcct 3120 tgtataaatc ctggttgctg tctctttatg aggagttgtg gcccgttgtc aggcaacgtg 3180 gcgtggtgtg cactgtgttt gctgacgcaa cccccactgg ttggggcatt gccaccacct 3240 gtcagctcct ttccgggact ttcgctttcc ccctccctat tgccacggcg gaactcatcg 3300 ccgcctgcct tgcccgctgc tggacagggg ctcggctgtt gggcactgac aattccgtgg 3360 tgttgtcggg gaagctgacg tccttttccgc ggctgctcgc ctgtgttgcc acctggattc 3420 tgcgcgggac gtccttctgc tacgtccctt cggccctcaa tccagcggac cttccttccc 3480 gcggcctgct gccggctctg cggcctcttc cgcctcttcg ccttcgccct cagacgagtc 3540 ggatctccct ttggggccgcc tccccgccca tgtatctttt tcacctgtgc cttgtttttg 3600 cctgtgttcc gcgtcctact tttcaagcct ccaagctgtg ccttgggcgg ctttggggca 3660 tggacataga tccctaaa gaatttggtt catcttatca gttgttgaat tttcttcctt tggactggct aataaagga atttattttc attgcaatag tgtgttgga ttttttgtgt ctctcactcg gaagacata tgggagggca aatcatttaa aacatcagaa tgagtatttg gtttaggtt tggcaacata tgcccatatg ctggctgcca tgaacaaagg ttggctaa agaggtcatc agtatatgaa acagccccct gctgtccatt ccttattcca tagaaagcc ttgacttgag gttagatttt ttttatattt tgttttgtgt tattttttc tttaacatcc ctaaaatttt ccttacatgt tttactagcc agatttttcc tcctctcctg actactccca 4080 gtcatagctg tccctcttct cttatggaga tcgttaccca ggctggagtg cagtggcaca 4140 tttctgctca ctgcaacctc ctcctccctg ggttcaagca atttcag 4187 <210> 40 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 40 ctctgggctc tggagacgac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 60 ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 120 ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 180 tcatatgcca agtccgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 240 tgcccagtac atgaccttac gggactttcc tacttggcag tacatctacg tattagtcat 300 cgctattacc atggtgatgc ggttttggca gtacaccaat gggcgtggat agcggtttga 360 ctcacgggga tttccaegtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 420 aaatcaacgg gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc aaatgggcgg 480 taggcgtgta cggtgggagg tctatatag cagagctcgt ttagtgaacc gtcagatcgc 540 ctggagaggc catccacgct gttttgacct catagtgga caccgggacc gatccagcct 600 ccgcggccgg gaacggtgca ttggaacgcg gattccccgt gccaagagtg actcagatcc 660 tcactctctt ccgcatcgct gtctgcgagg gccagctgtt gggctcgcgg ttgaggacaa 720 actcttcgcg gtctttccag tactcttgga tcggaaaccc gtcggcctc gaacggtact 780 ccgccaccga gggacctgag cgagtccgca tcgaccggat cggaaaacct ctcgagaaag 840 gcgtctaacc agtcacagtc gcaaggtagg ctgagcaccg tggcgggcgg cagcgggtgg 900 cggtcggggt tgttctggc ggaggtgctg ctgatgatgt attaaagta ggcggtcttg 960 agacggcgga tggtcgaggt gaggtgtggc aggcttgaga tccagctgtt ggggtgagta 1020 ctccctctca aaagcgggca ttacttctgc gctaagattg tcagtttcca aaaacgagga 1080 ggatttgata ttcacctggc ccgatctggc catacacttg agtgacaatg acatccactt 1140 tgcctttctc tccacaggtg tccactccca ggtccaagtt taaacgccgc cacccaccat 1200 gattgtgttt gtccggttca actcctccca tggtttcccg gtggaagtgg actcagacac 1260 cagcatcttc caactgaagg aagtggtggc caagcgtcag ggggtcccgg cagaccagtt 1320 gagagtgatc ttcgctggaa aggaactgag aaacgactgg actgtgcaga actgtgacct 1380 ggaccaacag tccattgtgc acattgtcca gcggccttgg cggaaaggtc aagagatgaa 1440 cgccactggt ggagatgacc ccaggaatgc agctgggggc tgtgaacggg aacctcagag 1500 cctgaccaga gtggacctca gctcctctgt cctcccggga gactccgtgg gactggcagt 1560 cattctgcac actgacagcc gcaaggattc cccccctgcg ggttcaccag ctggacggtc 1620 catctacaac tccttctatg tgtactgcaa gggaccctgc cagagggtgc agccgggaaa 1680 gctcagagtg cagtgcagca cttgcagaca agccaccctg accctgaccc agggcccatc 1740 ctgctgggat gatgtcctga tccccaaccg gatgtcaggg gaatgccaaa gccctcactg 1800 ccctggaacc tcggccgagt tcttcttcaa atgtggagcc caccccacct cggacaagga 1860 aacctcggtg gcccttcacc tcattgccac caactcccgc aacatcacct gtatcacttg cactgatgtt cgctctccgg tgctggtgtt cagtgcaac tcccgacacg tgatctgcct ggactgcttc cacctgtact gtgtgaccag actgaatgac aggcagtttg tccacgaccc ccaactgggc tactccttgc cttgtgtggc tggctgcccc aactccctga tcaaggagtt gcaccacttc cggatcctgg gagaggaca gtacaacaga taccagcagt acggggcaga ggaatgtgtc ctccaaatgg ggggagtgct gtgcccccgg cctggttgtg gagctggcct cctgccgga cctgaccagc ggaaggtcac ttgcgagggt ggaaacggcc tgggctgtgg cttcgccttc tgtcgggagt gcaaggaggc ctaccacgaa ggagaatgct ccgcggtgtt tgaagcctca gggaccacca cacaagccta cagagtggat gagagggcag cggagcaggc ccgctggga gcggcctcca aggagactat caagaaacc accaagccat gccctaggtg ccatgtgcct gtggaaaaga atggaggctg catgcacatg aagtgccccc agccacagtg 2520 ccgccttgaa tggtgctgga actgtggctg cgagtggaac agagtgtgta tgggggacca 2580 ctggtttgat gtgtgataat ggattcctgt taatcaacct ctggattaca aaatttgtga 2640 aagattgact ggtattctta actatgttgc tccttttacg ctatgtggat acgctgcttt 2700 aatgcctttg tatcatgcta ttgcttcccg tatggctttc attttctcct ccttgtataa 2760 atcctggttg ctgtctcttt atgaggagtt gtggcccgtt gtcaggcaac gtggcgtggt 2820 gtgcactgtg tttgctgacg caacccccac tggttggggc attgccacca cctgtcagct 2880 cctttccggg actttcgctt tccccctccc tattgccacg gcggaactca tcgccgcctg 2940 ccttgcccgc tgctggacag gggctcggct gttgggcact gacaattccg tggtgttgtc 3000 ggggaagctg acgtcctttc cgcggctgct cgcctgtgtt gccacctgga ttctgcgcgg 3060 gacgtccttc tgctacgtcc cttcggccct caatccagcg gaccttcctt cccgcggcct 3120 gctgccggct ctgcggcctc ttccgcctct tcgccttcgc cctcagacga gtcggatctc 3180 cctttgggcc gcctccccgc ccatgtatct ttttcacctg tgccttgttt ttgcctgtgt 3240 tccgcgtcct acttttcaag cctccaagct gtgccttggg cggctttggg gcatggacat 3300 agatccctat aaagaatttg gttcatctta tcagttgttg aattttcttc ctttggacgc 3360 tggagcctcg gtagccgttc ctcctgcccg ctgggcctcc caacgggccc tcctcccctc 3420 cttgcaccgg cccttcctgg tctttgaata aattcattgc tggctaataa aggaaattta 3480 ttttcattgc aatagtgtgt tggaattttt tgtgtctctc actcggaaga acatatggga 3540 gggcaaatca tttaaaacat cagaatgagt atttggttta gagtttggca acatatgccc 3600 atatgctggc tgccatgaac aaaggttggc tataaagagg tcatcagtat atgaaacagc 3660 cccctgctgt ccattcctta ttccatagaa aagccttgac ttgaggttag atttttttta 3720 tattttgttt tgtgttattt ttttctttaa catccctaaa attttcctta catgttttac 3780 tagccagatt tttcctcctc tcctgactac tcccagtcat agctgtccct cttctcttat 3840 ggagatcgtt acccaggctg gagtgcagtg gcacatttct gctcactgca acctcctcct 3900 ccctgggttc aagcaattct cctgcctcag cctcccaagt agctgtgatt ataggtgcac 3960 accaccaagc ctggctaatt tttatatctt tagtagagac gggagtctca ccatgttggc 4020 caggctagtc tctggcaagc catggtaaaa tgtaactatt taaggctgct ttaaattaga 4080 ctaatagcag agtggtcaga ctatactgaa agcttggtga atcacaatta agtacctcaa 4140 agaactattc ttgtttgcct tatcag 4166 <210> 41 <211> 4198 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 41 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccactgcaga gggccctgcg tatgagtgca agtgggtttt aggaccagga 360 tgaggcgggg tgggggtgcc tacctgacga ccgaccccga cccactggac aagcacccaa 420 cccccattcc ccaaattgcg catcccctat cagagagggg gaggggaac aggatgcggc 480 gaggcgcgtg cgcactgcca gcttcagcac cgcggacagt gccttcgccc ccgcctggcg 540 gcgcgcgcca ccgccgcctc agcactgaag gcgcgctgac gtcactcgcc ggtcccccgc 600. aaactcccct tcccggccac cttggtcgcg tccgcgccc cgccggccca gccggaccgc 660 accacgcgag gcgcgagata ggggggcacg ggcgcgacca tctgcgctgc ggcgccggcg 720 actcagcgct gcctcagtct gcggtgggca gcggaggagt cgtgtcgtgc ctgagagcgc 780 agctgtgctc ctgggcaccg cgcagtccgc ccccgcggct cctggccaga ccacccctag 840 gacccctgc cccaagtcgc agggattc aaagcaagcc gccaccatga ttgtgtttgt 900. 960. ccggttcaac tcctcccatg gtttcccggt ggagtggac tcagacacca gcatcttcca actgagga gtggtggcca agcgtcaggg ggtcccggca gaccagttga gagtgatctt 1080. cgctggaag gaactgagaa acgactggac tgtgcagaac tgtgacctgg accaacagtc cattgtgcac attgtccagc ggccttggcg gaaaggtcaa gagatgaacg ccactggtgg agatgacccc aggaatgcag ctgggggctg tgaacgggaa cctcagagcc tgaccagagt 1200 ggacctcagc tcctctgtcc tcccgggaga ctccgtggga ctggcagtca ttctgcacac 1260 tgacagccgc aaggattccc cccctgcggg ttcaccagct ggacggtcca tctacaactc 1320 cttctatgtg tactgcaagg gaccctgcca gagggtgcag ccgggaaagc tcagagtgca 1380 gtgcagcact tgcagacaag ccaccctgac cctgacccag ggcccatcct gctgggatga 1440 tgtcctgatc cccaaccgga tgtcagggga atgccaaagc cctcactgcc ctggaacctc 1500 ggccgagttc ttcttcaaat gtggagccca ccccacctcg gacaaggaaa cctcggtggc 1560 ccttcacctc attgccacca actcccgcaa catcacctgt atcacttgca ctgatgttcg 1620 ctctccggtg ctggtgttcc agtgcaactc ccgacacgtg atctgcctgg actgcttcca 1680 cctgtactgt gtgaccagac tgaatgacag gcagtttgtc cacgaccccc aactgggcta 1740 ctccttgcct tgtgtggctg gctgccccaa ctccctgatc aaggagttgc accacttccg 1800 gatcctggga gaggaacagt acaacagata ccagcagtac ggggcagagg aatgtgtcct 1860 ccaaatgggg ggagtgct gcccggcc tggttgtgga gctggcctcc tgccggacc 1920 tgaccagcgg aaggtcactt gcgaggtgg aaacggcctg ggctgtggct tcgccttg 1980 tcgggagtgc aaggaggcct accacgaagg agaatgctcc gcggtgtttg aagcctcagg 2040 gaccaccaca caagcctaca gagtggatga gagggcagcg gagcaggccc gctgggaagc 2100 ggcctccaag gagactatca agaaaaccac caagccatgc cctaggtgcc atgtgcctgt 2160 ggaaaagaat ggaggctgca tgcacatgaa gtgccccag ccacagtgcc gccttgaatg 2220 gtgctggaac tgtggctgcg agtggacacag agtgtgtatg ggggaccact gtttgatgt 2280 gtgataatgg actattcgag catcttaccg ccattattc ccatatttgt tctgtttttc 2340 ttgatttgggg tatacattta aatgttaata aaaaaaatg gtggggcaat catttacatt 2400 tttaggta tgtattact agttcaggtg tattgccaca agacaacat gttaagaac 2460 ttcccgtta tttacgctct gttcctgtta atcaacctct ggattacaa atttgtgaaa 2520 gattgactga tattcttaac tattgttgctc cttttacgct gtgtggatat gctgctttaa 2580 tgcctctgta tcatgctatt gcttcccgta cggctttcgt tttctcctcc ttgtataaat 2640 cctggttgct gtctctttat gaggagttgt ggcccgttgt ccgtcaacgt ggcgtggtgt 2700 gctctgtgtt tgctgacgca acccccactg gctggggcat tgccaccacc tgtcaactcc 2760 tttctgggac tttcgctttc cccctcccga tcgccacggc agaactcatc gccgcctgcc 2820 ttgcccgctg ctggacaggg gctaggttgc tgggcactga taattccgtg gtgttgtcgg 2880 ggaagggcct ttaattaggc tggagcctcg gtagccgttc ctcctgcccg ctgggcctcc 2940 caacgggccc tcctcccctc cttgcaccgg cccttcctgg tctttgaata aattatctta 3000 gcttattgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 3060 gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg 3120 tgtcattcta ttctgggggg tggggtgggg caggacagca agggggagga ttgggaatac 3180 aatagcaggc atgctgggga tgcggtgggc tctatgggta cccaggtgct gaagaattga 3240 cccggttcct cctggggtta cccaggctgg agtgcagtgg cacaattctg ctcactgcaa 3300 cctcctcctc cctgggttca agcaattctc ctgcctcagc ctcccaagta gctgtgatta 3360. snow snow snow snow snow snow snow snow snow snow snow snow catgttggcc aggctagtct ctggcaagcc atggtaaaat gtaactattt aaggctgctt 3540. 3540. 3540. 3540. 3540. 3540. 3540. 3540 gtacctcaaa gaactattct tgtttgcctt attcctatgt aataactga aatctttgtt tttcttccta aaaggggtca tgttgatttt tacttacaat gtattttaag tttgtcactc taaatggtta tgagcaagtt taagaaaat cttcagcaaa tactacctta gattatgacc ccaaaacaca tttacttatg attatgttga aaacataggg tctggggaa aagggattta 3840. cttgggactt aaaagtctt ttagaggcca gctcaccaac attcagaaca cccagtctgt gttgcacaat atgttactta ggtataaatc aaggattcat gtaattttgt cattccttgc gtgatatttt aaaaaacatt ctgtgtaagg tatttataaa 4020. gctctcttct aaaatacaa aaatttgtgg ggccttgtag tcccagctac ttggggaggct gaggcaggag gatttcttga actgggaggc agagcttgca gtgagcccac tgcactccag 4080 cctgggcaac agagtagaac tcctctcaaa aaaaaaaaaa aaaaagaaag aaagaaaaaa 4140 aagtggactg tgaaaactga aaggactaga aaaactacac tacaaagata cagatcag 4198 <210> 42 <211> 4198 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 42 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccatggtcga ggtgagcccc acgttctgct tcactctccc catctccccc 360 ccctccccac ccccaatttt gtatttattt attttttaat tattttgtgc agcgatgggg 420 gcgggggggg ggggggcgcg cgccaggcgg ggcggggcgg ggcgaggggc ggggcggggc 480 gaggcggaga ggtgcggcgg cagccaatca gagcggcgcg ctccgaaagt ttccttttat 540 ggcgaggcgg cggcggcggc ggccctataa aaagcgaagc gcgcggcggg cgggagtcgc 600 tgcgcgctgc cttcgccccg tgccccgctc cgccgccgcc tcgcgccgcc cgccccggct 660 ctgactgacc gcgttactcc cacaggtgag cgggcgggac ggcccttctc ctccgggctg 720 taattagcgc ttggtttaat gacggcttgt ttcttttctg tggctgcgtg aaagccttga 780 ggggctccgg gagggccctt tgtgcggggg gagcggctcg gggggtgcgt gcgtgtgtgt 840 gtgcgtgggg agcgccgcgt gcggctccgc gctgcccggc ggctgtgagc gctgcgggcg 900 cggcgcgggg ctttgtgcgc tccgcagtgt gcgcgagggg agcgcggccg ggggcggtgc 960 cccgcggtgc ggggggggct gcgaggggaa caaaggctgc gtgcggggtg tgtgcgtggg 1020 ggggtgagca gggggtgtgg gcgcgtcggt cgggctgcaa ccccccctgc acccccctcc 1080 ccgagttgct gagcacggcc cggcttcggg tgcggggctc cgtacggggc gtggcgcggg 1140 gctcgccgtg ccgggcgggg ggtggcggca ggtgggggtg ccgggcgggg cggggccgcc 1200 tcgggccggg gagggctcgg gggaggggcg cggcggcccc cggagcgccg gcggctgtcg 1260 aggcgcggcg agccgcagcc attgcctttt atggtaatcg tgcgagaggg cgcagggact 1320 tcctttgtcc caaatctgtg cggagccgaa atctgggagg cgccgccgca ccccctctag 1380 cgggcgcggg gcgaagcggt gcggcgccgg caggaaggaa atgggcgggg agggccttcg 1440 tgcgtcgccg cgccgccgtc cccttctccc tctccagcct cggggctgtc cgcggggga 1500 cggctgcctt cggggggac ggggcagggc ggggttcggc ttctggcgtg tgaccggcgg 1560 ctctagagcc tctgctaacc atgttcatgc cttcttcttt ttcctacagc tcctgggcaa 1620 cgtgctggtt attgtgctgt ctcatcattt tggcaaagaa ttcggcttga tcgaagccgt 1680 ctcaggggaa ttcaaagcaa gccgccacca tgattgtgtt tgtccggttc aactcctccc 1740 atggtttccc ggtggaagtg gactcagaca ccagcatctt ccaactgaag gaagtggtgg 1800 ccaagcgtca ggggtcccg gcagaccagt tgagagtgat cttcgctgga aaagactga 1860 gaacgactg gactgtgcag aactgtgacc tggaccaaca gtccattgtg cacattgtcc 1920 agcggccttg gcggaaaggt caagagatga acgccactgg tggagatgac cccaggaatg 1980 cagctgggggg ctgtgaacgg gaacctcaga gcctgaccag agtggacctc agctcctctg 2040 tcctcccggg agactccgtg ggactggcag tcattctgca cactgacagc cgcaaggatt 2100 ccccccctgc gggttcacca gctggacggt ccatctacaa ctccttctat gtgtactgca 2160 agggaccctg ccagagggtg cagccgggaa agctcagagt gcagtgcagc acttgcagac 2220 aagccaccct gaccctgacc cagggcccat cctgctggga tgatgtcctg atccccaacc 2280 ggatgtcagg ggaatgccaa agccctcact gccctggaac ctcggccgag ttcttcttca 2340 aatgtggagc ccaccccacc tcggacaagg aaacctcggt ggcccttcac ctcattgcca 2400 ccaactcccg caacatcacc tgtatcactt gcactgatgt tcgctctccg gtgctggtgt 2460 tccagtgcaa ctcccgacac gtgatctgcc tggactgctt ccacctgtac tgtgtgacca 2520 gactgaatga caggcagttt gtccacgacc cccaactggg ctactccttg ccttgtgtgg 2580 ctggctgccc caactccctg atcaaggagt tgcaccactt ccggatcctg ggagaggaac 2640 agtacaacag ataccagcag tacggggcag aggaatgtgt cctccaaatg gggggagtgc 2700 tgtgcccccg gcctggttgt ggagctggcc tcctgccgga acctgaccag cggaaggtca 2760 cttgcgaggg tggaaacggc ctgggctgtg gcttcgcctt ctgtcgggag tgcaaggagg 2820 cctaccacga aggagaatgc tccgcggtgt ttgaagcctc agggaccacc acacaagcct 2880 acagagtgga tgagagggca gcggagcagg cccgctggga agcggcctcc aaggagacta 2940 tcaagaaaac caccaagcca tgccctaggt gccatgtgcc tgtggaaaag aatggaggct 3000 gcatgcacat gaagtgcccc cagccacagt gccgccttga atggtgctgg aactgtggct 3060 gcgagtggaa cagagtgtgt atgggggacc actggtttga tgtgtgataa tggattaatc 3120 aattattgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 3180 gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg 3240 tgtcattcta ttctgggggg tggggtgggg caggacagca agggggagga ttgggaatac 3300 atagcaggc atgctgggga tgcggtgggc tctatggta cccaggtgct gaagaattga 3360 cccggttcct cctggggtta cccaggctgg agtgcagtgg cacattctg ctcactgca 3420 cctcctcctc cctgggttca agcaattctc ctgcctcagc ctcccaagta gctgtgatta 3480 taggtgcaca ccaccaagcc tggctaattt ttatatctt agtagagacg ggagtctcac 3540 catgttggcc aggctagctct ctggcaagcc atggtaaat gtaactattt aaggctgctt 3600 taaattagac tatagcaga gtggtcagac tatactgaaa gcttggtgaa tcacaattaa 3660 gtacctcaaa gaactattct tgtttgcctt attcctatgt aaataactga aatctttgtt 3720 tttctccta aaggggtca tgttgattt tacttacaat gtattttaag tttgtcactc 3780 taaatggtta tgagcaagtt tagaaaaat cttcagcaaa tactacctta gatttagacc 3840 ccaaaacaca tttacttg attatgttga aacataggg tctggggaa aagggatta 3900 aaaaagaag aaaaagaga cttgggactt aaaagtctt ttagaggcca gctcaccac 3960 attcagaaca cccagtctgt gttgcacaat atgttactta ggtataaatc aaggattcat 4020 gtaattttgt cattccttgc gtgatatttt aaaaaacatt ctgtgtaagg tatttataaa 4080 gctctcttct aaaaatacaa aaatttgtgg ggccttgtag tcccagctac ttgggaggct 4140 gaggcaggag gatttcttga actgggaggc agagcttgca gtgagcccac tgcatcag 4198 <210> 43 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 43 ctctggagac gcaacctttg gagctaagcc agcaatggta gagggaagat tctgcacgtc 60 ccttccaggc ggcctccccg tcaccacccc ccccaacccg ccccgaccgg agctgagagt 120 aattcataca aaaggactcg cccctgcctt ggggaatccc agggaccgtc gttaaactcc 180 cactaacgta gaacccagag atcgctgcgt tcccgccccc tcacccgccc gctctcgtca 240 tcactgaggt ggagaatagc atgcgtgagg ctccggtgcc cgtcagtggg cagagcgcac 300 atcgcccaca gtccccgaga agttgggggg aggggtcggc aattgaacgg gtgcctagag 360 aaggtggcgc ggggtaaact gggaaagtga tgtcgtgtac tggctccgcc tttttcccga 420 gggtggggga gaaccgtata taagtgcagt agtcgccgtg aacgttcttt ttcgcaacgg 480 gtttgccgcc agaacacagg taagtgccgt gtgtggttcc cgcgggcctg gcctctttac 540 gggttatggc ccttgcgtgc cttgaattac ttccacctgg ctccagtacg tgattcttga 600 tcccgagctg gagccagggg cgggccttgc gctttaggag ccccttcgcc tcgtgcttga 660 gttgaggcct ggcctgggcg ctggggccgc cgcgtgcgaa tctggtggca ccttcgcgcc 720 tgtctcgctg ctttcgataa gtctctagcc atttaaaatt tttgatgacg tgctgcgacg 780 ctttttttct ggcaagatag tcttgtaaat gcgggccagg atctgcacac tggtatttcg 840 gtttttgggc ccgcggccgg cgacggggcc cgtgcgtccc agcgcacatg ttcggcgagg 900 cggggcctgc gagcgcggcc accgagaatc ggacgggggt agtctcaagc tggccggcct 960 gctctggtgc ctggcctcgc gccgccgtgt atcgccccgc cctgggcggc aaggctggcc 1020 cggtcggcac cagttgcgtg agcggaaaga tggccgcttc ccggccctgc tccagggggc 1080 tcaaaatgga ggacgcggcg ctcgggagag cgggcgggtg agtcacccac acaaaggaaa 1140 agggcctttc cgtcctcagc cgtcgcttca tgtgactcca cggagtaccg ggcgccgtcc 1200 aggcacctcg attagttctg gagcttttgg agtacgtcgt ctttaggttg gggggagggg 1260 ttttatgcga tggagtttcc ccacactgag tgggtggaga ctgaagttag gccagcttgg 1320 cacttgatgt aattctcctt ggaatttggc ctttttgagt ttggatcttg gttcattctc 1380 aagcctcaga cagtggttca aagttttttt cttccatttc aggtgtcgtg aacacgtctc 1440 aggggaattc aaagcaagcc gccaccatga ttgtgtttgt ccggttcaac tcctcccatg 1500 gtttcccggt ggaagtggac tcagacacca gcatcttcca actgaaggaa gtggtggcca 1560 agcgtcaggg ggtcccggca gaccagttga gagtgatctt cgctggaaag gaactgagaa 1620 acgactggac tgtgcagaac tgtgacctgg accaacagtc cattgtgcac attgtccagc 1680 ggccttggcg gaaaggtcaa gagatgaacg ccactggtgg agatgacccc aggaatgcag 1740 ctgggggctg tgaacgggaa cctcagagcc tgaccagagt ggacctcagc tcctctgtcc 1800 tcccgggaga ctccgtggga ctggcagtca ttctgcacac tgacagccgc aaggattccc 1860 cccctgcggg ttcaccagct ggacggtcca tctacaactc cttctatgtg tactgcaagg 1920 gaccctgcca gagggtgcag ccgggaaagc tcagagtgca gtgcagcact tgcagacaag 1980 ccaccctgac cctgacccag ggcccatcct gctgggatga tgtcctgatc cccaaccgga 2040 tgtcaggga atgccaaagc cctcactgcc ctggaacctc ggccgagttc ttcttcaaat 2100 gtggagccca ccccacctcg gacaaggaaa cctcggtggc ccttcacctc attgccacca 2160 actcccgcaa catcacctgt atcacttgca ctgatgttcg ctctccggtg ctggtgttcc 2220 agtgcaactc ccgacacgtg atctgcctgg actgcttcca cctgtactgt gtgaccagac 2280 tgaatgacag gcagtttgtc cacgacccccc aactgggcta ctccttgcct tgtgtggctg 2340 gctgccccaa ctccctgatc aaggagttgc accacttccg gatcctggga gaggaacagt 2400 acaagata ccagcagtac ggggcagagg aatgtgtcct ccaaatgggg ggagtgctgt 2460 gccccccggcc tggttgtgga gctggcctcc tgccggaacc tgaccagcgg aaggtcactt 2520 gcgagggtgg aaacggcctg ggctgtggct tcgccttctg tcgggagtgc aaagggcct 2580 accacgaagg agaatgctcc gcggtgtttg aagcctcagg gaccaccaca caagcctaca 2640 gagtggatga gagggcagcg gagcaggccc gctgggaagc ggcctccaag gagactatca 2700 agaaaaccac caagccatgc cctaggtgcc atgtgcctgt ggaaaagaat ggaggctgca 2760 tgcacatgaa gtgcccccag ccacagtgcc gccttgaatg gtgctgggaac tgtggctgcg 2820 agtggaacag agtgtgtatg ggggaccact ggtttgatgt gtgataatgg agctggagcc 2880 tcggtagccg ttcctcctgc ccgctgggcc tcccaacggg ccctctccc ctccttgcac 2940 cggcccttcc tggtctttga ataaattcat tgctggctaa taaaggaaat ttattttcat 3000 tgcaatagtg tgttggaatt ttttgtgtct ctcactcgga agaacatatg ggagggcaaa 3060 tcatttaaaa catcagaatg agtatttggt ttagagtttg gcaacatatg cccatatgct 3120 ggctgccatg aacaaaggtt ggctataaag aggtcatcag tatatgaaac agccccctgc 3180 tgtccattcc ttattccata gaaaagcctt gacttgaggt tagattttt ttatatttg 3240 ttttgtgtta tttttttctt taacatccct aaaattttcc ttacatgttt tactagccag 3300 atttttcctc ctctcctgac tactcccagt catagctgtc cctcttctct tatggagatc 3360 gttacccagg ctggagtgca gtggcacatt tctgctcact gcaacctcct cctccctggg 3420 ttcaagcaat tctcctgcct cagcctccca agtagctgtg attataggtg cacaccacca 3480 agcctggcta atttttatat ctttagtaga gacgggagtc tcaccatgtt ggccaggcta 3540 gtctctggca agccatggta aaatgtaact atttaaggct gctttaaatt agactaatag 3600 cagagtggtc agactatact gaaagcttgg tgaatcacaa ttaagtacct caaagaacta 3660 ttcttgtttg ccttattcct atgtaaataa ctgaaatctt tgtttttctt cctaaaaggg 3720 gtcatgttga tttttactta caatgtattt taagtttgtc actctaaatg gttatgagca 3780 agtttaagaa aaatcttcag caaatactac cttagattat gaccccaaaa cacatttact 3840 tatgattatg ttgaaaacat agggtctggg gaaaaaggga tttaaaataa gaagaaaaag 3900 aagacttggg acttaaaaag tcttttagag gccagctcac caacattcag aacacccagt 3960 ctgtgttgca caatatgtta cttaggtata aatcaaggat tcatgtaatt ttgtcattcc 4020 ttgcgtgata ttttaaaaaa cattctgtgt aaggtattta taaagctctc ttctaaaaat 4080 acaaaaattt gtggggcctt gtagtcccag ctacttggga ggctgaggca ggaggatttc 4140 ttgaactggg aggcagagct tgtcag 4166 <210> 44 <211> 4173 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 44 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccagcccagc accccaaggc ggccaacgcc aaaactctcc ctcctcctct 360 tcctcaatct cgctctcgct cttttttttt ttcgcaaaag gaggggagag ggggtaaaaa 420 aatgctgcac tgtgcggcga agccggtgag tgagcggcgc ggggccaatc agcgtgcgcc 480 gttccgaaag ttgcctttta tggctcgagc ggccgcggcg gcgccctata aaacccagcg 540 gcgcgacgcg ccaccaccgc cgagtccgcg tccgcccgcg agcacagagc ctcgcctttg 600 ccgatccgcc gcccgtccac acccgccgcc aggtaagccc ggccagccga ccggggcatg 660 cggccgcggc ccttcgcccg tgcagagccg ccgtctgggc cgcagcgggg ggcgcatggg 720 gcggaaccgg accgccgtgg ggggcgcggg agaagcccct gggcctccgg agatggggga 780 caccccacgc cagttcgcag gcgcgaggcc gcgctcgggc gggcgcgctc cgggggtgcc 840 gctctcgggg cgggggcaac cggcggggtc tttgtctgag ccgggctctt gccaatgggg 900 atcgcacggt gggcgcggcg tagccccgt caggcccggt gggggctggg gcgccatgcg 960 cgtgcgcgct ggtcctttgg gcgctaactg cgtgcgcgct gggaattggc gctaattgcg cgtgcgcgct gggactcaat ggcgctaatc gcgcgtgcgt tctggggccc gggcgcttgc 1080 gccacttcct gcccgagccg ctggcgcccg agggtgtggc cgctgcgtgc gcgcgcgcga 1140 cccggtcgct gtttgaaccg ggcggaggcg gggctggcgc ccggttggga gggggttggg 1200 gcctggcttc ctgccgcgcg ccgcggggac gcctccgacc agtgtttgcc ttttatggta 1260 ataacgcggc cggcccggct tcctttgtcc ccaatctggg cgcgcgccgg cgccccctgg 1320 cggcctaagg actcggcgcg ccggaagtgg ccagggcggc agcggctgct cttggcggcc 1380 ccgaggtgac tatagccttc ttttgtgtct tgatagttcg ccagcctctg ctaaccatgt 1440 tcatgccttc ttctttttcc tacagctcct gggcaacgtg ctggttattg tgctgtctca 1500 tcattttggc aaagaattcg gcttgatcga agccgtctca ggggaattca aagcaagccg 1560 ccaccatgat tgtgtttgtc cggttcaact cctcccatgg tttcccggtg gaagtggact 1620 cagacaccag catcttccaa ctgaaggaag tggtggccaa gcgtcagggg gtcccggcag 1680 accagttgag agtgatcttc gctggaaagg aactgagaaa cgactggact gtgcagaact 1740 gtgacctgga ccaacagtcc attgtgcaca ttgtccagcg gccttggcgg aaaggtcaag 1800 agatgaacgc cactggtgga gatgacccca ggaatgcagc tgggggctgt gaacgggaac 1860 ctcagagcct gaccagagtg gacctcagct cctctgtcct cccgggagac tccgtgggac 1920 tggcagtcat tctgcacact gacagccgca aggattcccc ccctgcgggt tcaccagctg 1980 gacggtccat ctacaactcc ttctatgtgt actgcaaggg accctgccag agggtgcagc 2040 cgggaaagct cagagtgcag tgcagcactt gcagacaagc caccctgacc ctgacccagg 2100 gcccatcctg ctgggatgat gtcctgatcc ccaaccggat gtcaggggaa tgccaaagcc 2160 ctcactgccc tggaacctcg gccgagttct tcttcaaatg tggagcccac cccacctcgg 2220 acaaggaaac ctcggtggcc cttcacctca ttgccaccaa ctcccgcaac atcacctgta 2280 tcacttgcac tgatgttcgc tctccggtgc tggtgttcca gtgcaactcc cgacacgtga 2340 tctgcctgga ctgcttccac ctgtactgtg tgaccagact gaatgacagg cagtttgtcc 2400 acgaccccca actgggctac tccttgcctt gtgtggctgg ctgccccaac tccctgatca 2460 aggagttgca ccacttccgg atcctgggag aggaacagta caacagatac cagcagtacg 2520 gggcagagga atgtgtcctc caaatggggg gagtgctgtg cccccggcct ggttgtggag 2580 ctggcctcct gccggaacct gaccagcgga aggtcacttg cgagggtgga aacggcctgg 2640 gctgtggctt cgccttctgt cgggagtgca aggaggccta ccacgaagga gaatgctccg cggtgtttga agcctcaggg accaccacac aagcctacag agtggatgag agggcagcgg 2760. agcaggcccg ctgggaagcg gcctccaagg agactatcaa gaaaaccacc aagccatgcc ctaggtgcca tgtgcctgtg gaaaagaatg gaggctgcat gcacatgaag tgcccccagc cacagtgccg ccttgaatgg tgctggaact gtggctgcga gtggaacaga gtgtgtatgg gggaccactg gtttgatgtg tgataatgga ttcctgtaaa caggcctatt gattggaag tttgtcaacg aattgtgggt cttttggggt ttgctgcccc ttttacgcaa tgtggatatc 3060 3120. ctgctttaat gcctttatat gcatgtatac aagcaaaaca ggcttttact ttctcgccaa cttacaaggc ctttctcagt aaacagtata tgacccttta ccccgttgct cggcaacggc ctggtctgtg ccaagtgttt gctgacgcaa cccccactgg ttggggcttg gccataggcc 3240 atcagcgcat gcgtggaacc tttgtgtctc ctctgccgat ccatactgcg gaactcctag ccgcttgttt tgctcgcagc tggactggag caaacctcat cgggaccgac aattctgtcg 3360 tactctcccg caagcactca ccgtttccgc ggctgctcgc ctgtgttgcc acctggattc 3420 tgcgcgggac gtccttctgc tacgtccctt cggccctcaa tccagcggac cttccttccc 3480 gcggcctgct gccggctctg cggcctcttc cgcctcttcg ccttcgccct cagacgagtc 3540 ggatctccct ttgggccgcc tccccgccca tgtatctttt tcacctgtgc cttgtttttg 3600 cctgtgttcc gcgtcctact tttcaagcct ccaagctgtg ccttgggcgg ctttggggca 3660 tggacataga tccctataaa gaatttggtt catcttatca gttgttgaat tttcttcctt 3720 tggacgctgg agcctcggta gccgttcctc ctgcccgctg ggcctcccaa cgggccctcc 3780 tcccctcctt gcaccggccc ttcctggtct ttgaataaat tcattgcttg ccagccatct 3840 gttgtttgcc cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt 3900 tcctaataaa atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg 3960 ggtggggtgg ggcaggacag caagggggag gattgggaat acaatagcag gcatgctggg 4020 gatgcggtgg gctctatggg tacccaggtg ctgaagaatt gacccggttc ctcctggggt 4080 tacccaggct ggagtgcagt ggcacatttc tgctcactgc aacctcctcc tccctgggtt 4140 caagcaattc tcctgcctca gcctcccaat cag 4173 <210> 45 <211> 4172 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 45 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccactgcaga gggccctgcg tatgagtgca agtgggtttt aggaccagga 360 tgaggcgggg tgggggtgcc tacctgacga ccgaccccga cccactggac aagcacccaa 420 cccccattcc ccaaattgcg catcccctat cagagagggg gaggggaac aggatgcggc 480 gaggcgcgtg cgcactgcca gcttcagcac cgcggacagt gccttcgccc ccgcctggcg 540 gcgcgcgcca ccgccgcctc agcactgaag gcgcgctgac gtcactcgcc ggtcccccgc 600. aaactcccct tcccggccac cttggtcgcg tccgcgccc cgccggccca gccggaccgc 660 accacgcgag gcgcgagata ggggggcacg ggcgcgacca tctgcgctgc ggcgccggcg 720 actcagcgct gcctcagtct gcggtgggca gcggaggagt cgtgtcgtgc ctgagagcgc 780 agctgtgctc ctgggcaccg cgcagtccgc ccccgcggct cctggccaga ccacccctag 840 gacccctgc cccaagtcgc agggattc aaagcaagcc gccaccatga ttgtgtttgt 900. 960. ccggttcaac tcctcccatg gtttcccggt ggagtggac tcagacacca gcatcttcca actgagga gtggtggcca agcgtcaggg ggtcccggca gaccagttga gagtgatctt 1080. cgctggaag gaactgagaa acgactggac tgtgcagaac tgtgacctgg accaacagtc cattgtgcac attgtccagc ggccttggcg gaaaggtcaa gagatgaacg ccactggtgg agatgacccc aggaatgcag ctgggggctg tgaacgggaa cctcagagcc tgaccagagt 1200 ggacctcagc tcctctgtcc tcccgggaga ctccgtggga ctggcagtca ttctgcacac 1260 tgacagccgc aaggattccc cccctgcggg ttcaccagct ggacggtcca tctacaactc 1320 cttctatgtg tactgcaagg gaccctgcca gagggtgcag ccgggaaagc tcagagtgca 1380 gtgcagcact tgcagacaag ccaccctgac cctgacccag ggcccatcct gctgggatga 1440 tgtcctgatc cccaaccgga tgtcagggga atgccaaagc cctcactgcc ctggaacctc 1500 ggccgagttc ttcttcaaat gtggagccca ccccacctcg gacaaggaaa cctcggtggc 1560 ccttcacctc attgccacca actcccgcaa catcacctgt atcacttgca ctgatgttcg 1620 ctctccggtg ctggtgttcc agtgcaactc ccgacacgtg atctgcctgg actgcttcca 1680 cctgtactgt gtgaccagac tgaatgacag gcagtttgtc cacgaccccc aactgggcta 1740 ctccttgcct tgtgtggctg gctgccccaa ctccctgatc aaggagttgc accacttccg 1800 gatcctggga gaggaacagt acaacagata ccagcagtac ggggcagagg aatgtgtcct 1860 ccaaatgggg ggagtgctgt gcccccggcc tggttgtgga gctggcctcc tgccggaacc 1920 tgaccagcgg aaggtcactt gcgagggtgg aaacggcctg ggctgtggct tcgccttctg 1980 tcgggagtgc aaggaggcct accacgaagg agaatgctcc gcggtgtttg aagcctcagg 2040 gaccaccaca caagcctaca gagtggatga gagggcagcg gagcaggccc gctgggaagc 2100 ggcctccaag gagactatca agaaaaccac caagccatgc cctaggtgcc atgtgcctgt 2160 ggaaaagaat ggaggctgca tgcacatgaa gtgcccccag ccacagtgcc gccttgaatg 2220 gtgctggaac tgtggctgcg agtggaacag agtgtgtatg ggggaccact ggtttgatgt 2280 gtgataatgg attcctgtta atcaacctct ggattacaaa atttgtgaaa gattgactgg 2340 tattcttaac tatgttgctc cttttacgct atgtggatac gctgctttaa tgcctttgta 2400 tcatgctatt gcttcccgta tggctttcat tttctcctcc ttgtataaat cctggttgct 2460 gtctctttat gaggagttgt ggcccgttgt caggcaacgt ggcgtggtgt gcactgtgtt 2520 tgctgacgca acccccactg gttggggcat tgccaccacc tgtcagctcc tttccgggac 2580 tttcgctttc cccctcccta ttgccacggc ggaactcatc gccgcctgcc ttgcccgctg 2640 ctggacaggg gctcggctgt tgggcactga caattccgtg gtgttgtcgg ggaagctgac 2700 gtcctttccg cggctgctcg cctgtgttgc cacctggatt ctgcgcggga cgtccttctg 2760 ctacgtccct tcggccctca atccagcgga ccttccttcc cgcggcctgc tgccggctct 2820 gcggcctctt ccgcctcttc gccttcgccc tcagacgagt cggatctccc tttgggccgc 2880 ctccccgccc atgtatcttt ttcacctgtg ccttgttttt gcctgtgttc cgcgtcctac 2940 ttttcaagcc tccaagctgt gccttgggcg gctttggggc atggacatag atccctataa 3000 agaatttggt tcatcttatc agttgttgaa ttttcttcct ttggacgctg gagcctcggt 3060 agccgttcct cctgcccgct gggcctccca acgggccctc ctcccctcct tgcaccggcc 3120 cttcctggtc tttgaataaa ttcattgcct gcccgggtgg catccctgtg acccctcccc 3180 agtgcctctc ctggccctgg aagttgccac tccagtgccc accagccttg tcctaataaa 3240 attaagttgc atcattttgt ctgactaggt gtccttctat aatattatgg ggtggagggg 3300 ggtggtatgg agcaaggggc ccaagttggg aagaaacctg tagggcctgc gttacccagg 3360 ctggagtgca gtggcacatt tctgctcact gcaacctcct cctccctggg ttcaagcaat 3420 tctcctgcct cagcctccca agtagctgtg attataggtg cacaccacca agcctggcta 3480 atttttat ctttagtaga gacgggagtc tcaccatgtt ggccaggcta gtctctggca 3540 agccatggta aaatgtaact atttaaggct gctttaaatt agactaatag cagagtggtc 3600 agactatact gaaagcttgg tgaatcacaa ttaagtacct aaagaacta ttcttgtttg 3660 ccttattcct atgtaataa ctgaaatctt tgttttctt cctaaaaggg gtcatgttga 3720 tttttactta caatgtattt taagtttgtc actctaaatg gttatgagca agtttaagaa 3780 aaatcttcag caaatactac cttagattat gaccccaaaa cacattact tatgattatg 3840 ttgaaaacat agggtctggg gaaaaaggga ttaaaataa gaaaaaag aagacttggg 3900 acttaaaaag tcttttagag gccagctcac caacattcag aacacccagt ctgtgttgca 3960 caatatgtta cttaggtata aatcaaggat tcatgtaatt ttgtcattcc ttgcgtgata 4020 ttttaaaaaa cattctgtgt aaggtattta taaagctctc ttctaaaaat acaaaaattt 4080 gtggggcctt gtagtcccag ctacttggga ggctgaggca ggaggatttc ttgaactggg 4140 aggcagagct tgcagtgagc ccactgcatc ag 4172 <210> 46 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 46 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccaacttgtg gacaaagttt gctctattcc acctcctcca ggccctcctt 360 gggtccatca ccccaggggt gctgggtcca tcccaccccc aggcccacac aggcttgcag 420 tattgtgtgc ggtatggtca gggcgtccga gagcaggttt cgcagtggaa ggcaggcagg 480 tgttggggag gcagttaccg gggcaacggg aacagggcgt tttggaggtg gttgccatgg 540 ggacctggat gctgacgaag gctcgcgagg ctgtgagcag ccacagtgcc ctgctcagaa 600 gccccgggct cgtcagtcaa accggttctc tgtttgcact cggcagcacg ggcaggcaag 660 tggtccctag gttcgggggaa ttcaaagcaa gccgccacca tgattgtgtt tgtccggttc 720 aactcctccc atggtttccc ggtggaagtg gactcagaca ccagcatctt ccaactgaag 780 gaagtggtgg ccaagcgtca gggggtcccg gcagaccagt tgagagtgat cttcgctgga 840 aaagactga gaacgactg gactgtgcag aactgtgacc tggaccaaca gtccattgtg 900 cacattgtcc agcggccttg gcggaaaggt caagagatga acgccactgg tggagatgac 960 cccagggaatg cagctgggg ctgtgaacgg gaacctcaga gcctgaccag agtggacctc 1020 agctcctctg tcctcccggg agactccgtg ggactggcag tcattctgca cactgacagc 1080 cgcaaggatt ccccccctgc gggttcacca gctggacggt ccatctacaa ctccttctat 1140 gtgtactgca agggaccctg ccagagggtg cagccggga agctcagagt gcagtgcagc acttgcagac aagccaccct gaccctgacc cagggcccat cctgctggga tgatgtcctg atccccaacc ggatgtcagg ggatgccaa agccctcact gccctggaac ctcggccgag ttcttcttca aatgtggagc ccaccccacc tcggacaagg aaacctcggt ggcccttcac 1380 ctcattgcca ccaactcccg caacatcacc tgtatcactt gcactgatgt tcgctctccg gtgctggtgt tccagtgcaa ctcccgacac gtgatctgcc tggactgctt ccacctgtac 1560. tgtgtgacca gactgaatga caggcagttt gtccacgacc cccaactggg ctactccttg ccttgtgtgg ctggctgccc caactccctg atcaaggagt tgcaccactt ccggatcctg 1620 ggagaggaac agtacaacag ataccagcag tacggggcag aggaatgtgt cctccaaatg gggggagtgc tgtgccccg gcctggttgt ggagctggcc tcctgccgga acctgaccag 1740 cggaaggtca cttgcgaggg tggaaacggc ctgggctgtg gcttcgcctt ctgtcgggag tgcaaggagg cctaccacga aggagaatgc tccgcggtgt ttgaagcctc agggaccacc 1860. acacaagcct acagagtgga tgagagggca gcggagcagg cccgctggga agcggcctcc 1920 aaggacta tcaagaaaac caccaagcca tgccctaggt gccatgtgcc tgtggaaaag 1980 aatggaggct gcatgcacat gaagtgcccc cagccacagt gccgccttga atggtgctgg 2040 aactgtggct gcgagtggaa cagagtgtgt atgggggacc actggtttga tgtgtgataa 2100 tggattcctg ttaatcaacc tctggattac aaaatttgtg aaagattgac tggtattctt 2160 aactatgttg ctccttttac gctatgtgga tacgctgctt taatgccttt gtatcatgct 2220 attgcttcc gtatggcttt cattttctcc tccttgtata aatcctggtt gctgtctctt 2280 tatgaggat tgtggcccgt tgtcaggcaa cgtggcgtgg tgtgcactgt gtttgctgac 2340 gcaaccccca ctggttgggg cattgccacc acctgtcagc tcctttccgg gactttcgct 2400 ttccccctcc ctattgccac ggcggaactc atcgccgcct gccttgcccg ctgctggaca 2460 ggggctcggc tgttgggcac tgacaattcc gtggtgttgt cgggggaagct gacgtccttt 2520 ccgcggctgc tcgcctgtgt tgccacctgg attctgcgcg ggacgtcctt ctgctacgtc 2580 ccttcggccc tcaatccagc ggaccttcct tcccgcggcc tgctgccggc tctgcggcct 2640 cttccgcctc ttcgccttcg ccctcagacg agtcggatct ccctttgggc cgcctcccg 2700 cccatgtatc tttttcacct gtgccttgtt ttgcctgtg ttccgcgtcc tactttcaa 2760 gcctccaagc tgtgccttgg gcggctttgg ggcatggaca tagatcccta taaagaattt 2820 ggttcatctt atcagttgtt gaatttctt cctttggacc tgcccgggtg gcatccctgt 2880 gaccctccc cagtgcctct cctggccctg gaagttgcca ctccagtgcc caccagcctt 2940 gtcctaataa aattaagttg catcatttg tctgactagg tgtccttcta tatattatg 3000 gggtggaggg gggtggtatg gagcaagggg cccaagttgg gaagaaacct gtagggcctg 3060 cgttacccag gctggagtgc agtggcacat ttctgctcac tgcaacctcc tcctccctgg 3120 gttcaagcaa ttctcctgcc tcagcctccc aagtagctgt gattataggt gcacaccacc 3180 aagcctggct aatttttata tctttagtag agacgggagt ctcaccatgt tggccaggct 3240 agtctctggc aagccatggt aaaatgtaac tatttaaggc tgctttaaat tagactaata 3300 gcagagtggt cagactatac tgaaagcttg gtgaatcaca attaagtacc tcaaagaact 3360 attcttgttt gccttattcc tatgtaaata actgaaatct ttgtttttct tcctaaaagg 3420 ggtcatgttg atttttactt acaatgtatt ttaagttttgt cactctaaat ggttatgagc 3480 aagtttaaga aaaatcttca gcaatacta ccttagatta tgaccccaaa acacatttac 3540 ttatgattat gttgaaaaca tagggtctgg ggaaaaaggg attaaaata agaagaaaaa 3600 gaagacttgg gacttaaaaa gtcttttaga ggccagctca ccaacattca gaacacccag 3660 tctgtgttgc acaatatgtt acttaggtat aaatcaagga ttcatgtaat tttgtcattc 3720 cttgcgtgat attttaaaaa acattctgtg taaggtattt ataaagctct cttctaaaaa 3780 tacaaaaatt tgtggggcct tgtagtccca gctacttggg aggctgaggc aggaggatttt 3840 cttgaactgg gaggcagagc ttgcagtgag cccactgcac tccagcctgg gcaacagagt 3900 agaactcctc tcaaaaaaaa aaaaaaaaa gaaagaaaga aaaaaaagtg gactgtgaaa 3960 actgaaagga ctagaaaaac tacactacaa agatacagaa accaagaaag caccaaaggt 4020 ttgccttcaa ctgcttccca acttgttttc ctcttccaat ttgattgtgg tttcctctcc 4080 agaaggaact ccacagtact tagcgttggt cacatagtag gttctcaaat acttgttaat 4140 aaataagttt gttcgagaag cttcag 4166 <210> 47 <211> 4155 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 47 ctctgggctc tggagacgac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 60 ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 120 ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 180 tcatatgcca agtccgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 240 tgcccagtac atgaccttac gggactttcc tacttggcag tacatctacg tattagtcat 300 cgctattacc atggtgatgc ggttttggca gtacaccaat gggcgtggat agcggtttga 360 ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 420 aaatcaacgg gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc aaatgggcgg 480 taggcgtgta cggtgggagg tctatatag cagagctcgt ttagtgaacc gtcagatcgc 540 ctggagaggc catccacgct gttttgacct catagtgga caccgggacc gatccagcct 600 ccgcggccgg gaacggtgca ttggaacgcg gattccccgt gccaagagtg actcagatcc 660 tcactctctt ccgcatcgct gtctgcgagg gccagctgtt gggctcgcgg ttgaggacaa 720 actcttcgcg gtctttccag tactcttgga tcggaaaccc gtcggcctc gaacggtact 780 ccgccaccga gggacctgag cgagtccgca tcgaccggat cggaaaacct ctcgagaaag 840 gcgtctaacc agtcacagtc gcaaggtagg ctgagcaccg tggcgggcgg cagcgggtgg 900 cggtcggggt tgttctggc ggaggtgctg ctgatgatgt attaaagta ggcggtcttg 960 agacggcgga tggtcgaggt gaggtgtggc aggcttgaga tccagctgtt ggggtgagta 1020 ctccctctca aaagcgggca ttacttctgc gctaagattg tcagtttcca aaaacgagga 1080 ggatttgata ttcacctggc ccgatctggc catacacttg agtgacaatg acatccactt 1140 tgcctttctc tccacaggtg tccactccca ggtccaagtt taaacgccgc cacccaccat 1200 gattgtgttt gtccggttca actcctccca tggtttcccg gtggaagtgg actcagacac 1260 cagcatcttc caactgaagg aagtggtggc caagcgtcag ggggtcccgg cagaccagtt 1320 gagagtgatc ttcgctggaa aggaactgag aaacgactgg actgtgcaga actgtgacct 1380 ggaccaacag tccattgtgc acattgtcca gcggccttgg cggaaaggtc aagagatgaa 1440 cgccactggt ggagatgacc ccaggaatgc agctgggggc tgtgaacggg aacctcagag 1500 cctgaccaga gtggacctca gctcctctgt cctcccggga gactccgtgg gactggcagt 1560 cattctgcac actgacagcc gcaaggattc cccccctgcg ggttcaccag ctggacggtc 1620 catctacaac tccttctatg tgtactgcaa gggaccctgc cagagggtgc agccgggaaa 1680 gctcagagtg cagtgcagca cttgcagaca agccaccctg accctgaccc agggcccatc 1740 ctgctgggat gatgtcctga tccccaaccg gatgtcaggg gaatgccaaa gccctcactg 1800 ccctggaacc tcggccgagt tcttcttcaa atgtggagcc caccccacct cggacaagga 1860 aacctcggtg gcccttcacc tcattgccac caactcccgc aacatcacct gtatcacttg cactgatgtt cgctctccgg tgctggtgtt cagtgcaac tcccgacacg tgatctgcct ggactgcttc cacctgtact gtgtgaccag actgaatgac aggcagtttg tccacgaccc ccaactgggc tactccttgc cttgtgtggc tggctgcccc aactccctga tcaaggagtt gcaccacttc cggatcctgg gagaggaca gtacaacaga taccagcagt acggggcaga ggaatgtgtc ctccaaatgg ggggagtgct gtgcccccgg cctggttgtg gagctggcct cctgccgga cctgaccagc ggaaggtcac ttgcgagggt ggaaacggcc tgggctgtgg cttcgccttc tgtcgggagt gcaaggaggc ctaccacgaa ggagaatgct ccgcggtgtt tgaagcctca gggaccacca cacaagccta cagagtggat gagagggcag cggagcaggc ccgctggga gcggcctcca aggagactat caagaaacc accaagccat gccctaggtg ccatgtgcct gtggaaaaga atggaggctg catgcacatg aagtgccccc agccacagtg 2520 ccgccttgaa tggtgctgga actgtggctg cgagtggaac agagtgtgta tgggggacca 2580 ctggtttgat gtgtgataat ggactaatta aattcgagca tcttaccgcc atttattccc 2640 atatttgttc tgtttttctt gatttgggta tacatttaaa tgttaataaa acaaaatggt 2700 ggggcaatca tttacattt tagggatatg taattactag ttcaggtgta ttgccacaag 2760 acaaacatgt taagaaactt tcccgttatt tacgctctgt tcctgttaat caacctctgg 2820 attacaaaat ttgtgaaaga ttgactgata ttcttaacta tgttgctcct tttacgctgt 2880 gtggatatgc tgctttaatg cctctgtatc atgctattgc ttcccgtacg gctttcgttt 2940 tctcctcctt gtataaatcc tggttgctgt cctttatga ggagttgtgg cccgttgtcc 3000 gtcaacgtgg cgtggtgtgc tctgtgtttg ctgacgcaac ccccactggc tggggcattg 3060 ccaccacctg tcaactcctt tctgggactt tcgctttccc cctcccgatc gccacggcag 3120 aactcatcgc cgcctgcctt gccgctgct ggacaggggc taggttgctg ggcactgata 3180 attccgtggt gttgtcgggg aagggccttt aattagctgc ccgggtggca tccctgtgac 3240 ccctccccag tgcctctcct ggccctggaa gttgccactc cagtgcccac cagccttgtc 3300 ctataaaat taagttgcat cattttgtct gactaggtgt ccttctataa tattatgggg 3360 tggagggggg tggtatggag caggggccc aagttgggaa gaacctgta gggcctgcgt 3420 tacccaggct ggagtgcagt ggcacattc tgctcactgc aacctcctcc tccctggtt 3480 caagcaatc tcctgcctca gcctcccaag tagctgtgat tataggtgca caccaccaag 3540 cctggctaat ttttatatct ttagtagaga cgggagtctc accatgttgg ccaggctagt 3600 ctctggcaag ccatggtaaa atgtaactat ttaaggctgc ttaattag actaatagca 3660 gagtggtcag actatactga aagcttggtg aatcacaat aagtacctca aagactatt 3720 cttgtttgcc ttattcctat gtaaatact gaaatcttg ttttctcc taaaaggggt 3780 catgttgatt tttacttaca atgtatttta agtttgtcac tctaaatggt tatgagcaag 3840 tttaagaaaa atcttcagca atactacct tegttatga cccaaaaca catttactta 3900 tgatttagtt gaaaacatag ggtctgggga aaaagggatt taaataaga agaaaaagaa 3960 gacttgggac ttaaaaagtc ttttagaggc cagctcacca acatcagaa cacccagct 4020 gtgttgcaca atatgttact taggtataaa tcaaggattc atgtaatttt gtcattcctt 4080 gcgtgatatt ttaaaaaaca ttctgtgtaa ggtatttata aagctctctt ctaaaaatac 4140 aaaaatttgt gtcag 4155 <210> 48 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 48 ctctggagac gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 60 ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc 120 cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg 180 tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat 240 tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 300 atcgctatta ccagcccagc accccaaggc ggccaacgcc aaaactctcc ctcctcctct 360 tcctcaatct cgctctcgct cttttttttt ttcgcaaaag gaggggagag ggggtaaaaa 420 aatgctgcac tgtgcggcga agccggtgag tgagcggcgc ggggccaatc agcgtgcgcc 480 gttccgaaag ttgcctttta tggctcgagc ggccgcggcg gcgccctata aaacccagcg 540 gcgcgacgcg ccaccaccgc cgagtccgcg tccgcccgcg agcacagagc ctcgcctttg 600 ccgatccgcc gcccgtccac acccgccgcc aggtaagccc ggccagccga ccggggcatg 660 cggccgcggc ccttcgcccg tgcagagccg ccgtctgggc cgcagcgggg ggcgcatggg 720 gcggaaccgg accgccgtgg ggggcgcggg agaagcccct gggcctccgg agatggggga 780 caccccacgc cagttcgcag gcgcgaggcc gcgctcgggc gggcgcgctc cgggggtgcc 840 gctctcgggg cgggggcaac cggcggggtc tttgtctgag ccgggctctt gccaatgggg 900 atcgcacggt gggcgcggcg tagccccgt caggcccggt gggggctggg gcgccatgcg 960 cgtgcgcgct ggtcctttgg gcgctaactg cgtgcgcgct gggaattggc gctaattgcg cgtgcgcgct gggactcaat ggcgctaatc gcgcgtgcgt tctggggccc gggcgcttgc 1080 gccacttcct gcccgagccg ctggcgcccg agggtgtggc cgctgcgtgc gcgcgcgcga 1140 cccggtcgct gtttgaaccg ggcggaggcg gggctggcgc ccggttggga gggggttggg 1200 gcctggcttc ctgccgcgcg ccgcggggac gcctccgacc agtgtttgcc ttttatggta 1260 ataacgcggc cggcccggct tcctttgtcc ccaatctggg cgcgcgccgg cgccccctgg 1320 cggcctaagg actcggcgcg ccggaagtgg ccagggcggc agcggctgct cttggcggcc 1380 ccgaggtgac tatagccttc ttttgtgtct tgatagttcg ccagcctctg ctaaccatgt 1440 tcatgccttc ttctttttcc tacagctcct gggcaacgtg ctggttattg tgctgtctca 1500 tcattttggc aaagaattcg gcttgatcga agccgtctca ggggaattca aagcaagccg 1560 ccaccatgat tgtgtttgtc cggttcaact cctcccatgg tttcccggtg gaagtggact 1620 cagacaccag catcttccaa ctgaaggaag tggtggccaa gcgtcagggg gtcccggcag 1680 accagttgag agtgatcttc gctggaaagg aactgagaaa cgactggact gtgcagaact 1740 gtgacctgga ccaacagtcc attgtgcaca ttgtccagcg gccttggcgg aaaggtcaag 1800 agatgaacgc cactggtgga gatgacccca ggaatgcagc tgggggctgt gaacgggaac 1860 ctcagagcct gaccagagtg gacctcagct cctctgtcct cccgggagac tccgtgggac 1920 tggcagtcat tctgcacact gacagccgca aggattcccc ccctgcgggt tcaccagctg 1980 gacggtccat ctacaactcc ttctatgtgt actgcaaggg accctgccag agggtgcagc 2040 cgggaaagct cagagtgcag tgcagcactt gcagacaagc caccctgacc ctgacccagg 2100 gcccatcctg ctgggatgat gtcctgatcc ccaaccggat gtcaggggaa tgccaaagcc 2160 ctcactgccc tggaacctcg gccgagttct tcttcaaatg tggagcccac cccacctcgg 2220 acaaggaaac ctcggtggcc cttcacctca ttgccaccaa ctcccgcaac atcacctgta 2280 tcacttgcac tgatgttcgc tctccggtgc tggtgttcca gtgcaactcc cgacacgtga 2340 tctgcctgga ctgcttccac ctgtactgtg tgaccagact gaatgacagg cagtttgtcc 2400 acgaccccca actgggctac tccttgcctt gtgtggctgg ctgccccaac tccctgatca 2460 aggagttgca ccacttccgg atcctgggag aggaacagta caacagatac cagcagtacg 2520 gggcagagga atgtgtcctc caaatggggg gagtgctgtg cccccggcct ggttgtggag 2580 ctggcctcct gccggaacct gaccagcgga aggtcacttg cgagggtgga aacggcctgg 2640 gctgtggctt cgccttctgt cgggagtgca aggaggccta ccacgaagga gaatgctccg cggtgtttga agcctcaggg accaccacac aagcctacag agtggatgag agggcagcgg 2760. agcaggcccg ctgggaagcg gcctccaagg agactatcaa gaaaaccacc aagccatgcc ctaggtgcca tgtgcctgtg gaaaagaatg gaggctgcat gcacatgaag tgcccccagc cacagtgccg ccttgaatgg tgctggaact gtggctgcga gtggaacaga gtgtgtatgg gggaccactg gtttgatgtg tgataatgga ctgcccgggt ggcatccctg tgacccctcc 3000. ccgtgcctc tcctggccct ggagttgcc actccagtgc ccgcct tgtcctaata aaattaagtt gcatcatttt gtctgactag gtgtccttct fathers ggggtggagg ggggtggtat ggagcaaggg gcccaagttg ggaagaacc tgtagggcct gcgttaccca 3180 ggctggagtg cagtggcaca tttctgctca ctgcaacctc ctcctccctg ggttcaagca 3240 attctcctgc ctcagcctcc caagtagctg tgattatagg tgcacaccac caagcctggc 3300 taatttttat atctttagta gagacgggag tctcaccatg ttggccaggc tagtctctgg 3360 caagccatgg taaaatgtaa ctatttaagg ctgctttaaa ttagactaat agcagagtgg 3420 tcagactata ctgaaagctt ggtgaatcac aattaagtac ctcaaagaac tattcttgtt 3480 tgccttattc ctatgtaaat aactgaaatc tttgtttttc ttcctaaaag gggtcatgtt 3540 gatttttact tacaatgtat tttaagtttg tcactctaaa tggttatgag caagtttaag 3600 aaaaatcttc agcaaatact accttagatt atgaccccaa aacacattta cttatgatta 3660 tgttgaaaac atagggtctg gggaaaaagg gatttaaaat aagaagaaaa agaagacttg 3720 ggacttaaaa agtcttttag aggccagctc accaacattc agaacaccca gtctgtgttg 3780 cacaatatgt tacttaggta taaatcaagg attcatgtaa ttttgtcatt ccttgcgtga 3840 tattttaaaa aacattctgt gtaaggtatt tataaagctc tcttctaaaa atacaaaaat 3900 ttgtggggcc ttgtagtccc agctacttgg gaggctgagg caggaggatt tcttgaactg 3960 ggaggcagag cttgcagtga gcccactgca ctccagcctg ggcaacagag tagaactcct 4020 ctcaaaaaaa aaaaaaaaaa agaaagaaag aaaaaaaagt ggactgtgaa aactgaaagg 4080 actagaaaaa ctacactaca aagatacaga aaccaagaaa gcaccaaagg tttgccttca 4140 actgcttccc aacttgtttt cctcag 4166 <210> 49 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 49 ctctgggctc tggagacgac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 60 ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 120 ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 180 tcatatgcca agtccgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 240 tgcccagtac atgaccttac gggactttcc tacttggcag tacatctacg tattagtcat 300 cgctattacc atggtgatgc ggttttggca gtacaccaat gggcgtggat agcggtttga 360 ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 420 aaatcaacgg gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc aaatgggcgg 480 taggcgtgta cggtgggagg tctatatag cagagctcgt ttagtgaacc gtcagatcgc 540 ctggagaggc catccacgct gttttgacct catagtgga caccgggacc gatccagcct 600 ccgcggccgg gaacggtgca ttggaacgcg gattccccgt gccaagagtg actcagatcc 660 tcactctctt ccgcatcgct gtctgcgagg gccagctgtt gggctcgcgg ttgaggacaa 720 actcttcgcg gtctttccag tactcttgga tcggaaaccc gtcggcctc gaacggtact 780 ccgccaccga gggacctgag cgagtccgca tcgaccggat cggaaaacct ctcgagaaag 840 gcgtctaacc agtcacagtc gcaaggtagg ctgagcaccg tggcgggcgg cagcgggtgg 900 cggtcggggt tgttctggc ggaggtgctg ctgatgatgt attaaagta ggcggtcttg 960 agacggcgga tggtcgaggt gaggtgtggc aggcttgaga tccagctgtt ggggtgagta 1020 ctccctctca aaagcgggca ttacttctgc gctaagattg tcagtttcca aaaacgagga 1080 ggatttgata ttcacctggc ccgatctggc catacacttg agtgacaatg acatccactt 1140 tgcctttctc tccacaggtg tccactccca ggtccaagtt taaacgccgc cacccaccat 1200 gattgtgttt gtccggttca actcctccca tggtttcccg gtggaagtgg actcagacac 1260 cagcatcttc caactgaagg aagtggtggc caagcgtcag ggggtcccgg cagaccagtt 1320 gagagtgatc ttcgctggaa aggaactgag aaacgactgg actgtgcaga actgtgacct 1380 ggaccaacag tccattgtgc acattgtcca gcggccttgg cggaaaggtc aagagatgaa 1440 cgccactggt ggagatgacc ccaggaatgc agctgggggc tgtgaacggg aacctcagag 1500 cctgaccaga gtggacctca gctcctctgt cctcccggga gactccgtgg gactggcagt 1560 cattctgcac actgacagcc gcaaggattc cccccctgcg ggttcaccag ctggacggtc 1620 catctacaac tccttctatg tgtactgcaa gggaccctgc cagagggtgc agccgggaaa 1680 gctcagagtg cagtgcagca cttgcagaca agccaccctg accctgaccc agggcccatc 1740 ctgctgggat gatgtcctga tccccaaccg gatgtcaggg gaatgccaaa gccctcactg 1800 ccctggaacc tcggccgagt tcttcttcaa atgtggagcc caccccacct cggacaagga 1860 aacctcggtg gcccttcacc tcattgccac caactcccgc aacatcacct gtatcacttg cactgatgtt cgctctccgg tgctggtgtt cagtgcaac tcccgacacg tgatctgcct ggactgcttc cacctgtact gtgtgaccag actgaatgac aggcagtttg tccacgaccc ccaactgggc tactccttgc cttgtgtggc tggctgcccc aactccctga tcaaggagtt gcaccacttc cggatcctgg gagaggaca gtacaacaga taccagcagt acggggcaga ggaatgtgtc ctccaaatgg ggggagtgct gtgcccccgg cctggttgtg gagctggcct cctgccgga cctgaccagc ggaaggtcac ttgcgagggt ggaaacggcc tgggctgtgg cttcgccttc tgtcgggagt gcaaggaggc ctaccacgaa ggagaatgct ccgcggtgtt tgaagcctca gggaccacca cacaagccta cagagtggat gagagggcag cggagcaggc ccgctggga gcggcctcca aggagactat caagaaacc accaagccat gccctaggtg ccatgtgcct gtggaaaaga atggaggctg catgcacatg aagtgccccc agccacagtg 2520 ccgccttgaa tggtgctgga actgtggctg cgagtggaac agagtgtgta tgggggacca 2580 ctggtttgat gtgtgataat ggattcctgt aaacaggcct attgattgga aagtttgtca 2640 acgaattgtg ggtcttttgg ggtttgctgc cccttttacg caatgtggat atcctgcttt 2700 aatgccttta tatgcatgta tacaagcaaa acaggctttt actttctcgc caacttacaa 2760 ggcctttctc agtaaacagt atatgaccct ttaccccgtt gctcggcaac ggcctggtct 2820 gtgccaagtg tttgctgacg caacccccac tggttggggc ttggccatag gccatcagcg 2880 catgcgtgga acctttgtgt ctcctctgcc gatccatact gcggaactcc tagccgcttg 2940 ttttgctcgc agctggactg gagcaaacct catcgggacc gacaattctg tcgtactctc 3000 ccgcaagcac tcaccgtttc cgcggctgct cgcctgtgtt gccacctgga ttctgcgcgg 3060 gacgtccttc tgctacgtcc cttcggccct caatccagcg gaccttcctt cccgcggcct 3120 gctgccggct ctgcggcctc ttccgcctct tcgccttcgc cctcagacga gtcggatctc 3180 cctttgggcc gcctccccgc ccatgtatct ttttcacctg tgccttgttt ttgcctgtgt 3240 tccgcgtcct acttttcaag cctccaagct gtgccttggg cggctttggg gcatggacat 3300 agatccctat aaagaatttg gttcatctta tcagttgttg aattttcttc ctttggacgc 3360 tggagcctcg gtagccgttc ctcctgcccg ctgggcctcc caacgggccc tcctcccctc 3420 cttgcaccgg cccttcctgg tctttgaata aattcattgc ttgccagcca tctgttgttt 3480 gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc ctttcctaat 3540 aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtgggg 3600 tggggcagga cagcaagggg gaggattggg aatacaatag caggcatgct ggggatgcgg 3660 tgggctctat gggtacccag gtgctgaaga attgacccgg ttcctcctgg ggttacccag 3720 gctggagtgc agtggcacat ttctgctcac tgcaacctcc tcctccctgg gttcaagcaa 3780 ttctcctgcc tcagcctccc aagtagctgt gattataggt gcacaccacc aagcctggct 3840 aatttttata tctttagtag agacgggagt ctcaccatgt tggccaggct agtctctggc 3900 aagccatggt aaaatgtaac tatttaaggc tgctttaaat tagactaata gcagagtggt 3960 cagactatac tgaaagcttg gtgaatcaca attaagtacc tcaaagaact attcttgttt 4020 gccttattcc tatgtaaata actgaaatct ttgtttttct tcctaaaagg ggtcatgttg 4080 atttttactt acaatgtatt ttaagtttgt cactctaaat ggttatgagc aagtttaaga 4140 aaaatcttca gcaaatacta cctcag 4166 <210> 50 <211> 4166 <212> DNA <213> Artificial Sequence <220> <223> Prepared in the laboratory - AAV expression cassette construct <400> 50 ctctggagac gcaacctttg gagctaagcc agcaatggta gagggaagat tctgcacgtc 60 ccttccaggc ggcctccccg tcaccacccc ccccaacccg ccccgaccgg agctgagagt 120 aattcataca aaaggactcg cccctgcctt ggggaatccc agggaccgtc gttaaactcc 180 cactaacgta gaacccagag atcgctgcgt tcccgccccc tcacccgccc gctctcgtca 240 tcactgaggt ggagaatagc atgcgtgagg ctccggtgcc cgtcagtggg cagagcgcac 300 atcgcccaca gtccccgaga agttgggggg aggggtcggc aattgaacgg gtgcctagag 360 aaggtggcgc ggggtaaact gggaaagtga tgtcgtgtac tggctccgcc tttttcccga 420 gggtggggga gaaccgtata taagtgcagt agtcgccgtg aacgttcttt ttcgcaacgg 480 gtttgccgcc agaacacagg taagtgccgt gtgtggttcc cgcgggcctg gcctctttac 540 gggttatggc ccttgcgtgc cttgaattac ttccacctgg ctccagtacg tgattcttga 600 tcccgagctg gagccagggg cgggccttgc gctttaggag ccccttcgcc tcgtgcttga 660 gttgaggcct ggcctgggcg ctggggccgc cgcgtgcgaa tctggtggca ccttcgcgcc 720 tgtctcgctg ctttcgataa gtctctagcc atttaaaatt tttgatgacg tgctgcgacg 780 ctttttttct ggcaagatag tcttgtaaat gcgggccagg atctgcacac tggtatttcg 840 gtttttgggc ccgcggccgg cgacggggcc cgtgcgtccc agcgcacatg ttcggcgagg 900 cggggcctgc gagcgcggcc accgagaatc ggacgggggt agtctcaagc tggccggcct 960 gctctggtgc ctggcctcgc gccgccgtgt atcgccccgc cctgggcggc aaggctggcc 1020 cggtcggcac cagttgcgtg agcggaaaga tggccgcttc ccggccctgc tccagggggc 1080 tcaaaatgga ggacgcggcg ctcgggagag cgggcgggtg agtcacccac acaaaggaaa 1140 agggcctttc cgtcctcagc cgtcgcttca tgtgactcca cggagtaccg ggcgccgtcc 1200 aggcacctcg attagttctg gagcttttgg agtacgtcgt ctttaggttg gggggagggg 1260 ttttatgcga tggagtttcc ccacactgag tgggtggaga ctgaagttag gccagcttgg 1320 cacttgatgt aattctcctt ggaatttggc ctttttgagt ttggatcttg gttcattctc 1380 aagcctcaga cagtggttca aagttttttt cttccatttc aggtgtcgtg aacacgtctc 1440 aggggaattc aaagcaagcc gccaccatga ttgtgtttgt ccggttcaac tcctcccatg 1500 gtttcccggt ggaagtggac tcagacacca gcatcttcca actgaaggaa gtggtggcca 1560 agcgtcaggg ggtcccggca gaccagttga gagtgatctt cgctggaaag gaactgagaa 1620 acgactggac tgtgcagaac tgtgacctgg accaacagtc cattgtgcac attgtccagc 1680 ggccttggcg gaaaggtcaa gagatgaacg ccactggtgg agatgacccc aggaatgcag 1740 ctgggggctg tgaacgggaa cctcagagcc tgaccagagt ggacctcagc tcctctgtcc 1800 tcccgggaga ctccgtggga ctggcagtca ttctgcaca...
Claims
1. A recombinant gene therapy vector comprising an expression cassette, the expression cassette comprising a transgenic polynucleotide, the transgenic polynucleotide comprising a transgene encoding an E3 ubiquitin protein ligase (PARK2), wherein the transgenic polynucleotide is operably linked to a eukaryotic active promoter sequence, wherein the transgenic polynucleotide is SEQ ID NO: 38, and wherein the vector is an adeno-associated virus (AAV) vector.
2. The vector according to claim 1, wherein the promoter sequence is selected from Table 5.
3. The vector of claim 1, wherein the expression cassette further comprises a CMV enhancer.
4. The vector of claim 1, wherein the expression cassette further comprises a 5' untranslated region (UTR) selected from Table 6.
5. The vector according to claim 1, wherein the expression cassette further comprises a 3' untranslated region selected from Table 7.
6. The vector according to claim 1, wherein the expression cassette further comprises a polyadenylation sequence (polyA) selected from Table 8.
7. The vector of claim 1, wherein the expression cassette shares at least 99% sequence identity with any one of SEQ ID NOs: 39-58.
8. The vector according to claim 1, wherein the expression cassette comprises, in 5' to 3' order: HuBA promoter, the transgene, WPRE-x, and pA-globin-Oc; CMV promoter, TPL-eMLP enhancer, the transgene, WPRE-r, and pA-globin-Oc; Syn promoter, the transgene, WPRE-r, 3'UTR of globin, and pAGH-Bt; CBA promoter, the transgene and pAGH-Bt; EF1α promoter, the transgene, and pA-globin-Oc; HuBA promoter, the transgene, R2V17 and pAGH-Bt; Syn promoter, the transgene, WPRE-x, 3'UTR of globin, and pAGH-Hs; CaMKIIa promoter, the transgene, WPRE-r and pAGH-Hs; CMV promoter, TPL-eMLP 5' enhancer, the transgene, WPRE-r, and pAGH-Hs; HuBA promoter, the transgene and pAGH-Hs; CMV and TPL promoters, eMPL, the transgene, R2V17, 3'UTR of globin, and pAGH-Bt; EF1α promoter, the transgene, WPRE-r and pAGH-Bt; Syn promoter, the transgene, R2V17, and pA globin-Oc; CaMKIIa promoter, the transgene, R2V17, and pA-globin-Oc; CBA promoter, the transgene, WPRE-x, 3'UTR of globin, and pAGH-Hs; CBA promoter, the transgene, 3'UTR of globin, and pA globin-Oc; CaMKIIa promoter, the transgene, R2V17 and pAGH-Bt; EF1α promoter, the transgene, R2V17, 3'UTR of globin, and pAGH-Hs; CMV promoter, the transgene, R2V17, 3'UTR of globin and pAGH-Hs; or CMV promoter, the transgene and pAGH-Hs.
9. The vector of claim 1, wherein the vector comprises two AAV inverted terminal repeats (ITRs) flanking the expression cassette.
10. The vector of claim 1, wherein the AAV is of serotype AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10, or AAVrh74.
11. The vector of claim 1, wherein the recombinant gene therapy vector comprises a self-complementary AAV or a single-stranded AAV.
12. The vector of claim 1, wherein the AAV is a wild-type AAV or a modified AAV.
13. The vector of claim 1, wherein the AAV comprises a capsid protein that is at least 95% identical to a wild-type VP1, VP2 or VP3 capsid protein.
14. A host cell comprising the vector according to any one of claims 1 to 13.
15. Use of the recombinant gene therapy vector of any one of claims 1 to 13 for the preparation of a medicament for inhibiting degeneration or death of dopaminergic neurons comprising a mutation in a gene associated with Parkinson's Disease (PD).
16. The use according to claim 15, wherein the neurons produce and / or release increased amounts of dopamine after contact with the recombinant gene therapy vector.
17. The use according to claim 15, wherein the neurons undergo increased mitophagy after contact with the recombinant gene therapy vector.
18. The use according to claim 15, wherein the neurons are primary tyrosine hydroxylase-positive neurons.
19. The use according to claim 15, wherein the neurons are generated from induced pluripotent stem cells prepared from cells obtained from a subject diagnosed with Parkinson's disease.
20. Use of the recombinant gene therapy vector of any one of claims 1 to 13 for the preparation of a medicament for treating Parkinson's disease (PD) in a subject suffering from or at risk of suffering from the PD or inhibiting the onset of the PD.
21. The use according to claim 20, wherein the PD is early-onset PD.
22. The use according to claim 21, wherein the PD is early-onset autosomal recessive PD.
23. The use according to claim 20, wherein the subject comprises a mutation in the PARK2 gene.
24. The use according to claim 23, wherein the PARK2 is the amino acid sequence shown in SEQ ID NO:
1.
25. The use according to claim 20, wherein the subject is an adult.
26. The use of claim 20, wherein the number of dopaminergic neurons in the subject after administration of the medicament is greater than the number of dopaminergic neurons in the subject before administration.
27. The use of claim 20, wherein the dopamine level in the subject after administration of the medicament is higher than the dopamine level in the subject before administration.
28. The use according to claim 20, wherein the number of dopaminergic neurons in the subject after administration of the drug is increased compared to the number of dopaminergic neurons in a subject not administered with the drug.
29. The use of claim 20, wherein the dopamine level of the subject is increased after administration of the drug compared to the dopamine level of a subject not administered the drug.
30. The use according to claim 20, wherein the dopamine level in the substantia nigra of the subject after administration of the drug is increased compared to the dopamine level in the substantia nigra of a subject not administered with the drug.
31. The use of claim 20, wherein the subject's Unified Parkinson's Disease Rating Scale (UPDRS) score is improved after administration of the medicament compared to the subject's UPDRS score before administration.
32. The use according to claim 20, wherein the UPDRS score of the subject after administration of the drug is improved compared to the UPDRS score of a subject not administered the drug.
33. Use of the recombinant gene therapy vector of any one of claims 1 to 13 in the preparation of a medicament for inhibiting degeneration or death of dopaminergic neurons comprising a mutation in a gene associated with Parkinson's disease (PD), wherein the mutated gene is an E3 ubiquitin protein ligase (PARK2) gene; Wherein after administration of the drug, the neurons express wild-type PARK2 protein or a functional variant or fragment thereof.
34. The use according to claim 33, wherein the wild-type PARK2 protein comprises the amino acid sequence shown in SEQ ID NO:
1.
35. The use according to claim 33, wherein the wild-type PARK2 protein comprises the amino acid sequence shown in any one of SEQ ID NOs: 10-17.
36. The use according to claim 33, wherein the recombinant gene therapy vector further comprises one or more of the following: a neuron-specific promoter, the neuron-specific promoter optionally selected from the group consisting of: hSYN1 (human synapsin), INA (α-filament nectin), NES (nestin), tyrosine hydroxylase (TH), forkhead box A2 (FOXA2), calmodulin-dependent protein kinase II (CaMKII) and neuron-specific enolase (NSE) promoter; A ubiquitous promoter selected from the group consisting of CMV, CAG, UBC, PGK, EF1-α, GAPDH, SV40, HBV and chicken β-actin, human β-actin promoter; Enhancer; Introns; poly-A signal; A sequence encoding a 2A peptide; and Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).
37. The use according to claim 33, wherein the neurons produce and / or release increased amounts of dopamine after contact with the recombinant gene therapy vector.
38. The use of claim 33, wherein the neurons undergo increased mitophagy after contact with the recombinant gene therapy vector.
39. The use according to claim 33, wherein the neurons are primary tyrosine hydroxylase-positive neurons.
40. The use according to claim 33, wherein the neurons are generated from induced pluripotent stem cells prepared from cells obtained from a subject diagnosed with Parkinson's disease.
